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Abstract
Protein kinase C has been implicated in the regulation of insulin 
signalling by many previous studies. This phenomenon was further 
investigated here using both established and novel experimental systems.
Using the streptozotocin-induced diabetic rat model, protein kinase 
C activity was assessed after partial purification of the enzyme from the 
liver of both normal and diabetic rats. It was found that inducing diabetes 
in rats using streptozotocin resulted in a decrease in total protein kinase C 
activity. Further analysis of protein kinase C activity showed that this 
difference was accounted for both by a reduction in activity of Ca2+- 
dependent and Ca2+-independent isoforms. To enable correlation of 
protein kinase C isoform expression with activity changes in these 
samples, antibodies were raised to specifically detect individual protein 
kinase C isoforms. Results from immunoblotting studies using isoform 
specific antisera suggested that, in rat liver, the reduced Ca2+-dependent 
protein kinase C activity might be associated with alterations in the a  and 
pH isoforms, whilst modified activity of the PKC-e species may have been 
responsible for the reduced Ca2+-independent activity observed.
The availability of a set of Chinese hamster ovary cell clones 
overexpressing the human insulin receptor, both alone and combined with 
a specific protein kinase C isoform, allowed direct in vitro analysis of the 
interaction of insulin and protein kinase C. In this case their control of 
intracellular cyclic AMP metabolism was studied. Results obtained by 
directly measuring intracellular cyclic AMP concentration in cells suggest 
that insulin can attenuate agonist stimulated increases in intracellular 
cyclic AMP concentration. However, this effect of insulin was only 
evident in cells overexpressing both the human insulin receptor and PKC-e
(xiii)
(CHO-e cells).
Upon directly measuring cyclic AMP phosphodiesterase activity in 
all CHO cell clones available, it was observed that CHO-e cells exhibited a 
higher basal phosphodiesterase activity than any other cell clone and that 
this activity was substantially increased by treating cells with insulin. Both 
of these observations were no longer apparent after cells had undergone 
long-term phorbol ester treatment to down-regulate protein kinase C. 
These results confirmed that PKC-e plays a crucial role in regulating both 
basal phosphodiesterase activity and insulin induced changes in 
phosphodiesterase activity within these cells. They also suggested that 
insulin's ability to attenuate agonist induced increases in intracellular 
cyclic AMP concentrations in these cells was due, at least partly, to 
stimulation of cyclic AMP phosphodiesterase activity.
(xiv)
Chapter 1
Introduction
1.1. An introduction to signal transduction
The basic tenet of drug and hormone action is that they must exert 
some influence on one or more cells in such a way as to result in a 
biological response. Since in the majority of cases target cell number will 
vastly exceed the number of drug molecules, if these were merely 
distributed such that they interacted at random the chance of a response 
occurring would be negligible. We now know that to ensure accurate drug 
targetting, ligands bind to specific receptors located on or within the cell. 
The signal resulting from this interaction then needs to be amplified and 
apportioned to produce the desired response in the cell.
Events occuring after hormone-receptor binding can become 
extremely complex. They may, for example, simply alter membrane 
permeability directly via an ion channel or may involve a complex signal 
transduction process involving many second messengers. The main classes 
of receptor mediated signal transduction systems are summarized in Figure
1. 1.
The sheer complexity of many systems, whereby a given cell 
contains a myriad of cell surface receptors each connected to a particular 
signal transduction system, begs the question how are these transduction 
mechanisms regulated and how might they relate to each other? The past 
two decades have seen expeditious progress in our understanding of signal 
transduction systems and their interaction with each other. Those of 
relevance to the work presented here will be discussed in further detail.
1.2. Insulin
1.2.1. Introduction
It is now more than sixty years since the initial discovery of 
insulin, yet the precise sequence of events whereby insulin triggers a 
cellular response is still unknown. This fact conveys the elaborate nature
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of the programme of events involved in the insulin mediated signalling 
pathway, as in recent times no other single hormone has been the subject 
of such intense research interest. Whilst much has been learned, protein 
purification and molecular cloning studies, for example, have provided 
information on the structure and kinase activity of the insulin receptor, it 
is still not entirely clear as to how insulin propagates signals within the 
cell.
Information in Section 1.2.4 will provide an up to date summary of 
what is currently known about the signal transduction system for insulin.
1.2.2. Effects of insulin
Insulin regulates a wide range of effects, some of which are very 
rapid and seen in seconds, for example, transport processes and enzyme 
regulation. Others, affecting enzyme concentrations and cell growth, may 
be manifest only over a period of minutes or hours. This reinforces the fact 
that insulin may exert its effects via different signalling pathways.
Some idea of the pleiotropic nature of insulin's action is given by 
the following categories of response that are regulated by insulin:
a) Transport of molecules across the plasma membrane.
b) Control over intracellular levels of cyclic nucleotides.
c) Activities of key enzymes in intermediary metabolism.
d) Rates of protein synthesis.
e) Rates of DNA and RNA synthesis, including specific gene expression.
f) Cell growth.
g) Cell differentiation.
In relation to the discussion to follow concerning the condition of 
diabetes mellitus (Section 1.4) it is advantageous to examine more closely 
one of insulin's most important effects, namely glucose homeostasis.
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Under normal circumstances, in response to increased glucose, 
pancreatic insulin secretion is stimulated and the com bination of 
hyperinsulinaemia plus hyperglycaemia promotes glucose uptake by 
primarily liver, gut and muscle, in addition to suppressing hepatic glucose 
production. The initial step of insulin stimulated glucose metabolism 
involves activation of the glucose transport system, with increased 
transport of glucose into insulin sensitive tissues. The free glucose in the 
cell is subsequently phosphorylated by hexokinase and metabolized by a 
series of enzymatic steps under the control of insulin. Of these the most 
important are glycogen synthase (which controls glycogen synthesis) and 
pyruvate dehydrogenase (which regulates glucose oxidation).
Looking at this process in greater detail, whole body glucose 
homeostasis can be viewed as being dependent on the following three 
tightly coupled mechanisms:
a. Suppression of hepatic glucose production: After glucose ingestion, 
insulin is released into the portal vein and is transported to the liver where 
it binds to receptors on hepatocytes and suppresses hepatic glucose output. 
Failure of the liver to perceive this signal results in impaired suppression 
of hepatic glucose production and results in hyperglycaemia. In non 
insulin dependent diabetes mellitus (NIDDM) subjects, a consistent 
increase in hepatic glucose production has been demonstrated (Golay, et 
aL, 1988; Groop, et al.y 1989).
b. Augmentation of glucose uptake by splanchic (hepatic/gastrointestinal) 
tissues. All evidence suggests that there is no difference between control 
and diabetic subjects in the amount of glucose uptake in this area (De 
Fronzo, et al.y 1983). This illustrates that the splanchic tissues are fairly 
insensitive to insulin with very little glucose being taken up by these 
organs, even under hyperinsulinaemic conditions.
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c. Peripheral (muscle) glucose uptake. As both examples given above are 
normal in NIDDM it is possible to assume by exclusion that peripheral 
tissues are the primary site of insulin resistance. There is infact an 
accelerated rate of glucose uptake in NIDDM (Gerich, et a l., 1990), 
explained by the mass action effect of hyperglycaemia that passively 
drives glucose into cells. However, the metabolic fate of the glucose taken 
up is abnormal as oxidation is impaired and there is no net flux of glucose 
into glycogen.
The numerous metabolic alterations that are characteristic of the 
diabetic state are becoming well defined, although the underlying lesions 
are proving more difficult to establish. Assessing the metabolic actions of 
insulin does however provide a useful estimation of insulin action in both 
normal and disease states.
1.2.3. The insulin receptor
1.2.3.1. Molecular biology
The insulin receptor gene is situated on the short arm of 
chromosome 19, far removed from the insulin gene on chromosome 11 
(Yang-Feng, et al., 1985). From this, a single proreceptor is synthesized 
and is cleaved in the endoplasmic reticulum to produce an alpha and beta 
subunit. A recent aspect of the insulin receptor to attract attention is the 
existence in most tissues of two isoforms, HIR-A and HIR-B (the latter 
lacking amino acid residues 720-731), produced by tissue specific 
alternative splicing at exon 11 of a primary proreceptor mRNA transcript 
(Mosthaf, et al., 1990).
1-2-3.2. Structure
The holomeric insulin receptor is a symmetrical heterotetramer of 
Mr -4 5 0  000 kDa, each heterodimer containing an extracellular,
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hydrophilic a  subunit (Mr -135 000) linked to a membrane spanning p 
subunit (Mr -95  000). Both subunits are glycosylated, which indicates the 
presence of extracellular domains in each. The heterotetramer (a2p2) 
structure is maintained by disulphide bridges between both subunits with 
additional disulphide bridges between the a  subunits.
The hydrophilic a-subunits are totally extracellular and provide the 
insulin binding site. They are anchored by means of their covalent 
attachment to the membrane spanning p-subunit. The p-subunit consists of 
an extracellular portion linked to its cytoplasmic domain by a single twist 
o f a-helix  across the plasma membrane. The above information is 
summarized in Figure 1.2.
The structure of the insulin receptor is such that dissection of 
signalling pathways at this stage is possible. Domains are being identified 
that are important in signalling one class of insulin action (metabolic 
responses) but are not involved in, and may even mask, the signalling of 
other types of responses (mitogenic).
1.2.3.3. Insulin binding
The insulin receptor was first identified by binding studies using 
mono-iodinated l25I-insulin of high specific radioactivity many years 
before its molecular structure was determined (Kahn, 1976). These studies 
have shown that only one high affinity binding site occurs on each 
receptor molecule (Pang and Shafer, 1984) despite each receptor molecule 
possessing two putative binding sites. Binding of insulin to one such site is 
sufficient to cause receptor activation. Indeed, insulin is only transiently 
required to initiate insulin receptor activation, activity still being elevated 
after the liganded insulin has dissociated.
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Such studies on the binding of insulin to target tissues and 
solubilized receptors is complex and difficult to reconcile with a 
hom ogenous population of non-interacting receptors. Possible 
explanations are that different receptor populations exist, each with 
differing affinities, or negative cooperativity between receptors. We now 
know that different receptor populations may exist and although 
theoretically each receptor could bind two insulin molecules, occupancy of 
one decreases the affinity of the other for insulin -100  fold (Pang and 
Shafer, 1984).
The cysteine rich portion of the a-subunit seems important in 
ligand binding. It shows one of the lowest levels of sequence identity 
between the insulin and insulin-like growth factor 1 receptors, which is 
consistent with a role in defining the stereospecificity of ligand binding.
Insulin binding is followed by rapid internalization of the insulin- 
receptor complex, the insulin generally being passed to lysosomes to be 
degraded and the receptor m ainly recycled. In the basal state 
approximately 10% of the receptor pool is intracellular, this figure 
increasing upon insulin exposure (Marshall, et a l., 1985). Each rat 
adipocyte, for example, can contain a total of around 200 000 insulin 
receptors.
It appears that the insulin receptor can also be activated by, for 
example, anti-receptor antibodies and trypsin to provoke insulin-like 
responses in the absence of tyrosine kinase activation  and 
autophosphorylation (Sung, et al., 1989). It has been proposed that this is 
achieved, perhaps in an analagous way to insulin, by relieving an 
inhibitory constraint, allowing the receptor to switch from an inactive to 
an active conformation.
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1.2.4. The insulin signalling system
1.2.4.1. Tyrosine kinase activity
As recently as 1982 it was noted that the insulin receptor was a 
tyrosine protein kinase, a function now understood to be an integral part of 
the means by which insulin controls cellular function. Upon insulin 
binding to the extracellular domain of the receptor, activation of the 
intracellular domain incorporating the kinase activity ensues and initiates a 
unique sequence of tyrosine phosphorylations of both the receptor itself 
and specific cellular substrates. Prior to stimulation with insulin, the 
receptor is basally phosphorylated on serine and threonine residues 
(Kasuga, e ta l ., 1982).
We know that insulin receptor tyrosine kinase activity is initially 
stimulated by insulin binding and subsequently augmented by insulin- 
stimulated receptor autophosphorylation, although the means by which the 
insulin signal is transmitted through the short transmembrane region of the 
receptor is not understood. Whilst some mutations in this region have 
resulted in loss of receptor function (Longo, et al.y 1992), others have no 
effect (Frattali, et al., 1991). Indeed several lines of evidence suggest that 
the extracellular and transmembrane domains of the receptor may not be 
an absolute requirement for effective receptor function; recombinant 
insulin receptors possessing only the kinase domain are active (Rosen, 
1989) and trypsin activates the tyrosine kinase by removing most of the a- 
subunit. It seems that the unoccupied extracellular domain exerts tonic 
inhibition of the receptor kinase.
Establishing the theme of autophosphorylation and tyrosine kinase 
activity as central to any hypothesis regarding insulin's action is the fact 
that conservative mutations in the ATP binding site which abolish this 
activity appear to inactivate signal transduction. A lysine residue at 
position 1018 plays a critical role in the ATP binding site, the absence or
7
mutation of this amino acid having been documented to attenuate 
autophosphorylation and substrate phosphorylation (Chou, et al., 1987).
Other important domains on the receptor p-subunit besides the 
active site described above include the C-terminal portion. Deletion of the 
43 C-terminal amino acids results in a receptor exhibiting normal kinetics 
for the binding of insulin, receptor autophosphorylation, receptor 
endocytosis and recycling as well as similar substrate phosphorylation as 
native receptor. When expressed in intact fibroblasts, unlike the native 
insulin receptor its function was lost, suggesting that this domain may be 
involved in associating with a downstream effector molecule in the 
signalling pathway (M aegawa, et al.y 1988). The significance of 
phosphorylation at tyrosine 960 and at the principal sites of 
autophosphorylation (tyrosines 1146, 1150 and 1151) will be discussed 
below.
1.2.4.2. Autophosphorvlation.
Autophosphorylation appears to occur through a trans-mechanism 
in which insulin binding to the a-subunit of one a-p  dimer stimulates the 
phosphorylation of the adjacent covalently linked p-subunit (Lammerst, et 
al.y 1990). Several of the parameters associated with the phenomenon of 
insulin receptor autophosphorylation are outlined briefly below:
a) Ligand specificity. In vitro  the ED50 for insulin stim ulated 
autophosphorylation is 2-5nM, corresponding to half-maximal insulin 
binding. Maximal stimulation usually occurs at lOOnM insulin, with a 
small inhibition (~15%) seen above this concentration. Insulin analogues 
promote autophosphorylation directly in parallel with their receptor 
binding affinity, for example IGF-I has a very low binding affinity and is 
about 5% as effective as insulin in its action.
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b) Metal ion requirements. Divalent metal cations are necessary for insulin 
receptor kinase activity, serving as substrate cofactors and/or allosteric 
activators. M n2+ and Mg2+ are the most effective.
c) Nucleotide dependency. ATP is the only phosphate donor known to be 
accepted by the insulin receptor kinase with a Km highly dependent on 
assay conditions but ranging from 30 - 150pM. Autophosphorylation 
appears to increase Vmax but not alter Km for either ATP or substrate.
d) Inhibitors. Certain divalent metal ions (Cu2+, Zn2+) inhibit the insulin 
receptor. Specific inhibition has also been attained with antibodies. An 
antibody directed to a sequence surrounding the tyrosine-960 residue binds 
to the receptor, blocking autophosphorylation, although once 
autophosphorylated the receptor is no longer open to such inhibition.
e) Activators. Trypsinisation, hydrogen peroxide (H2O 2), anti-receptor 
antibodies and sodium vanadate can all activate the insulin receptor.
1.2.4.3. Sites of autophosphorylation
Upon receptor activation, phosphotyrosines first appear within the 
tyrosine kinase domain at residues 1146, 1150 and 1151. This is generally 
found to be sufficient to cause maximal ( 10-20 fold) stimulation of 
receptor kinase activity (White, et al., 1988). Concomitant with the 
appearance of the third phosphotyrosine at residue 1150 or 1151, 
phosphotyrosine also appears in residues 1316 and 1322 at the C- terminal 
tail of the receptor. These seem to play a regulatory role but are not 
essential for insulin signalling as their mutation or deletion does not alter 
receptor autophosphorylation or biological activity (Yamamoto-Honda, et 
a l ., 1993). The intracellular juxtamembrane region o f the receptor, 
however, is essential for signal transduction. It contains at least one 
autophosphorylation site (tyrosine 960), where if tyrosine is replaced by 
phenylalanine or alanine signal transmission is inhibited despite
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autophosphorylation and kinase activity being unaffected (Kaburagi, et al.,
1993). It is proposed then that this region is involved in substrate, for 
example IRS-1, selection as overexpression of IRS-1 can rescue certain 
biological effects lost upon tyrosine 960 mutation (White and Kahn,
1994).
Proof that autophosphorylation alters conformation of the receptor 
comes from the fact that antibodies raised against a sequence containing 
the major autophosphorylation sites will immunoprecipitate receptors only 
after autophosphorylation and vice versa. It has been proposed that, for at 
least some forms of insulin mediated signal transduction, the altered 
conformation caused by autophosphorylation is required simply to allow 
physical interaction with a component of the signalling system allowing 
signal propagation.
1.2.4.4. The role of SH2 and SH3 domains
An intriguing question is how do growth factors exhibiting tyrosine 
kinase activity select their targets? Recent years have seen this clarified 
via the identification of Src homology 2 (SH2) domains (Pawson and 
Gish, 1992). These protein sequences of approximately 100 amino acids 
are conserved in even the most diverse cytoplasmic signalling proteins. 
Most of these proteins will also contain a distinct sequence of about 50 
residues, the SH3 domain, which is also involved in regulating protein- 
protein interactions during signal transduction. SH2 and SH3 domains 
specifically recognize and bind phosphotyrosine, albeit only when 
implanted within a specific amino acid sequence.
In the case of the insulin receptor there is no evidence of direct 
association with signalling proteins. Instead, the best characterized 
substrate, insulin receptor substrate 1 (IRS-1), contains multiple potential 
tyrosine phosphorylation sites. Tyrosine phosphorylation of these sites in
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insulin stimulated cells has been shown to allow binding of IR S-1 to, for 
example, PI 3'-kinase (Sun, et a l., 1991). This suggests that the insulin 
receptor, rather than having SH2 binding domains as part of the receptor, 
uses its direct tyrosine phosphorylation substrate, IRS-1, as an SH2 
docking protein.
1.2.4.5. Substrates of the insulin receptor kinase
Many cellular components involved in insulin signalling have been 
proposed as substrates for phosphorylation. These include, protein kinases 
and phosphatases, G-proteins, calmodulin, enzymes involved in glucose 
metabolism or enzymes catalyzing the production of mediators such as 
PIP2 (Kasuga, et al., 1990).
Several approaches have been used to confirm cellular substrates 
of the insulin receptor. These include, phosphorylation of candidate 
proteins in cell free systems, immunoprecipitation of candidate substrates 
with specific antibodies, SDS-PAGE separation of labelled proteins from 
cells incubated with 32P and immunoprecipitation of cellular proteins with 
anti-phosphotyrosine antibodies (W hite, et al., 1985). Substrates 
determined using these techniques include MAP-2 (Kadowaki, et al., 
1985b), the a-subunit of tubulin (Kadowaki, et al., 1985a), calmodulin 
(Graves, et al., 1986), and protein phosphatase 2A (Chen, et al., 1992), all 
identified using purified receptor preparations. Few proteins have been 
conclusively established to be substrates in the intact cell. One such 
protein, however, is HA4, identified as an ATPase on hepatocyte plasma 
membranes (Lin and Guidotti, 1989). Immunoprecipitation of a 185kDa 
protein (ppl85) with anti-phosphotyrosine antibodies following insulin 
stimulation of Fao hepatoma cells first highlighted this important cellular
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substrate (White, et al., 1985). Subsequently pp 185 has been found in all 
cell types studied, being immediately phosphorylated after insulin 
stimulation, and is now known as IRS-1 (Sun, et al., 1991).
IRS-1 contains no sequence motifs to suggest it is a protein kinase 
and contains 21 potential tyrosine phosphorylation sites, including 6 in 
YMXM motifs, 3 in YXXM motifs and 12 in other hydrophobic motifs as 
well as 30 potential serine/threonine phosphorylation sites in motifs 
recognized by various kinases (White and Kahn, 1994). At least 8 of the 
tyrosine residues are phosphorylated by the activated insulin receptor 
(Sun, etal., 1993).
IRS-1 is highly conserved between species, rat and human being 
90% identical, with the tyrosines totally conserved (Nishiyama and 
Wands, 1992) and is essential for most, if not all, of insulin's biological 
effects.
I.2.4.6. Signal transduction via IRS-1
Activity of PI-3' kinase, an important mediator of cellular growth 
and metabolism, increases following insulin stimulation, suggesting that it 
is somehow activated by the insulin receptor. IRS-1 is known to bind 
strongly to this enzyme (Sun, et al.y 1991), this being attributed to binding 
of tyrosine phosphorylated YMXM motifs of IRS-1 to SH2 domains 
present in the 85 kDa subunit of PI-3’ kinase.
These findings established a new mechanism of allosteric enzyme 
regulation which may be generalized to other SH2 domain-containing 
proteins, such as SH-PTP-2 (Kuhne, et al., 1993), GRB-2 (Skolnik, et al.,
1993) and Nek (Li, et al., 1994), with IRS-1 as a central molecule in the 
insulin transducing pathway. SH-PTP-2 (or Syp) is a protein tyrosine 
phosphatase containing two SH2 domains which is activated when these 
bind to IRS-1. GRB-2 contains two SH3 domains and one SH2 domain
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and acts to link the guanine nucleotide exchange factor for p21ras (mSOS) 
to IRS-1, the GRB-2/mSOS complex activating p21ras by stimulating 
GTP binding. In the future many more cellular elements interacting with 
IRS-1 will be identified, and indeed molecules similar to IRS-1 may still 
await discovery.
1.2.4.7. Insulin signal transduction via protein kinase cascades
In common with many other growth promoting hormones, 
compelling evidence gathered over recent years points to the involvement 
of a phosphorylation cascade in insulin action. Although this originates 
from receptor tyrosine kinase activ ity , serine and threonine 
phosphorylation play the major role. Indeed, tyrosine phosphorylation 
represents only 0.03% of all protein phosphorylation in cells.
Several protein kinases are activated in cells by insulin, including 
casein kinase II, MAP kinases, raf-1 kinase, acetylCoA carboxylase kinase 
and ribosomal S6 kinases. Conversely, many actions of insulin are brought 
about by dephosphorylation of proteins, including glycogen synthase, 
pyruvate dehydrogenase, triacylglycerol lipase and phosphorylase kinase 
(Denton, 1990). Protein phosphatases, such as PP1 are, however, in turn 
activated by insulin-sensitive protein kinases (ISPK) such as S6 kinase 
(p90rsk) in the case of PP1 (Lavoinne, et al., 1991), whose activation is 
mediated by yet another ISPK known as MAP-2 kinase (Sturgill, et al.,
1988).
It is now known that the upstream activator of MAP kinase, the 
MAP kinase kinase, is activated by c-raf-1 kinase m ediated 
phosphorylation and inactivated by phosphatase 2A (Kyriakis, et al., 
1992). A putative signal transduction sequence might thus involve insulin 
binding - receptor activation - phosphorylation of IRS-1 - binding of a 
GRB-2/mSOS complex to IRS-1 - activation of p21ras - activation of raf-1
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kinase - activation of MAP kinases - activation of S6 kinases and 
ultimately activation of PP1. The components of such a pathway will now 
be discussed in more detail.
Mitogen Activated Protein Kinases
MAP kinase was infact identified as an insulin stimulated kinase in 
3T3-L1 fibroblasts that had been converted to adipocytes (70-80%) by 
treatment with dexamethasone and isobutylmethylxanthine (Sturgill and 
Ray, 1986). Over the last two years these proteins have acquired a number 
of names and acronyms. MAP kinase is now generally used to mean 
mitogen activated protein kinase although confusingly is still often used to 
imply microtubule associated protein. Other members of the same family 
were first, and are still often described by other names such as ERK 
(extracellular-signal related kinase), MBP (myelin basic protein) kinase 
and ERT (EGF receptor threonine) kinase.
Many potential substrates for MAP kinase have been proposed, for 
example, raf-1 kinase (Anderson, et al., 1991), S6 kinase (Sturgill and Wu,
1991) and PP1 (Lavoinne, et al., 1991), and identified following the 
identification of a consensus sequence, namely Pro-X-Ser/Thr-Pro, for 
MAP kinase mediated phosphorylation (Alvarez, et al., 1991). This will 
hopefully further aid identification of physiologically im portant 
downstream components in the signalling pathway which interact with 
MAP kinase. Upstream regulation of MAP kinase involves tyrosine or 
serine/threonine kinases, including protein kinase C, and possibly a cyclin 
like molecule which stimulates MAP kinase autophosphorylation (Ahn, et 
al., 1991).
Protein kinase C
Another possible component of the insulin signalling pathway is 
protein kinase C. In BC3H-1 myocytes diacylglycerol levels increased 
within 30 seconds of stimulation by insulin. Membrane protein kinase C
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activity increased two-fold within 60 seconds, and cytosolic protein kinase 
C activity increased by 80% over 20 minutes (Cooper, et al., 1987). 
Further recent studies suggest that diacylglycerol produced in response to 
insulin is synthesized mainly from glycerol through phosphatidic acid and 
by hydrolysis of phosphatidylcholine by an insulin-dependent 
phospholipase D (Baldini, et al., 1992). Several other groups have 
demonstrated insulin stimulated increases in both cytosolic and membrane 
bound activity (Cooper, e ta l., 1990; Ishizuka, et al., 1989). However, this 
was not a consistent observation (Vaartjes, et al., 1986; Blackshear, e ta l.,
1991), thus making this an area of considerable controversy. Interactions 
between protein kinase C and insulin are discussed in much greater detail 
in Section 1.5.
Phosphatases
Introduction of phosphoryl groups from ATP onto intracellular 
proteins by protein kinases is recognized as a fundamental mechanism in 
the signal transduction process. Protein phosphatases reverse the action of 
protein kinases by hydrolyzing phosphoryl groups from proteins. 
Maintenance of steady state basal phosphorylation levels and inactivation 
or activation of proteins regulated by their phosphorylation state requires 
finely tuned phosphatase activity as the basal phosphorylation state of a 
protein is determined by a dynamic equilibrium between the activities of 
the kinase(s) and phosphatase(s) that catalyze the phosphorylation and 
dephosphorylation reactions respectively. The protein phosphatase family 
is extensive (Brautigan, 1992) although its members seem more related 
through action than by heredity. Several diverse m olecules have 
apparently converged on a function, utilizing different protein backbones 
to exhibit a critical surface nucleophile and small supporting cast of 
sidechains to carry out hydrolysis.
15
Insulin is capable of dephosphorylating and activating glycogen 
synthase or dephosphorylating and inactivating glycogen phosphorylase 
by activation of protein phosphatase 1 via serine phosphorylation, an 
effect antagonized by adrenaline (Cohen, 1992). In insulin-dependant 
diabetic subjects the inability of glycogen synthase activity to be 
stimulated by a glucose load has been shown to be due to a decreased 
synthase phosphatase activity (Langdon and Curnow, 1983). This is not 
seen in NIDDM suggesting that actual lack of insulin, rather than 
increased blood glucose, is responsible for this decreased synthase 
phosphatase activity. 
p21 ras
The insulin receptor appears to be able to interact with the GDP- 
bound form of the ras oncogene product p21 (O'Brien, et al., 1987), a G- 
protein which may be involved in certain processes whereby insulin 
controls cellular events (Korn, et al., 1987).
In mammals there are at least three distinct ras proteins; H-ras, K- 
ras and N-ras. A variety of related gene products displaying ~50% 
homology to ras, including rho, ral and YP2, have been identified. With 
the discovery of mutant ras alleles in human tumours it became clear that 
p21ras had an important role in signal transduction pathways of growth 
promoting hormones, including insulin. The p21ras contains a GDP/GTP 
binding site and a low intrinsic GTPase activity. This allows ras to serve 
as a biological 'switch' that is 'on' when GTP is bound and 'o ff when GDP 
is bound. This feature is in turn regulated by two accessory proteins, 
GTPase activating protein (GAP) and guanine nucleotide releasing protein 
(GNRP).
16
The p21ras has been implicated as part of the insulin signal 
transduction pathway leading to the expression of certain genes (Haubruck 
and McCormick, 1991; Burgering, et al., 1991; Korn, et al., 1987). Whilst 
still somewhat unclear, it may be that GAP links the insulin receptor to 
p21ras, either directly or via IRS-1, since it contains two SH2 domains. 
More recently, GRB-2 has been identified as another possible linking 
molecule since it binds ras and contains one SH2 and two SH3 domains. 
Subsequently ras has been shown to bind directly to raf-1 serine/threonine 
kinase which in turn activates MAP kinase by phosphorylation and 
activation of MAP kinase kinase (Crews and Erikson, 1993).
Insulin induced maturation of oocytes was blocked using anti-ras 
antibodies (Korn, et al., 1987). Subsequent sim ilar experim ents 
highlighted that ras inactivation blocked growth factor receptor tyrosine 
kinase stimulated phosphorylation and activation of MAP kinase and 
protein kinase C (Thomas, et al., 1992) Therefore, it seems that ras and 
protein kinase C can function upstream or downstream from each other in 
distinct signalling pathways. A further intriguing aspect of ras 
involvement in signalling is that protein kinase C activation also induces a 
rapid activation of p21ras.GTP (Downward, et al., 1990). Dominant- 
negative ras alleles can block growth factor activation of Raf-1 kinase and 
MAP kinase, placing ras upstream of both kinases (Itoh, et al., 1988).
1.2.4.8. The role of phosphoinositol glycans
There seems little doubt that insulin provokes rapid changes in 
phospholipid metabolism in many of its target tissues. Possible routes by 
which this is mediated include via:
a) hydrolysis of phosphoinositol glycan or other glycolipids. One possible 
means of signal transduction is release of a phosphoinositol glycan and 
DAG by PLC action.
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b) activation of de novo PA synthesis. Insulin increases PA synthesis by 
increasing activity of glycerol-3-phosphate acyltransferase, apparently by 
decreasing its Km . This appears to be PTX sensitive and requires 
activation of a PLC.
c) PC hydrolysis. Increased incorporation of 3H-glycerol into lipids (eg. 
PC (Nair, et al.y 1988)) during insulin action has been shown in a number 
of cell types.
All three possibilities can result in DAG production. In cells where 
both Pl-glycan hydrolysis and PA synthesis have been blocked by PTX 
treatment (leaving PC hydrolysis intact), insulin stimulated increases in 
DAG levels are initially intact. However, increases after 1 minute are 
diminished (Luttrell, et al., 1988), suggesting that individual pathways are 
responsible for different phases of DAG production. The production of 
structurally distinct DAG, for example, lacking the usual arachidonate, by 
these means may also be an underlying factor in the selective regulation of 
protein kinase C isoforms.
1.3. Clinical syndromes associated with defects in insulin signalling: 
diabetes mellitus and associated molecular defects.
Insulin resistance of skeletal muscle, liver and fat combined with 
an abnormality of insulin secretion characterizes type 2 non-insulin 
dependant diabetes mellitus (NIDDM ). This condition affects at least 5% 
of the general population. It must be stressed that insulin resistance is only 
seen as it is partial, complete resistance leaving the subject with almost 
zero chance of survival.
Whilst much attention is focussed on the genetic basis of insulin 
resistance in NIDDM, acquired factors such as obesity and decreased 
physical activity can also contribute significantly to the development of
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impaired insulin action in NIDDM.
NIDDM results from an imbalance between insulin sensitivity and 
insulin secretion with the earliest detectable abnormality being an 
impairment in the body's ability to respond to insulin. Initially, the 
pancreas can correspondingly augment its secretion of insulin to offset any 
resistance such that glucose tolerance remains normal. With time however, 
the (3-cells fail to maintain this high output of insulin and glucose tolerance 
is impaired, leading eventually to overt diabetes mellitus. This implies 
therefore, that full-blown NIDDM initially requires two major defects, 
insulin resistance and impaired p-cell function.
It is certainly fashionable to assume that insulin resistance is the 
primary defect in NIDDM with hyperinsulinaemia being regarded solely 
as a compensatory response. It must be stressed however, that while this is 
almost certainly the case, it is plausible that increased insulin secretion 
represents the primary disturbance. Insulin resistance may then arise as a 
downregulation of both the receptor and postreceptor events caused by 
chronic sustained hyperinsulinaemia, as seems to be the case in at least 
one study group (Lillioja, et al., 1991).
In some cases of NIDDM the primary defect can be at the level of 
the p-cell with resultant impaired insulin secretion and subsequent 
development of insulin resistance. Such individuals are relatively rare and 
are represented by the lean diabetic.
Normal insulin secretion is biphasic (De Fronzo, et al., 1979) with 
an early burst of release within the first ten minutes after stimulation 
followed by progressively increasing pulsatile secretions (Lang, et al., 
1979). Evidence suggests that pulsatile insulin secretions or delivery is 
more effective in prom oting glucose disposal than continuous 
administration (Paolisso, et al., 1987). Recently one study has suggested
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that as loss of oscillatory insulin secretion is a characteristic feature of 
relatives of patients with NIDDM, and this could represent the earliest 
natural lesion in NIDDM (Gulli, et al., 1990).
Many recent studies have shown that the onset of type 2 diabetes in 
different high-risk populations is preceded by an undefined time period 
when insulin resistance may be detected through exhibited symptoms 
including increased abdominal fat, obesity, hypertension, elevated very 
low density lipoproteins and decreased high density lipoproteins as well as 
increased fasting (Modan, et al., 1985; Haring and M ehnert, 1993). 
Diabetes mellitus manifests itself by being associated with blindness, end 
stage renal disease, and a variety of atherosclerotic cardiovascular 
disorders. It is likely that disorders of intracellular signalling lie at the 
heart of clinical problems of insulin resistance. Several candidates for the 
location of such a lesion will now be discussed.
1.3.1. Possible defects causing insulin resistance in NIDDM
1.3.1.1. Insulin receptor
As the first element of the insulin mediated signal transduction 
pathway, the insulin receptor is a strong candidate for the location of any 
defect. Decreases in insulin binding in NIDDM are observed, reflecting 
either decreased receptor number or affinity (Olefsky and Reavan, 1977). 
These results are dubious, however, since they were performed on studies 
showing hyperinsulinaemia which naturally would lead to receptor down- 
regulation. In general, most studies suggest that decreased receptor 
number is not a prevalent phenomenon in NIDDM cases.
Can analysis of the insulin receptor gene highlight any associated 
defect? In studying cases of severe insulin resistance several point 
mutations of the insulin receptor have infact been found to occur (Taylor, 
et al., 1990). However, in testing over 100 type 2 diabetic patients only a
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few showed mutations of the insulin receptor gene, and for these there was 
no proof that they affected signalling of the resulting receptor (Cocozza, et 
a l., 1992). Such studies do not allow for the fact that, while the insulin 
gene itself may be normal, the possibility exists for functionally significant 
aberrations to occur during processing.
Alterations in receptor kinase activity in normal and diabetic states 
has also been assessed. In a type 2 case, kinase isolated from skeletal 
muscle was found to have an altered autoactivation process resulting in 
higher levels of inactivity (Obermaier-Kusser, et al., 1989). In general it 
appears that receptor tyrosine kinase activity is diminished in disease 
states (Considine and Caro, 1993; Comi, et al., 1987)
In conclusion, evidence suggests that a genetically determined, 
inherent defect of the receptor is unlikely. This infact, only accounts for a 
fraction of the NIDDM population. Rather, it appears that either altered 
receptor kinase activity or a secondary defect in the signalling cascade, 
diminished glucose transport or an abnormality in some critical enzyme 
step during glucose utilization seems more plausible.
1.3.1.2. Protein kinase C
Since decreased tyrosine kinase activity is exhibited by insulin 
receptors from NIDDM patients and protein kinase C can be responsible 
for attenuating receptor function it is tempting to speculate that the two are 
related. Supporting this hypothesis is data showing increased PIP2-PLC 
activity in diabetic rat liver (Thakker, et al., 1989), increased protein 
kinase C activity in the liver of rats made diabetic by starvation (Karasik, 
et al.y 1990), increases of 82% in the diacylglycerol content of insulin- 
resistant rat liver (Turinsky, et a l., 1990), and elevated glucose stimulated 
de novo diacylglycerol synthesis (Wolf, et al., 1991) as a direct result of 
glucose conversion (Lee, et al., 1989).
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These results strongly im plicate protein kinase C in the 
pathogenesis of insulin resistance, although these findings, once again, are 
not always apparent when assessed. In addition, protein kinase C has also 
been shown to have 'insulin-like' effects in increasing glucose transport 
(Henriksen, et a l,  1989) and lipogenesis (Van de Werve, et al., 1985).
Note that as well as being able to attenuate insulin receptor 
activity, protein kinase C may also cause insulin resistance by 
phosphorylating a target enzyme, such as glycogen synthase, either 
directly or via other protein kinases downstream of protein kinase C.
1.3.1.3. Phosphatases
Phosphatases are a vitally important target for insulin action, as 
seen, for example, in the regulation of glycogen synthase activity (Cohen,
1992). If we consider the proposed phosphorylation cascade initiated by 
insulin then phosphatases have the potential to regulate insulin mediated 
activity at every stage from basal receptor phosphorylation state, through 
phosphorylation state of components in the signalling pathway to the 
phosphorylation state of the ultimate target protein.
Evidence has emerged recently for an altered type-1 protein 
phosphatase (PP-1) activity in insulin resistant individuals, a decreased 
basal and insulin stimulated activity of this serine kinase now having been 
well documented (Freymond, et al., 1988; Kida, et a l, 1992).
1.3.1.4. Loss of Gi function
A loss of tonic inhibitory G-protein mediated inhibition of 
adenylate cyclase leads to enhanced activity in the presence or absence of 
any hormonal stimulation, as is the case in streptozotocin-induced diabetic 
rats (Strassheim, et al., 1990). Since this effect can readily be reversed by
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insulin therapy it is suspected that it may be of consequence in the 
pathogenesis of diabetes.
1.3.1.5. Glycogen synthase
A pivotal role for glycogen synthase is suggested by the 
observation that in type 2 diabetes both oxidative and non-oxidative 
glucose disposal is impaired (De Fronzo, et al., 1992), whereas in the pre­
diabetic state only non-oxidative disposal is affected (Warram, et a l.,
1990).
Activity of this enzyme is regulated by phosphorylation (serine 
kinases) and dephosphorylation (at least two phosphatases), the latter 
converting the enzyme to a glucose 6-phosphate independent form. Insulin 
activates the enzyme by promoting dephosphorylation (Lamer, 1983), this 
effect of insulin being reduced in type 2 diabetic patients (Damsbo, et al., 
1991; Nyomba, e ta l ., 1990).
Collectively, the data do not suggest that glycogen synthase itself 
is defective, rather that the defect occurs at a discrete point somewhere 
along the signal transduction pathway between the insulin receptor and 
glycogen synthase.
1.3.1.6. B-cell number
This factor is a critical determinant of insulin secretion volume. 
Most studies (Clark, et al., 1988; W estermark and W ilander, 1978) 
demonstrate a loss of up to 40% in |}-cell mass in patients with well 
established NIDDM, although this figure is qualified by the observation 
that a decrease of around 80% is required to induce overt diabetes mellitus 
(Eisenbarth, etal., 1987).
1.3.1.7. Glucose  toxicity
Evidence suggests that chronic hyperglycaemia is responsible, at 
least in part, for the p-cells' inability to respond to an acute 
hyperglycaemic challenge (Rossetti, et a l., 1990) This means that 
hyperglycaemia is not only to be viewed as a symptom of diabetes 
mellitus but also a pathogenic factor perpetuating the diabetic state. In 
addition, drug treatments to lower blood glucose, such as insulin or 
sulphonylureas, will alleviate symptoms somewhat and are associated with 
a concomitant increase in insulin secretion (Kosaka, et al., 1980).
1.3.1.8. Amvlin
Amylin is a novel pancreatic hormone, similar in structure to 
calcitonin gene related peptide, co-secreted with insulin by the p-cell. It is 
the precursor for the amyloid deposits that frequently are observed in 
patients with NIDDM (Nishi, et al., 1990) and at very high doses can 
inhibit insulin secretion (Ohsawa, et al., 1989). Originally called diabetes- 
associated peptide, amylin has now been isolated and completely 
characterized as a 37 amino acid peptide. At this time however, the way in 
which amylin causes insulin resistance is unclear. Another similar peptide, 
galanin, has also been implicated in inhibiting insulin secretion (Dunning 
and Taborsky, 1988).
1.3.1.9. Glucose transporter
Insulin promotes increased glucose transport by inducing the 
translocation of a large intracellular pool of glucose transporters to the 
plasma membrane. GLUT1 represents the predominant glucose transporter 
and regulates basal glucose uptake. GLUT2, the glucose sensitive 
transporter, predominates in liver and pancreatic p-cells, allowing these 
cells to act as glucose sensors. O f the seven facilitative glucose
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transporters characterised to date, only GLUT4 has been identified as 
being insulin sensitive.
Although the molecular mechanism is unclear, glucose transport 
has been extensively studied and found to be consistently decreased in, for 
example, adipocytes and muscle cells of NIDDM sufferers (Rothmann, et 
al., 1992; Dohm, et al., 1988; Garvey, et al., 1988). Available evidence 
points to no primary defect at the level of the glucose transporter itself 
(Pedersen, et al., 1990; Eriksson, et al., 1992). Despite obvious interest no 
phosphorylaton or dephosphorylation of glucose transporters in response 
to insulin has yet been described. Hence other mechanisms of regulation 
by insulin must be sought.
There are other explanations for insulin resistance, such as the 
developm ent of auto-inhibitory antibodies to insulin or the insulin 
receptor, the overproduction of counter-regulatory hormones and the 
synthesis of mutant insulin. Genetic abnormalities only account for a very 
small percentage of cases and are likely to differ among different 
population groups. Such conditions appear to be multigenic, the NIDDM 
phenotype manifesting itself only when more than one gene defect is 
apparent.
1.4. Protein kinase C
1.4.1. Background.
Protein Kinase C was first discovered in 1977 as an undefined 
protein kinase found in almost every cell studied, which was activated by 
limited proteolysis with the neutral protease calpain (Takai, et al., 1977). 
Infact the co-factor independent kinase, protein kinase M (PKM), 
generated upon proteolysis was at first thought to be the important 
molecule in terms of kinase activity. However, it is thought that generation
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of PKM is a transient step on the pathway to complete proteolysis and 
inactivation of protein kinase C.
Protein kinase C is now known to represent a structurally 
homologous group of proteins similar in size, structure and mechanism of 
activation which can elicit a variety of cellu lar responses by 
phosphorylating target proteins, most of which remain unknown, on serine 
and threonine residues. Full understanding of protein kinase C function 
requires identification and characterisation of physiological substrates for 
the enzyme as well as elucidation of the function of these target proteins.
Interest in the enzyme accelerated greatly upon the observation that 
it was activated by tumour promoting phorbol esters and the subsequent 
realization that the structurally similar diacylglycerol was indeed the 
physiological activator of protein kinase C. The fact that diacylglycerol 
production could be elicited by a variety of hormones that caused receptor 
mediated hydrolysis of membrane phospholipids opened up a whole new 
branch of the complex intracellular signalling network mediated via 
protein phosphorylation.
The enzyme is synthesized in membranes as a non-phosphorylated 
and inactive form that is converted to the active protein kinase C molecule 
by post-translational modification (Borner, et a l., 1989). At least ten 
isoforms of protein kinase C have now been identified, all of which are 
encoded by a large gene family. These have been termed PKC- a, Pi, Pn, 
y, e, C, 8, 0, n, (L) and X, as described in Table 1.1. These isoenzymes are 
often divided broadly into two categories, namely those which are calcium 
sensitive and those which are not. A great deal of work has been carried 
out on their structure, biochemical properties, expression, localization and 
activation within resting, proliferating and differentiated cells.
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A question we must ask is to what extent do the protein kinase Cs 
that have been identified through cDNA cloning studies represent a 
discrete family of kinases, and if so, how are the limits for such a family 
defined. One would have to say that the protein kinase C family is 
primarily bound together by their regulatory properties as they can clearly 
differ with respect to reactions catalyzed. Indeed the possibility that 
protein kinase C subspecies have specific cellular substrates allows for 
diverse and specific responses from cells in response to protein kinase C 
activation. This explains how in some instances protein kinase C can be 
involved in mediating the mitogenic responses of cells while conversely 
may also inhibit cell proliferation and induce differentiation. Protein 
kinase C has been implicated in diverse effects, including regulation of ion 
channel conductance, exocytosis, secretion, receptor down-regulation and 
cross-talk with other signalling systems.
1.4.2. Structure
The primary structure of the protein kinase C isoenzymes consists 
of a single polypeptide chain showing conserved structural motifs with a 
high degree of sequence homology. This sequence can be considered as 
having four conserved (C) regions separated by five variable (V) regions. 
The N-terminal half (regions C l, C2, V I and V2) constitutes the 
regulatory domain while the C-terminal half (regions C3, C4, V4 and V5) 
represent the catalytic domain, the two domains being separated by the 
variable region V3.
The so-called conventional protein kinase Cs (cPKCs - a, Pi, pn, 
and y) have a structure similar to that described above, but the non- 
conventional (nPKCs - 8, e, and Q which are calcium independent lack the 
C2 region.
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As the name implies, the regulatory domain interacts with calcium 
ions, phospholipids and diacylglycerol. The catalytic domain contains the 
active site and shows homology to many other protein kinases. Also in the 
N-terminal half is the pseudosubstrate region, an amino acid sequence 
which closely resembles protein kinase C substrate recognition sites. The 
following sections focus on individual areas in greater detail.
1.4.2.1. C l-region
The C 1 domain of all protein kinase Cs except PKC-£ contains a 
tandem repeat of a cysteine rich sequence (Parker, et al., 1986): 
Cys-X2-Cys-Xi3(i4)-Cys-X2-Cys-X7-Cys-X7-Cys 
Where X = Any amino acid.
The sequence outlined above resembles the consensus of a so- 
called zinc-finger. A zinc-finger is comprised of an approximately thirty 
amino acid repeat with two zinc ions tetrahedrally co-ordinated between 
six cysteine residues. Studies on purified PKC-Pi from insect cells suggest 
the existence of four zinc ions per molecule (Hubbard, e ta l.y 1991). In the 
case of most protein kinase Cs, the C l domain consists of two zinc-finger 
like motifs, although as previously mentioned PKC-£ does not bind PS or 
DAG and contains only one cysteine rich sequence (Ono, et al., 1987). 
This correlates with this isoform exhibiting, at least in vitro , constitutive 
activity (Liyange, et al.y 1992).
This region appears to be involved in phorbol ester and 
diacylglycerol binding since activity stimulated by these agents is 
abolished by deletion and point mutations within this region (Ono, et al.t 
1989). It has recently been proposed that phorbol esters and diacylglycerol 
bind by virtue of hydrogen bonding to the cysteine sulphydryl groups 
prominent in this region (Gschwendt, e ta l.y 1991).
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1.4.2.2. C2-region.
The C a2+ binding site on protein kinase C is unknown, although 
the C2 region is thought to confer calcium dependence on the a, p and y 
isoforms. Those protein kinase Cs lacking C2 are insensitive to Ca2+, 
showing significant catalytic activity in its absence (Ono, et al.y 1988). In 
addition, deletion of C2 by mutagenesis makes the kinase activity and 
phorbol ester binding independent of calcium (Ono, et al.y 1989). Despite 
this, the C2 region has no obvious calcium binding structure such as an E- 
F hand or calelectrin-like-sequence (Parker, et al., 1986).
1.4.2.3. C3 / C4-region.
The protein kinase domain covers regions C3 and C4 which are 
highly homologous to other protein kinases (Parker, et al., 1986). The
ATP binding sequence Gly-X-Gly-X-X-Gly Lys is to be found in both
C3 and C4 regions, although why two should exist is unclear. Deletion of 
C3 does indeed produce a protein kinase C which has no kinase activity 
(Kaibuchik, et al., 1989) and a similar effect is produced by a point 
mutation in the C3 ATP binding site sequence (Ohno, et al., 1990).
1.4.2.4. V 1-region.
This region is most likely to represent the sequence regulating 
substrate selection. The fact that it varies considerably between the various 
isoenzymes allows for the possibility that isoenzymes can have specific 
substrates not phosphorylated by others.
1.4.2.5. V5-region.
The variable C-terminal region is divergent among all the protein 
kinase Cs and also covers the splice variation between the Pi and pn 
isoforms.
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1.4.2.6. Pseudosubstrate
Autoinhibitory domains have been detected and characterized for 
many protein kinases and are thought to inhibit basal kinase activity by 
interacting with the catalytic domain, for example, at the substrate binding 
site. Such a region in protein kinase C was first identified as residues 19 - 
36 of PKC-a (House and Kemp, 1987) In all protein kinase Cs so far 
examined an analagous sequence is conserved and localized just N- 
terminal, about 1 3 -3 0  residues preceding the C l region.
This region contains one or more basic residues with a sequence 
paralleling the natural substrate recognition sequence for the kinase, but 
lacking the phosphorylatable serine or threonine residue which is replaced 
by alanine.
A synthetic peptide representing this region is a potent inhibitor of 
protein kinase C in vitro (House and Kemp, 1987), and substitution of 
alanine with serine transforms this same peptide into an excellent substrate 
for the enzyme. In keeping with the proposed model of pseudosubstrate 
autoinhibition the complete deletion of this sequence from protein kinase 
C led to enhanced constitutive kinase activity. The pseudosubstrate model 
is summarized in Figure 1.3.
While the pseudosubstrate model is widely accepted and supported 
it does not predict how co-factors relieve the autoinhibition or explain the 
co-factor independent activity observed with some substrates.
1.4.3. Heterogeneity
As mentioned previously, m olecular cloning analysis and 
enzymatic studies have shown that a family of protein kinase C molecules 
exist. At least ten members of the family are now known to exist, being 
derived from multiple genes and alternative splicing of a single RNA
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transcript. Initially four cDNA clones (encoding the a, Pi, pn, and y 
isoforms) were identified (Parker, et al., 1986), and these were later shown 
to be derived from three distinct genes on human chromosomes 17(a), 
16(p) and 19(y) (Coussens, et al., 1986). Subsequently homologous 
cDNAs for a further three isoforms, designated 8, e and C, were isolated 
from a rat brain library using a mixture of a, Pn and y cDNAs as probes 
under low stringency conditions (Ono, et al., 1987). More recently two 
further cDNA clones encoding tj-PKC and L-PKC have been identified 
(Osada, et al., 1990; Backer, et al., 1991), L-PKC being the human 
homologue of rat q-PKC.
Partial genomic analysis established that Pi and Pn are derived from 
differential splicing at the 3' end of the PKC-p gene giving proteins 
identical for 621 residues then 50 (pi) and 52 (pn) residues showing 
around 50% homology. There is also evidence for alternative splicing of 
PKC-e (Schaap, et al., 1990a)
Due to this extensive variation within the protein kinase C family, 
it is tempting to speculate that protein kinase C subspecies may have 
distinct roles in the processing and modulation of a variety o f 
physiological and pathological cellular responses. However, we are still 
far away from a clear cut picture of the distribution and physiological 
function of protein kinase C isoforms within distinct signalling pathways 
in different cells.
Several cases of 'selectivity' in the behaviour of individual 
isoforms are apparent; for example PKC-y (when compared with PKC a  
and p) is much less sensitive to stimulation by TPA but more sensitive to 
arachidonic acid (Marais and Parker, 1989) and within the group of 
calcium dependent protein kinase Cs the p isoform is much less dependent 
on the cation than the a  or y isoforms. In addition, PKC-C is the only 
isoform which has not been shown to down-regulate in response to TPA
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(Ways, et al., 1992). However, since the properties (or lack of) defined to 
date for PKC-£ contrast with other isoforms it may be appropriate to 
question its alignment within the protein kinase C family. Other brief 
examples include the fact that protein kinase C expression in B cells is 
dependent on the stage of differentiation (Mischak, et a l., 1991) and that 
thyrotropin-releasing-hormone selectively down-regulates PKC-e with no 
effect on PKC a  or p (Kiley, et a l., 1990), selective compartmentalization 
having been suggested as an explanation for this.
Such differential signalling via individual protein kinase C 
isoforms would explain how from cell type to cell type, certain effects of 
hormones , for example insulin, can be impaired by chronic phorbol ester 
treatment whereas in others the same phenomenon is unaffected. This is 
reviewed in detail by Farese (Farese, et al., 1992a), and underlines the 
substantial difficulties in considering together studies on protein kinase C 
performed using different cell systems or even from lab to lab where 
results can also vary significantly in this area of research.
Finally, as well as leading to the discovery of new members of the 
protein kinase C family, further low stringency screening of cDNA 
libraries with full length PKC probes may lead to the isolation of a 
spectrum of 'related' kinases. Indeed, the close similarity of the rac-family 
kinase domain to that of protein kinase C (Coffer and Woodgett, 1991) 
already indicates a close evolutionary relationship.
1.4.4. Expression
Since it is possible that specific effects observed with particular 
cell lines and not others are mediated via protein kinase C isoforms, it is 
important to establish the relative activity and individual pattern of 
expression of multiple protein kinase C isoenzymes in various cells and 
tissues. This has been done to a certain extent with the relatively recent
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emergence of isoenzyme specific antibodies. Results obtained to date are 
summarized in Table 1.1. Such work will help lead towards elucidating a 
role for individual protein kinase C isoforms in cellular signalling, 
although equally if not more important than protein kinase C isoform 
expression, is the availability within the cell (or indeed within a distinct 
cellular compartment) of the required substrate. Intracellular protein 
kinase C receptors (RACKs) have been proposed to contribute towards 
control o f the subcellular localization of protein kinase C isoforms 
(Mochly-Rosen, e ta l ., 1991).
1.4.5. Regulation of activation
The initial event in the activation of protein kinase C is the 
formation of an enzyme/phospholipid/(calcium) complex. The second step 
involves the association o f d iacylg lycero l which prom otes a 
conformational change resulting in activation. Although diacylglycerol 
may be formed in various ways, it is adequate at this stage to state that an 
overwhelming amount of evidence supports the idea that agonist induced 
phospholipid breakdown to produce diacylglycerol results in activation of 
protein kinase C. The precursor role of, for example, phosphatidylinositol- 
4,5-bisphosphate cannot be over-exaggerated as the inosito l-1,4,5- 
trisphosphate produced in conjunction with diacylglycerol causes 
liberation of Ca2+ within the cell which will influence the activity of the a, 
p and y protein kinase C isoforms as they display calcium dependence. For 
these isoforms, calcium acts by increasing their membrane occupancy, 
where they will be more effectively activated by the limiting amount of 
diacylglycerol produced, and elevated Ca2+ can infact prime protein 
kinase C responses in the cell (Akers and Routtenberg, 1987).
1.4.6. Substrate specificity
In vitro assay of protein kinase C originally involved measurement 
of transfer from the y position of ATP onto histones in the presence of 
sonicated lipid vesicles (Kikkawa, et al., 1983). Many cationic, water- 
soluble proteins have since been used as substrates for protein kinase C. 
Histone, however, remains the most extensively used artificial substrate 
as, unlike, for example, protamine sulphate, it displays classical 
dependance on anionic lipid and Ca2+ for protein kinase C activation. 
Specifically designed peptides, such as that representing part of the 
sequence in the pseudosubstrate domain, make ideal substrates and are 
now becoming more widely employed.
Results of protein kinase C activity assays are largely dependent on 
the choice of substrate. It seems that whilst a given substrate may be 
effectively phosphorylated by some isoforms, it may not be by others. 
However, data regarding this is often contradictory, with histone III-S, for 
example, having been shown to be very poorly phosphorylated by PKC-e 
(activity ratio of 1:68 c f  peptide-e) (Schaap, et al., 1989; Schaap and 
Parker, 1990b). Conversely, other data (M.G. Kazanietz, personal 
communication) suggest that histone, as well as being a good broad 
spectrum substrate, is one of the better PKC-e substrates. Protamine is 
also used extensively as it is a good broad spectrum substrate for many 
protein kinase Cs, especially PKC-e and PKC-y.
1.5. Cross-talk between insulin and protein kinase C.
The insulin receptor can be phosphorylated by protein kinase C 
(Jacobs, et al., 1983; Hunter, et al., 1984; Bollag, et al., 1986; Takayama, 
et al., 1984). Note moreover that the insulin receptor also appears to 
contain additional serine / threonine residues that are substrates for other 
protein kinases, such as cyclic AMP dependent kinase (Roth and
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Beaudoin, 1987). This, therefore, represents an important point of 
integration between the serine/threonine kinase dominated and tyrosine 
kinase mediated signalling pathways.
Phorbol ester treatment of intact cells gives a dramatic increase in 
phosphorylation of the insulin receptor p-subunit (Jacobs and Cuatrecasas, 
1986; Takayama, et al., 1984).This has been shown in hepatoma cells and 
adipocytes to lead to a decrease in receptor tyrosine kinase activity 
(Haring, et al., 1986; Takayama, et al., 1988). More recently, decreased 
insulin stimulated tyrosine phosphorylation of IRS-1 subsequent to TPA 
treatment of cells transfected with PKC-a has been observed (Chin, et al.,
1994). There is also evidence that purified protein kinase C itself can elicit 
the direct phosphorylation of the insulin receptor in vitro , with associated 
attenuation of insulin stimulated tyrosine kinase activity (Bollag, et al., 
1986). In these experiments and others, no change in receptor binding was 
observed. However, in some cases phorbol ester treatment of cells does 
appear to decrease insulin binding and there is some evidence suggesting 
this is due to increased internalization of the receptor (Haring, et al., 1986; 
Grunberger and Levy, 1990).
Several distinct sites on the insulin receptor p-subunit appear to 
become phosphorylated after phorbol ester treatment, the phosphorylated 
serine residues appearing to be identical to those whose phosphorylation is 
promoted by insulin itself (Lewis, et al., 1990). A distinctive difference is 
the prominent increase in phosphothreonine achieved by phorbol ester 
treatment.
Inspection of the insulin receptor p-subunit allows for the 
identification of possible sites where protein kinase C m ight 
phosphorylate. These include:
Ser 1315 - In the autophosphorylation domain B in the C-terminal region, 
Ser 1294 - In the functionally sensitive C-terminal region, and
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Thr 1336 - In the extreme C-terminal region.
There are also four serine residues at 951-964 (in tyrosine 960 domain) on 
the insulin receptor (3-subunit although none of these has a basic residue 
one removed on the N-terminal side as is usual for C-kinase substrates, 
hence these residues are not phosphorylated by protein kinase C.
From studies em ploying radiosequencing, com parison with 
synthetic peptides and use of monoclonal antibodies (Kasuga, et a l .,
1989), threonine 1336 seems to be preferentially phosphorylated (Lewis, 
et al .y  1990). This residue appears to be of crucial functional importance as 
deletion of the last 43 C-term inal amino acids of the p-subunit 
(incorporating threonine 1336), although failing to affect kinetics of 
binding, endocytosis, recycling or auto / substrate phosphorylation, did fail 
to mediate insulin's ability to stimulate either glucose uptake or glycogen 
synthase (Maegawa, et al .y  1988; McClain, et al .y  1988) upon transfection 
into fibroblasts.
Several studies have suggested insulin may exert its actions on 
target cells by activating protein kinase C (Considine and Caro, 1993), 
although this is an area of considerable controversy. This possibility grew 
from the realization that insulin was intimately involved in controlling 
similar key physiological processes in both growth and development as 
protein kinase C, hence it was natural to focus on possible interactions 
between their signalling pathways.
Although insulin and protein kinase C both phosphorylate, for 
example, the MARCKS protein (Roth and Beaudoin, 1987) the pattern of 
substrate phosphorylation elicited by insulin and TPA shows some 
differences (Farese, et a l . y  1992). Thus we must ask why they should 
induce different patterns of substrate phosphorylation? The following 
possibilities are proposed as explanations -
a. Insulin activates other protein kinases in addition to protein kinase C.
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b. Insulin activates protein phosphatases.
c. Diacylglycerols formed from PIP2 hydrolysis as opposed to PC 
hydrolysis differentially activate protein kinase Cs.
d. Insulin increases diacylglycerol levels in different subcellular 
compartments.
e. Protein kinase C isoforms differ in their activation by insulin, 
diacylglycerol, TPA, and other activators.
The insulin receptor cannot activate inositol phospholipid 
m etabolism  by causing breakdown o f phosphatidylinosito l-4 ,5- 
bisphosphate to IP3 and diacylglycerol. Insulin does however rapidly 
stimulate diacylglycerol production, as measured by 3H-glycerol labelled 
diacylglycerol formation (Iskizuka, et a l., 1990). Insulin can elicit this 
increase in diacylglycerol levels in some cells apparently through 
increasing de novo PA synthesis (from glycerol 3-phosphate and fatty 
acylCoA) (Farese, et al., 1987) and phospholipid hydrolysis (Farese, e ta l.y 
1985; Nair, et al.y 1988) as well as hydrolysis of inositol glycolipids 
(Saltiel, et al.y 1986). Once again, controversy surrounds the question of 
whether these insulin induced increases in diacylglycerol levels result in 
protein kinase C activation (Cooper, et al.y 1987; Blackshear, et al., 1991). 
A major reason for the prevailing controversy is that results can vary 
greatly from system to system and even between different research groups. 
It is likely that the actions of insulin mediated by protein kinase C are 
restricted to certain cells.
More and more evidence would suggest that protein kinase C is 
intimately involved in insulin signalling. For example, elevated glucose 
has previously been reported to activate protein kinase C, consistent with a 
potential role of protein kinase C in modulating insulin's action in diabetes 
(Lee, et al.y 1989). Recent data show that glucose induces an increased 
serine phosphorylation and subsequent decreased tyrosine kinase activity
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of the insulin receptor as well as decreased phosphorylation of IRS-1 
(Berti, et a l., 1994). This effect is paralleled by an overall increase in 
protein kinase C activity and translocation of the a, 8, e and £ isoforms to 
the membrane, and can be inhibited by H7 (Berti, et al., 1994).
Other examples include recent work by Farese (Farese, et a l.,
1992) where insulin stimulates the translocation of PKC- a, p, y, e and £ in 
various tissues studied, as does TPA, although differences do occur; 
insulin seemingly having a higher affinity for PKC-p. Secondly, studies 
using HL-60 cells highlight the fact that TPA at least partially replaces the 
requirement for insulin in cell proliferation (Trayner and Clemens, 1992). 
Thirdly, using TPA to down-regulate protein kinase C inhibits (60 - 87%) 
subsequent insulin stimulated deoxyglucose uptake (Tanti, eta l.y 1989).
1.6. Cyclic AMP metabolism
As cyclic AMP is an important intracellular second messenger, this 
necessitates that its metabolism must be tightly regulated. Systems for 
both synthesis and degradation have evolved to highly sophisticated 
levels. Controlling the synthesis of cyclic AMP from adenosine are the 
family of adenylate cyclase isoforms, degradation of cyclic AMP to 5'- 
AMP being managed by a series of phosphodiesterase isoenzymes. These 
are now discussed in further detail.
1.7. Adenylate cyclase
Adenylate cyclase exists as a series of isoenzymes, at least eight of 
which are now known, there being 70-75% sequence homology between 
them. All adenylate cyclase isoforms have similar overall structure, with 
12 hydrophobic membrane spanning sequences, two hydrophilic 
intracellular domains essential for activity and both N- and C-termini 
intracellularly located (Kelley Bentley and Beavo, 1992). These
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isoenzymes are subdivided into those whose activity is stimulated by 
calcium-calmodulin and those whose are not. They can also differ in their 
sensitivity to the a-subunit of Gs as well as to py-subunits.
The receptor regulated adenylate cyclase system can be considered 
as being composed of several functional units: i) a receptor which binds 
the stimulatory (eg. p-adrenoceptor) or inhibitory (eg. a 2-adrenoceptor) 
hormone or neurotransmitter, ii) G-Proteins. The stimulatory G-protein 
(Gs) or the inhibitory G-protein (Gi). The a-subunits of Gs and Gi are 
highly homologous, as expected, in the GTP binding domain but have 
divergent sequences in C-terminal regions which participate in G-protein 
receptor and effector interactions, with the Py-subunits being so similar as 
to be interchangeable, iii) the catalytic unit (C) of the enzyme which is a 
hydrophobic protein having 12 transmembrane domains with the catalytic 
site situated on the cytoplasmic side. The catalytic unit is highly conserved 
between different tissues and species as evidenced by the equipotent 
association of individual components of the system from different sources 
(Feder, et al.> 1986).
There are two proposed mechanisms whereby adenylate cyclase is 
inhibited by Gi. The first is via a direct effect of a - i  on the catalytic unit of 
the enzyme, while the second is via release of excess Py-subunits upon Gi 
dissociation which inhibits Gs dissociation and activation.
As would be expected from sequence inspection, it also appears 
that phosphorylation of a number of forms of adenylate cyclase can be 
mediated by protein kinase C (Yoshimasa, et al., 1987), although the 
regulatory function, if any, of such phosphorylation has yet to be 
established. Similarly, phorbol ester treatment of cells (Simmoteit, et al.t
1991) has also been shown to increase the incorporation of 32P into the 
catalytic unit of adenylate cyclase 5-fold, an effect again resulting in 
activation of the enzyme. Phorbol ester-mediated activation of adenylate
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cyclase, however, is not a universal observation. This might reflect current 
awareness of multiple forms of both protein kinase C and adenylate 
cyclase. Indeed, futher recent studies suggest that adenylate cyclase 
isoforms do differ in their sensitivity to phosphorylation by protein kinase 
C, with types AC-I, AC-II and AC-III being most susceptible (Jacobowitz, 
e ta l.y 1993).
1.8. G -proteins
The family of heterotetrameric guanine nucleotide-binding proteins 
play an essential role in transducing receptor mediated signals for many 
ligands. G-proteins are composed of three distinct subunits termed a  (Mr 
39 - 46 kDa), p (37 kDa) and y (8 kDa). The a-subunits have a single, high 
affinity binding site for guanine nucleotides such that when GDP is bound 
the a-subunit binds tightly to Py and is inactive. The GTP-bound form of a  
dissociates readily from py and becomes active as an effector in a given 
system. All a-subunits possess intrinsic GTPase activity, allowing 
hydrolysis of the terminal phosphate on bound GTP to return the system to 
an inactive state. To date cDNAs for 21 distinct a-subunits (the products 
of 17 genes) have been cloned.
Bacterial toxins act by virtue of their effect on G-proteins, a fact 
that has been well exploited as an experimental tool. Cholera toxin 
catalyses the transfer of the ADP-ribose moiety of NAD to a specific 
arginine residue in certain a-subunits (eg. G s). This modification activates 
these G-proteins by inhibiting their GTPase activity. Pertussis toxin ADP- 
ribosylates specific cysteine residues near the C-terminus on some a- 
subunits (eg. Gi), which prevents receptor mediated activation of these G- 
proteins.
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1.9. Phosphodiesterases.
1.9.1. Introduction and background.
Some of the oldest and best understood signal transduction 
pathways use cyclic nucleotides as second messengers. Compared with 
our understanding of cyclic nucleotide synthesis, much less is known 
about the complex regulation of degradation, despite the fact that 
phosphodiesterase activity was first identified and characterised over 
twenty years ago, almost immediately after the discovery that cyclic 
nucleotides existed in cells. It was only more recently that the occurrence 
of a large number of isoenzymes was established along with the fact that 
these were differentially expressed and regulated from cell to cell.
Cyclic nucleotide phosphodiesterases show specificity for purine 
cyclic nucleotide substrates and, as the majority o f cells are unable to 
extrude cyclic AMP, represent the only known means of lowering 
intracellular cyclic AMP and cyclic GMP levels by catalyzing their 
hydrolysis. This activity plays a crucial role in determining steady state 
cyclic nucleotide levels within cells, hence these enzymes are of interest 
therapeutically as a means of manipulating cellular function.
The development of a sensitive assay to measure phosphodi­
esterase activity (Thomson and Appleman, 1971) has facilitated advances 
in the understanding of this class of enzymes. The basis of the assay is to 
use a radioactive tracer, allowing assay of enzyme activity at subsaturating 
concentrations of substrate. An initial incubation allows sample 
phosphodiesterase to catalyse conversion of cyclic-3',5’-AMP to 5'- 
adenosine monophosphate. A second incubation uses an excess of the 
enzyme 5-nucleotidase, present in snake venom, to convert 5'-adenosine 
monophosphate to 5'-adenosine. This step allows more efficient separation 
of reaction product from unreacted substrate, making quantification more 
accurate. Separation is achieved using Dowex-1-chloride anion exchange
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resin which selectively binds the cyclic nucleotide and quantification is by 
liquid scintillation counting of the isolated product, namely [^H]5'- 
adenosine.
Phosphodiesterases are found in cytoplasmic fractions as well as in 
association with cellular membranes, these enzymes differing in their 
kinetic characteristics, substrate affinities, responsiveness to effectors and 
inhibitors and mechanisms of regulation. The fact that cyclic nucleotide 
phosphodiesterases are localized in distinct subcellular fractions in most 
cells is a feature which greatly influences both enzyme action and inhibitor 
effectiveness. As an example, differences in subcellular localization of 
phosphodiesterases in cardiac sarcoplasmic reticulum between species has 
been proposed as an explanation for the variable contractile responses to 
milrinone in different species (Weishaar, et al., 1987).
Some suggestions propose that while there can be no arguing about 
the role of phosphodiesterases in controlling cyclic nucleotide levels 
within cells they may have another, perhaps even more important role. 
Since we know that cyclic AMP and cyclic GMP turn over very rapidly in 
most cells (Goldberg, et al., 1983) and that the enthalpy associated with 
their hydrolysis is very large (10 - 14 kcal/mol) (Rudolph, et al., 1971) it 
has been proposed that this source of energy is of crucial importance in 
allowing the cell to do work. The analogy drawn is that a similarly large 
number of ATPase isoenzymes have evolved to couple the high energy of 
ATP hydrolysis to many different processes so why not a similar story for 
phosphodiesterases?
1.9.2. Nomenclature and classes.
All classes of phosphodiesterase isoenzymes are thought to be 
coded for by related but distinct members of a larger supergene family as 
they consist of highly conserved and homologous catalytic domains yet
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have multivariant regulatory (e.g. calmodulin or cyclic GMP binding) and 
functional domains.
W e still do not know precisely  how m any d ifferen t 
phosphodiesterase isoenzymes are present in most cells. At present there 
are at least 25 tentatively identified phosphodiesterase isoenzymes, a 
number that is sure to expand. Information gained using selective drugs 
and from cloning and sequencing experiments suggests that a large family 
of at least five distinct isoenzymes exists.
The classification of phosphodiesterase isoenzymes used here is 
that proposed by Beavo (Beavo and Reifsnyder, 1990) and is as follows:
Class I - Calcium / Calmodulin-dependent phosphodiesterases.
Class II - Cyclic GMP stimulated phosphodiesterases.
Class III - Cyclic GMP inhibited phosphodiesterases.
Class IV - Cyclic AMP specific phosphodiesterases.
Class V - Cyclic GMP specific phosphodiesterases.
Each of the above classes is composed of varying numbers of 
subfamilies with further subdivision of these also being necessary due to 
alternative splicing. As a guide it appears that any of the above classes are 
related to each other by approximately 15 - 20% sequence identity, the 
bulk of which occurs in one catalytically active domain. Within classes all 
enzymes show greater than 70% identity to each other (Hall, 1993).
Currently available drugs and antibodies are able to distinguish 
between the five main classes and to a lesser extent within these classes, 
although with the massive potential for therapeutic exploitation of such 
drugs more and more effort is being directed towards this goal.
Many phosphodiesterases now appear to be regulated by cyclic 
nucleotide- or Ca2+-dependent phosphorylation. In this way they represent
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a vital stage where integration of cellular responses mediated by a variety 
of signals (ie. cross-talk) can occur.
1.9.3. Structure-function relationships among cyclic nucleotide phosphodi­
esterases
The multiple intracellular phosphodiesterase enzymes listed above 
account for the total cyclic nucleotide phosphodiesterase activity measured 
in mammalian cells. The different classes can be distinguished by their 
molecular weight, substrate preference, sensitivity to drugs, amino acid 
sequence and mode of regulation. The relatively large size o f these 
isoenzymes and the complexity of their regulatory features suggest that 
m ost phosphodiesterases are composed of multiple domains. This 
multidomain character and the diversity of regulatory features provide 
intriguing questions at the molecular level and at the level of control of 
cyclic nucleotide metabolism.
The homology among different phosphodiesterase isoenzymes was 
first demonstrated by comparisons of partial amino acid sequence data 
from two m am m alian isoenzym es, the cyclic GM P stim ulated 
phosphodiesterase  and the 61kDa Ca^+/calm odulin dependent 
phosphodiesterase (Charbonneau, et al., 1986). Since these studies, the 
sequence of several different phosphodiesterase isoenzymes have been 
deduced from the nucleotide sequence of cDNA clones (Charbonneau, 
1990). The bulk of phosphodiesterases are related by bearing a 250 residue 
conserved segment representing the catalytic domain (Charbonneau, et al
1986). This conserved region appears to be a unique feature of 
phosphodiesterases since searches of sequence databases reveal no other 
proteins with significant similarities.
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1.9.4. C lass I
C alcium /calm odulin  dependent phosphodiesterases
Calmodulin-stimulated cyclic nucleotide phosphodiesterase was 
discovered in close parallel with calmodulin itself during the late 1960's 
and early 1970's (Appleman, et al., 1985). Initially a calcium stimulated 
phosphodiesterase activity was established which was in turn seen to be 
enhanced by a protein-activating factor. Subsequently, in the late 1970's 
Cheung and co-workers termed this protein-activating factor calmodulin 
(Cheung, e t a l , 1978).
This class of phosphodiesterase, the first to be purified and 
characterized, is now one of the most extensively studied and best 
characterized. A lot of attention was focussed on it simply because it was 
one of the first known functions of calmodulin (Cheung, 1980). Originally, 
it was thought that this was an enzyme of ~60kDa subunit molecular 
weight, which appeared to exist as a homodimer in the native state 
(Morrill, et al., 1979). More recently, with the advent of specific 
m onoclonal an tibodies allow ing the use o f im m unoaffin ity  
ch ro m a to g ra p h y , we know  th a t C a2+/calmodulin-stimulated 
phosphodiesterases exist as tissue specific and immunologically distinct 
isoenzymes (Rossi, et al., 1988; Sharma and W ang, 1986). Despite 
exhibiting clear differences, bovine brain and bovine heart class I 
phosphodiesterases, for example, have sequences that are almost identical, 
excepting a small insertion proximal to the N-terminus in the brain 
enzyme (Charbonneau, et al., 1986). This ratifies the fact that these, along 
with other varying forms of this class, are isoenzymes arising from 
differential splicing of mRNA.
This class of enzyme has a widespread, yet not ubiquitous, 
distribution although is generally present in very low abundance. By far 
the best source is mammalian brain, yielding approximately lOmg/kg
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tissue. In most studies the bulk of class I phosphodiesterase activity is 
cytosolic although small amounts can be found associated with particulate 
fractions (Grab, et a l., 1981). On the basis of kinetic criteria, the 
calcium /calm odulin-stim ulated phosphodiesterase isoforms may be 
divided into two general groups; a group showing high affinity for cyclic 
GMP but low affinity for cyclic AMP, and a group showing high affinity 
for both cyclic nucleotides.
A lthough these enzym es are usually  referred  to as 
Ca2+/calmodulin-stimulated it is important to note that other metal ions 
such as Mn2+, Hg2+, Pb2+ and Cd2+ can substitute for calcium in this role. 
Because of its well established signalling role calcium is considered the 
physiological metal activator; however the possibility that heavy metal 
toxicity is mediated by calmodulin has been suggested (Chao, et a l.y 
1984). In most tissues the amount of calmodulin (estimated at 22pM, for 
example, in bovine brain) is in excess of the quantity of phosphodiesterase 
(Hansen and Beavo, 1986), such that the limiting factor for stimulation is 
the concentration of free calcium. It is also interesting to note that 
phosphatidylserine (viz. protein kinase C story) has been shown to activate 
this PDE, albeit in a calcium independent manner. However, the effective 
concentration of phosphatidylserine required to stimulate the enzyme is 
above the critical micellar concentration (Gietzen, et al., 1982).
Looking at how broadly used the inhibitors of Ca2+ / calmodulin- 
stimulated phosphodiesterases are (see over) gives a clear indication of the 
importance of this particular class of enzyme (Prozialeck, 1983; Asano 
and Hidaka, 1984).
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Inhibitor Clinical Use
Trifluoperazine Antipsychotic agent
Vinblastin Antitumour agent
W7 Muscle relaxant
Vinpocetine Coronary artery relaxant
Imipramine Antidiarrheal agent
Cyclosporin Immunosuppressant.
1.9.5. Class II
Cyclic GMP stimulated phosphodiesterases
This class of enzyme was originally described in rat liver, although 
further investigation and characterization has shown it to be most 
abundant in adrenal glands (Beavo, et a l., 1970). It is named due to the 
fact that relatively low concentrations of cyclic GMP will increase the rate 
of cyclic AMP hydrolysis. It represents a potentially important point of 
interaction between two second messenger systems, namely cyclic AMP 
and cyclic GMP. In this respect it resembles the Ca2+/calmodulin- 
stimulated phosphodiesterase which impinges on calcium and cyclic 
nucleotide utilizing systems. In this class of phosphodiesterases there 
exists a tandem repeat sequence within the N-terminal portion which 
represents the site of cyclic GMP binding (Trong, et al.> 1990).
Allosteric regulation of both cyclic AMP and cyclic GM P 
hydrolysis is the main feature of this class of phosphodiesterase. 
Hydrolysis of both cyclic nucleotides displays positive co-operative 
behaviour (Yamamoto, et al., 1983). As well as being the most potent 
activator, cyclic GMP is the preferred substrate (Emeaux, e ta l ., 1981) for 
this phosphodiesterase (ie. Km cGMP (10-15pM) < Km cAM P (33- 
40pM)), although in early studies the enzyme was initially on occasion 
called 'cyclic GMP stimulated cyclic AMP phosphodiesterase'. The
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contribution of membrane and cytosolic forms to total activity has been 
found to differ significantly between tissues, soluble activity accounting 
for 80% of total in adrenal tissue, 60% in spleen, 40% in heart and 25% in 
testis (Hurwitz, eta l., 1984).
The enzym e isolated from bovine sources appears to have a 
subunit molecular weight of between 102-107kDa (Yamamoto, et al., 
1983) whilst the rat liver enzymes have smaller subunit molecular weights 
of ~67kDa (Pyne, et al., 1986). Native molecular weight determinations 
indicate that all bovine and rat forms are similar in that they exist as 
dimers.
Relatively little is known concerning the regulation of the cyclic 
GMP stimulated phosphodiesterase or its physiological role in the control 
of cyclic nucleotide metabolism in intact cells. One suggested role for this 
enzyme is being the means by which insulin lowers intracell ular cyclic 
AMP in hepatocytes (Pyne and Houslay, 1988). It is also appealing to 
suggest these enzymes represent the main cellular receptor for cyclic GMP 
and can act as a point of crossover between cyclic AMP and cyclic GMP 
metabolism, one nucleotide regulating the metabolism of the other. 
Established roles for which evidence does exist include regulation of 
cardiac calcium channels (Fischmeister and Hartzell, 1991) and regulation 
of ACTH induced aldosterone secretion in glomerulosa cells (MacFarland, 
e ta l ., 1991).
Specific inhibitors for this class of enzym es have not yet 
flourished, although AR-L57, for example, exhibits a somewhat greater 
inhibitory effect on cardiac PDE-II than on PDE-I or PDE-III (Quade, et 
al., 1984).
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L2A  Class III
Cyclic GMP inhibited phosphodiesterase
This class of phosphodiesterase was one of the first to be 
classified. It exhibited a low Km for both cyclic AMP and cyclic GMP but 
a much greater Vmax for cyclic AMP than for cyclic GMP (Appleman and 
Terasaki, 1975), such that cyclic GMP was hydrolyzed at less than 1% of 
the rate of cyclic AMP by these enzymes. Hence, they are generally 
referred to as cyclic AMP specific.
This class of phosphodiesterase have been purified from many 
tissues, such as adipose (Degerman, et al., 1987) and liver (Pyne, et al.y
1987). These enzymes are represented by single bands upon non­
denaturing gel electrophoresis, and appeared as single peaks of ~110kDa 
upon Sephadex G-200 chrom atography (Degerm an, et a l.y 1988; 
Degerman, et al.y 1987). Considering all tissues so far examined, this Mr 
value ranges from 105-135kDa, with these polypeptides in turn being 
proteolyzed to produce 30-80kDa fragments upon SDS-PAGE.
The apparent subcellular localization of the phosphodiesterase 
varies depending on the tissue, being cytosolic in human platelets 
(MacPhee, et al.y 1986) and membrane bound in rat liver (Heyworth, et 
al., 1983a). Localization also varies within tissue depending on the species 
in question, being membrane bound in humans and soluble in guinea pig 
(Reeves, eta l., 1987).
The activity of this class of enzymes may be modulated by 
hormones in, for example, liver (Heyworth, et al.y 1983a) and adipocytes 
(Degerman, et al., 1987). In platelets it is the target of many 
pharmacological agents that inhibit platelet aggregation (MacPhee, et al.y 
1986). In addition, a number of cardiotonic agents such as milrinone and 
amrinone, which act as positive inotropes, are potent and selective 
inhibitors of this class of phosphodiesterase (Harrison, et al.y 1986).
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1.9.7. C lass IV
C yclic  A M P  sp ec ific  phosphodiesterases
Initially, these were identified as activities that elute at high salt 
concentrations as the third peak of activity from DEAE-cellulose columns 
('PDE-IIT or 'low Km' cyclic AMP phosphodiesterase) and show a marked 
preference for cyclic AMP as a substrate. The best characterized inhibitor 
for this series is rolipram, such that this class is on occasion referred to as 
rolipram-sensitive cyclic AMP phosphodiesterase. It would appear that 
within this species are both soluble and membrane bound forms, 
displaying quite different subunit molecular weights. Further subdivision 
of this group has relied upon extensive purification protocols and 
improved separation methods that allow separation from the cyclic GMP 
stimulated phosphodiesterase, an activity that could serve to mask the 
presence of these isoenzymes (Reeves, et al., 1987)
Cyclic AMP hydrolysis is insensitive to concentrations of cyclic 
GMP, distinguishing these from cyclic GMP inhibited phosphodiesterases 
which are also relatively cyclic AMP specific. Purification, however, must 
account for contamination and hence, for example, chromatography of 
liver supernatant on N6-H 2N(CH2)-cyclic AMP agarose separated the 
cyclic GMP stimulated phosphodiesterase from the 'low Km' cyclic AMP 
phosphodiesterase activity which did not bind to this matrix. Further 
chromatography on Ultrogel AcA-34 separated the cyclic GMP inhibited 
phosphodiesterase from the cyclic GMP insensitive phosphodiesterase 
(Yamamoto, et al., 1984). It would appear that within this species are both 
soluble and membrane bound forms, each displaying quite different 
subunit molecular weights.
One enzyme in this class identified in rat liver membranes is 
associated exclusively with the plasma membrane (M archmont and 
Houslay, 1980) and has thus been termed the peripheral plasma membrane
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phosphodiesterase. Interestingly, it can be activated by phosphorylation 
triggered by insulin (Marchmont and Houslay, 1980).
1.9.8. Class V
Cyclic GMP specific phosphodiesterases
Cyclic GMP binding cyclic GMP specific phosphodiesterases are a 
heterogenous family o f enzymes consisting of several subgroups, 
including the widely distributed cyclic GMP stimulated cyclic nucleotide 
phosphodiesterase (Erneaux, et a l.y 1981), the retinal cyclic GMP 
phosphodiesterases in both rods and cones (Gillespie and Beavo, 1988), a 
cyclic GMP specific phosphodiesterase from dictyostelium discoideum 
(Dicou and Brachet, 1980) and cyclic GMP specific phosphodiesterase in 
lung (Francis, et al.y 1980) and platelets (Hamet, et al.y 1984). Indeed, the 
cyclic GMP specific phosphodiesterases represent a major portion of 
phosphodiesterase activity in mammalian heart, liver, adipose tissue and 
adrenal gland.
These phosphodiesterases exhibit high specificity for cyclic GMP 
with, for example, bovine lung cyclic GMP specific phosphodiesterase 
hydrolysing cyclic AMP at a rate which is approximately 100 times slower 
than the hydrolytic rate for cyclic GMP (Francis, et al.y 1980). In addition 
to their high specificity for cyclic GMP over cyclic AMP, class V 
phosphodiesterases are related by several other common features. These 
include, noncatalytic cyclic GMP binding sites of relatively high affinity 
and unknown function, similar catalytic subunit size and association into 
dimers, micromolar Km values for cyclic GMP and submicromolar Ki 
values for inhibition by dipyridamole, a relatively specific inhibitor of this 
class of enzymes.
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1.9.9. T issue distribution.
Examination of the tissue distribution of individual isoenzymes 
have revealed that there are marked regional differences in the distribution 
of phosphodiesterase isoenzym es, with some isoenzym es being 
widespread and others having only limited distribution. The type Vbi 
isoenzyme, for example, is only present in high concentration in the outer 
segments of retinal rod cells where it is involved in photoreceptor 
responses (Hurwitz, et a l., 1985). Conversely type III isoenzymes are 
found as physiologically important enzymes in heart, platelets, smooth 
m uscle, ad ipocy tes and liver (H all, 1993). In ad d itio n , 
compartmentalization within tissues is viewed as a means to explain 
discrepancies amongst published results.
1.9.10. Inhibitors
Having used methylxanthines for decades to treat asthma, only in 
1962 did Butcher & Sutherland discover their mechanism of action. 
Naturally this stimulated a great deal of enthusiasm as regards the possible 
therapeutic potential of such drugs. Unfortunately the ensuing research 
provided few therapeutically effective drugs. Recent advances however, 
have rekindled interest such that development of selective inhibitors 
remains an active area of research and indeed pharmaceutical companies 
have been rewarded with several drugs exhibiting selectivity for individual 
phosphodiesterases. Such drugs have been exploited as smooth muscle 
relaxants (especially blood vessels), cardiotonic agents, antithrombotic 
compounds and antidepressants. By far the most established are type III 
inhibitors, reflecting the pharmaceutical industries interest in identifying 
novel positive inotropic agents.
Since the phosphodiesterase isoenzyme(s) of physiological 
importance in controlling tissue cyclic nucleotide content vary in different
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tissues, it follows that useful inhibitors must almost always be at least 
partially selective. If this is achieved however, the potential benefits of 
such selectivity are enormous.
1.9.11. Functional significance and pharmacological implications of 
multiple isoforms.
Given our current knowledge of phosphodiesterase isoenzymes an 
obvious question to ask would be what is the functional significance of 
there being so many isoenzymes responsible for cyclic nucleotide 
degradation? Evidence to date suggests that many of the isoenzymes are 
differentially expressed in selected cells and that they are crucial for 
function of that particular cell. Another possible reason for such diversity 
is to allow for differential regulation of individual isoenzymes by discrete 
signalling processes. In addition, individual forms may respond at 
different rates, allowing for short and long term effects in response to one 
signal.
1.9.12. Summary and conclusions.
Much more information is needed to rationalise the exact number 
of different isoenzymes in the supergene family. Only when this is 
accomplished and their characterization complete will we fully understand 
the regulation of cyclic nucleotide degradation in cells by these enzymes. 
Even more importantly, it remains to be established exactly which 
isoenzyme genes are translated and expressed in individual cells, a 
potentially important factor in drug tissue selectivity. The existence of a 
large number of phosphodiesterase isoenzymes and their differential 
expression does however create scope for precise and even cell specific 
regulation of intracellular cyclic nucleotide levels.
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The wealth of information discussed above will hopefully highlight 
the fact that cyclic nucleotide phosphodiesterases provide one of the main 
mechanisms for integrating, at an intracellular level, the control of 
multiple signals that may regulate a particular cellular response. This 
important feature of cell signalling is now being appreciated and the 
contribution of phosphodiesterases should not be understated.
1.10. Influence of insulin on cyclic AMP metabolism
Insulin has been shown in various tissues and cell culture systems 
to influence intracellular cyclic AMP concentrations. This includes 
evidence for its modulation at the level of the receptor, G-protein, 
adenylate cyclase catalytic subunit and cyclic AMP phosphodiesterase.
1.10.1. Insulin's m odulation o f  adenylate cyc lase
Whilst insulin cannot modify unstimulated cyclic AMP levels in 
intact hepatocytes (Pilkis, 1970) it is well established that insulin can 
lower cyclic AMP levels which have been previously raised by another 
hormone. This effect has been suggested to be mediated by an inhibitory 
effect on adenylate cyclase (Heyworth and Houslay, 1983) and by an 
activation of cyclic AMP phosphodiesterase (Beavo, 1990). Insulin was 
shown to inhibit adenylyl cyclase (Heyworth and Houslay, 1983). The 
GTP dependent nature of this inhibitory effect, its toxin sensitivity and its 
abolition by glucagon desensitization suggest involvement of a G-protein 
(Heyworth, et al., 1986; Houslay, 1990). This suggests that insulin exerts 
its action on adenylate cyclase via a G-protein. Insulin treatment of cells 
has also been reported to stimulate a high affinity GTPase in human 
platelets (Gawler and Houslay, 1987). Evidence such as this clearly 
suggests an interaction of the insulin receptor with the G-protein system. 
Finally, insulin has been shown to phosphorylate and attenuate functioning
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of the p-adrenoceptor in smooth muscle cells (Hadcock, et al., 1992) 
whilst insulin treatment of leukocytes acutely increases the number of cell 
surface p-adrenoceptors (Sager, e ta l., 1990).
1.10.2. Insulin's control of phosphodiesterase activity
One potential mechanism for the anti-lipolytic actions of insulin in 
adipose tissue (Steinberg, et al., 1975) and its anti-glycogenolytic actions 
in liver (Denton, et al., 1981) is its ability to decrease cyclic AMP levels 
by stimulating the activity of a 'low Km1 cyclic AMP and cyclic GMP 
hydrolysing particulate phosphodiesterase activity that was inhibited by 
cyclic GMP and cilostamide (Schmitz-Peiffer, et al., 1992). Evidence for 
insulin regulation of phosphodiesterase activity was established in 1985 
(Beebe, et al., 1985). Here Beebe et al. showed that insulin could 
selectively antagonize the lipolytic glycogenolic actions of a variety of 
analogues of cyclic AMP, and this correlated with the ability of these 
analogues to serve as phosphodiesterase substrates, insulin antagonizing 
the action of those which were readily hydrolysed. In hepatocytes, for 
example, insulin can decrease cyclic AMP levels which are elevated by 
previous challenge with glucagon (Heyworth, et al., 1983). Subsequently, 
others have also concluded that the anti-lipolytic effect of insulin in human 
adipocytes requires phosphodiesterase activation (Lonroth and Smith, 
1986; Kather and Scheureer, 1987).
In hepatocytes three phosphodiesterase subtypes are known to be 
activated by insulin and whilst the molecular basis of this is uncertain, the 
activation of a 52kDa plasma membrane phosphodiesterase is thought to 
be achieved by tyrosyl phosphorylation (Pyne, et al., 1989). Further 
investigation has revealed that insulin regulates at least two other 
phosphodiesterases in liver, both of which are membrane bound. The 
peripheral plasma membrane phosphodiesterase is activated by insulin
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(Marchmont and Houslay, 1980) and belongs to the type IV cAMP 
specific, cGMP insensitive class of phosphodiesterase. Dense vesicle 
phosphodiesterase activity is also raised by insulin, this enzyme belonging 
to the type III cGMP inhibited cAMP phosphodiesterase class (Heyworth, 
et a l., 1983). A similar increased cyclic GMP inhibited cyclic AMP 
phosphodiesterase activity is also seen in platelets in response to insulin. 
This was due to insulin induced serine phosphorylation of the enzyme 
(Lopez-Aparicio, et a l., 1992). As expected, therefore, the insulin 
stimulated protein kinase involved did not absorb to anti-phosphotyrosine 
antibodies (Lopez-Aparicio, et al., 1992).
1.11. The role of p ro te in  kinase C in the control of cyclic AM P 
metabolism.
1.11.1.  Introduction
The interaction of protein kinase C with components of the cyclic 
AMP metabolizing system has been documented in many instances and 
current knowledge is summarized below. The level of importance this has 
in regulating endogenous intracellular cyclic AMP levels is still uncertain.
1.11.2. Interaction with inhibitory G-proteins
Phosphorylation of purified 'Gi' by protein kinase C has now been 
shown to occur in vitro (Katada, et al., 1985) but only when in its 
holomeric, GDP-bound state (O'Brien, et al., 1987). This suggests that 
phosphorylation may serve to stabilize the inactive, GDP-bound form of 
Gi. Indeed, work in hepatocytes (Bushfield, et al., 1990) shows that the 
rate of Gi-2 phosphorylation closely matches the rate of loss of Gi 
function. Further supporting this theory is work showing that ADP- 
ribosylation of a-Gj, which can only occur on the GDP-bound holomeric
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form, was significantly increased in cells pre-treated with phorbol ester for 
15 minutes (Choi and Toscano, 1988).
Inactivation of Gj as a mechanism of phorbol ester mediated 
sensitization of adenylate cyclase was first proposed by Jakobs and co­
workers (Katada, et al., 1985). Such a mechanism is supported by work 
where pertussis toxin treatment of cells, to inactivate Gi, results in 
potentiation of the capacity of stimulatory hormones to activate adenylate 
cyclase, presumably via removal of a 'tonic' inhibitory input (Bushfield, et 
a l ., 1990; Senogles, et a l., 1990). In all studies documented, the 
augmentation in hormonal stimulation of adenylate cyclase caused by 
phorbol esters was of similar magnitude to the potentiating effects of 
pertussis toxin (Abou-Samra, et al.t 1987). Perhaps more importantly the 
effects of phorbol esters and pertussis toxin were not additive, suggesting 
a similar target for action in each case, namely inactivation of Gi.
It must be stated that the ability of phorbol esters to elicit the 
phosphorylation of Gi is not a ubiquitous phenomenon. Speculation as to 
why this is so could be that a particular isoform of protein kinase C is 
required, that Gi-2 is present principally in a dissociated state and is 
therefore a poor substrate or that cell specific co-factors are needed for 
protein kinase C and Gi-2 to interact productively.
1.11.3. Interaction with the catalytic subunit of adenylate cyclase
Protein kinase C has been shown to phosphorylate adenylate 
cyclase, conferring a 'sensitization' on the enzyme, with enhanced GTP-, 
N a(A l)F-, PG E i- and isoprenaline-stim ulated activity observed 
(Jacobowitz, et al., 1993). The extent of such an effect varied between 
subtypes of adenylate cyclase, with the effect on the type 2 enzyme being 
most pronounced (Jacobowitz, et al., 1993). Treatm ent of purified
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adipocyte plasma membranes with purified protein kinase C has also been 
shown to magnify adenylate cyclase activity (Nagshineh, etal., 1986).
As discussed above, there is the possibility with such an 
observation that the 'sensitizing' effect of protein kinase C on adenylate 
cyclase in cells is due to withdrawl of a 'tonic' inhibitory input from Gi. 
Reconstitution of the purified enzyme with Gs seems the logical step to 
determine if this is so.
Once again, phorbol-ester mediated activation of adenylate cyclase 
is not a ubiquitous observation and may reflect differences in sensitivity of 
adenylate cyclase isoforms as well as the complement of protein kinase C 
isoforms in the cells studied. After treating NIH3T3 cells with phorbol 
ester, the fact that y-PKC has a facilitatory and a-PKC an inhibitory effect 
on forskolin stimulated cAMP levels (Gusovsky and Gutkind, 1990) 
highlights again how the protein kinase C isoform complement in a given 
cell is of crucial importance.
1.11.4. Interaction with cy c lic  A M P phosphodiesterases
Treatment of hepatocytes with phorbol esters is known to 
potentiate glucagon stimulated increases in cyclic AMP. This effect is 
abolished, and in fact reversed, in the presence of IBMX (Irvine, et al., 
1986). This sensitizing action seems to be due to protein kinase C 
activation and therefore possibly phosphorylation and inhibition of cyclic 
AMP phosphodiesterase activity. Phorbol ester induced potentiation of 
hormone stimulated increases in intracellular cyclic AMP concentrations 
due to phosphodiesterase inhibition has since also been shown in anterior 
pituitary cells (Abou-Samra, et al., 1987).
Despite the abtruse nature of the above experiments they clearly 
demonstrate the profound effects that activation of protein kinase C has on 
intracellular cyclic AMP concentrations.
58
Figure 1.1. An introduction to signal transduction
Depicted in this diagram are some of the major cellular signal 
transduction systems. In addition, some of the agonists which act via these 
systems are also listed.
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Figure 1.2. Structure of the insulin receptor
Shown in this figure is a diagrammatic representation of insulin 
receptor structure.
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Table 1.1. The protein kinase C family
Characteristics of subspecies within the protein kinase C family are 
detailed here. Calculated molecular masses are from the cDNA sequence, 
apparent molecular masses are estimated from SDS-PAGE. Information 
taken from the following references, (Kikkawa, et al., 1989; Hug and Sarre, 
1993; Nishizuka, 1988).
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Figure 1.3. Structure and function of the pseudosuhstrate region of 
protein kinase C
The proposed mechanism for autoinhibition of protein kinase C by 
the pseudosubstrate region is highlighted. Also listed are the amino acid 
sequences in the pseudosubstrate region for various protein kinase C 
isoforms.
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Serine substitution here generates a functional substrate
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C hapter 2 
M ethods and m aterials
2.1. Methods
2.1.1. Assay of intracellular cyclic AMP concentration.
2.1.1.1. Introduction.
The receptor protein binding displacement assay was used to 
determine intracellular cyclic AMP concentration in cells. It is based on 
competition for protein binding sites between radiolabelled cyclic AMP 
and the unlabelled cyclic AMP to be quantified. This can be considered as 
a radioimmunoassay like system where antibody is replaced by binding 
protein. Use of a naturally occurring binding protein preparation (usually a 
crude preparation of the regulatory subunit of cyclic AMP dependent 
protein kinase) which interacts with cyclic AMP with high affinity results 
in a comparatively simple, but highly sensitive and specific assay. The 
method used here is essentially a modification of those developed by 
Gilman (Gilman, 1970) and Brown et al. (Brown, e ta l ., 1972).
2.1.1.2. Preparation of cyclic AMP binding protein.
This procedure was carried out essentially as described by Brown 
et al. (Brown, eta l., 1972). Briefly, bovine adrenal glands (approximately 
30) were obtained and transported to the laboratory on ice. After removal 
of excessive fat, the glands were hemisected and the medulla removed. 
Cortical tissue was then scraped from the gland capsule, pooled and 
transferred into a pre-cooled Waring blender along with 1.5 volumes of ice 
cold homogenization buffer (0.25M sucrose, 25mM KC1, 5mM MgCl2 and 
50mM Tris HC1, pH 7.4). After homogenization at maximum speed the 
tissue was transferred to centrifuge tubes on ice and centrifuged at 2000g 
for five minutes at 4°C. The supernatant was decanted then re-centrifuged 
at 6000g for 15 minutes at 4°C and the final supernatant fraction pooled, 
aliquoted as a homogenous mixture and stored at -20°C until use.
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2.1.1.3. Sample preparation.
Chinese hamster ovary cells were grown to confluence in 6-well 
plates under conditions described in Section 2.1.15, at which stage they 
were used for experimental purposes and numbered approximately 1 
million cells per well. Wells were prepared such that they contained a final 
volume of 0.5ml Ham's F12 medium upon addition of any ligands at the 
desired concentration and for the desired time. Note that ligands were 
prepared in medium and added in a volume not exceeding 10% of the total 
incubation volume.
After stimulation of the cells, as detailed in legends for individual 
experiments in Chapter 5, medium was aspirated and cyclic AMP 
extracted in 2% (w/v) ice-cold perchloric acid (250pl per well). After an 
incubation on ice for between 15-30 minutes, each well was thoroughly 
scraped to disturb the cell monolayer. A high degree of efficiency at this stage was 
obtained and ensured by monitoring cell number under a microscope. The 
contents of each well were then centrifuged at 13 OOOg for two minutes at 
4°C. The supernatant fraction was neutralized with 0.5M triethanolamine 
in 2M KOH using universal indicator. The precipitate at this stage was 
pelleted by centrifuging as above and the supernatant fraction used as 
sample for the binding protein assay.
2.1.1.4. Assay procedure for intracellular cAMP determination
The incubation buffer used in the assay was 50mM Tris HC1, pH
7.4. containing 4mM EDTA. Using this, various dilutions (0-320 
pmols/ml) of unlabelled cyclic AMP were prepared giving corresponding 
values in the assay of 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 
pmol/50pl. These were used to prepare a standard curve for unknown 
cyclic AMP determination by incubating with a fixed concentration of
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labelled cyclic AMP and binding protein, also used for unknown samples 
as shown below.
[5',8-^H]-cAMP was diluted in assay buffer to give approximately 500 000 
cpm/ml. Binding protein was diluted 1:30 in assay buffer for use. Samples 
were then set up as shown below:
Sample Buffer 3H-cAMP Bind.
Background - 200pl lOOpl -
Total bound - lOOpl lOOpl lOOpl
Standards 50pl 50pl lOOpl lOOpl
Unknowns 5-50fil 95-50pl lOOpl lOOpl
The incubation was commenced by the addition of binding protein, hence 
this was always added last. Samples were mixed then allowed to reach 
equilibrium by incubation at 4°C for two hours. At this time the reaction 
was terminated by adding 250pl of a well mixed suspension of 2% (w/v) 
Norit-GSX charcoal and 1% (w/v) BSA in ice-cold assay buffer. Tubes 
were rapidly vortexed then centrifuged for 4 min at 13 OOOg and 4°C to 
sediment the charcoal containing cyclic AMP which had not bound to binding 
protein during the incubation. 0.3ml of each supernatant was taken for 
counting, incorporating a purpose-designed curve fitting programme 
which allowed quantification of unknown cyclic AMP values.
2.1.2. Phosphodiesterase assay
This assay is essentially based on that originally described by 
Thomson and Appleman (Thomson and Appleman, 1971).
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2.1.2.1. Preparation of reagents
- 3', 5' cyclic AMP: Prepared at a concentration of lOmM in 20mM Tris 
HC1 pH 7.4 containing 5mM M gCh and frozen as stock. A lpM solution 
was freshly prepared on the day of each assay. Note, M g2+ ions are 
required as an essential co-factor for phosphodiesterase activity.
- 3', 5' [8-3H] cyclic AMP: Added to give approximately 100 000 d.p.m. 
per tube.
- Hannah ophiophagus snake venom: Stock solution of 10 mg/ml prepared 
in distilled water and frozen. Diluted to 1 mg/ml using distilled water for 
use in assay.
- Dowex 1-chloride: lOOg of Dowex 1-chloride resin was washed in 1M 
NaOH for 15 minutes after which it was extensively washed with 
deionized water until the pH of the eluate fell to 7.0. The resin at this stage 
was then washed further in 1M HC1 for 15 minutes followed by yet more 
extensive washing until the pH of the eluate was between 4.0 and 5.0. For 
use in the assay 2 parts of Dowex slurry (Dowex:water 1:2) was mixed 
with 1 part ethanol. Ethanol is used to prevent non-specific binding of 
labelled adenosine to Dowex and to inhibit adenosine deaminase (often 
present in samples) converting adenosine to inosine, which does bind to 
Dowex.
- Samples were all prepared from CHO cell clones. The following 
procedure was always followed: Cells were split upon reaching confluence 
into the desired number of Corning 75cm cell culture flasks at a dilution of 
1:6. Two days later cells were ~80% confluent and were fed again with 
fresh medium in the evening. The following morning cells were treated 
with ligand (same evening in the case of TPA down-regulation) as 
indicated, if at all. Subsequently, medium was aspirated and ice cold 
homogenization buffer (lOmM Tris HC1 pH 7.5, O.lmM EDTA and 
protease inhibitor cocktail (2.5mM benzamidine, 0.2mM PMSF, lpg/ml
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antipain, lpg/ml leupeptin and lpg/ml pepstatin A)) was added. Cells were 
scraped into this medium and pelleted by centrifugation at 13 OOOg (4°C). 
At this stage pellets were frozen at -80°C. On day of assay pellets were 
thawed and resuspended in homogenization buffer to give required protein 
concentration (see Section 2.1.2.2). Disruption of cells was completed by 
homogenization with 15 strokes in a glass ground hand driven tissue 
homogenizer.
2.1.2.2. Assay procedure for phosphodiesterase activity determination
At 4°C, 25pl of enzyme sample (containing ~30pg of protein) was 
added to 25pl of 20mM Tris HC1 pH 7.4 containing 5mM MgCl2, which 
contained any inhibitory drugs to be used at four times the desired final 
concentration. Blanks, containing 50pl of Tris/Mg2+ buffer only, were 
incorporated in every assay. To this, 50jil of ^H-cyclic AMP was added. In
0 t
all results shown a cold cyclic AMP concentration of lpM  was used. 
Tubes were mixed then incubated at 30°C for 10 minutes. Samples were 
boiled immediately for two minutes and allowed to cool to 4°C again. 
Boiling term inates the initial reaction by com pletely inactivating 
phosphodiesterase activity. 25pg (25pl of 1 mg/ml solution) of snake 
venom was added, and tubes incubated again at 30°C for 10 minutes 
before addition of 400pl Dowex. Note, Dowex was kept well stirred 
during use to ensure a homogenous suspension. Tubes were mixed well 
and left to stand for 15 minutes then vortexed again before sedimenting 
the Dowex resin by centrifugation at 13 OOOg using a bench-top 
microcentrifuge. A 150pl aliquot of the resulting supernatant was added to 
3ml of scintillation fluid for counting.
67
2.1.2.3. Calculation of results.
Correct c.p.m. per sample was calculated by subtracting the blank 
value in each case. This is necessary as it is generally found that 2-5% of 
tritiated cyclic AMP does not bind to the Dowex resin. Determining the 
protein content of each sample allowed results to be expressed relative to 
protein content of each sample. Finally, specific activity in each case was 
calculated as pmol/min/mg protein.
2.1.3. Purification of human insulin receptors
2.1.3.1. Preparation of human placental membranes
To lim it proteolysis, all experim ental m anipulations were 
performed at 4°C and all buffers contained 0.2mM PMSF and 2.5mM 
benzamidine. Normal placentae were obtained immediately after delivery 
and kept on ice. Each placenta was trimmed of amnion and chorion, cut 
into small pieces, washed with 1 litre of ice-cold homogenization buffer 
(50mM Hepes pH 7.6, 0.25M  sucrose) and then resuspended to 
approximately 750ml using this buffer. Hom ogenisation was then 
performed for 1.5 minutes (30 sec low speed, 1 min high speed) using an 
Ato-mix homogeniser (MSE). The homogenate was then filtered through 
one layer of nylon netting to remove most of the fibrous tissue before 
further homogenisation for 1.5 mins using a polytron homogeniser at 
setting 7. This homogenate was centrifuged at 600g for 10 minutes and the 
resulting supernatant fraction centrifuged at 10 OOOg for 20 minutes. 
Whilst stirring on ice the supernatant from this step was adjusted to 0.1M 
NaCl and 0.2mM MgSC>4 and centrifuged at 50 OOOg for 1 hour to pellet 
the membranes, which were then washed twice by resuspension (~300ml) 
in 50mM Hepes pH 7.6 and centrifuged as before. Finally, the membranes 
were resuspended to approximately 20mg of protein per ml in 50mM
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Hepes pH 7.6, lpg/ml pepstatin A, lpg/ml leupeptin, lpg/ml antipain and 
were either solubilized immediately or flash-frozen in liquid N2 until use.
2.1.3.2. Solubilization of insulin receptors from human placental 
membranes
The resuspended placental membranes were solubilized using the 
non-ionic detergent Triton X-100. Membranes were stirred for 1 hour at 
4°C with 1% (w/v) Triton X-100 and then centrifuged at 150 OOOg for 1 
hour at 4°C. The supernatant, containing approximately 95% of the insulin 
binding activity, termed crude placental extract, was flash-frozen as small 
aliquots (normally 30jj1) in liquid N2 and stored at -70°C until use.
2.1.3.3. Immunopurification of insulin receptor from crude placental 
extract
Having previously determined the ratio of crude placental extract 
to immunoadsorbent that was sufficient to barely saturate the insulin 
receptor binding sites on the immunoadsorbent, 0.4mg of cellulose/0.1 mg 
of antibody were used per ml of crude placental extract. (O'Brien, et al., 
1986) All operations were performed at 4°C. Immunoadsorbent was pre­
washed three times with 50mM Hepes pH 7.6, 1M NaCl, 10% (v/v) 
glycerol and 0.1% (w/v) Triton X-100, using 1ml of buffer per mg of 
cellulose in immunoadsorbent. A further three washes (again 1 ml/mg 
cellulose) with 50mM sodium acetate pH 5, 1M NaCl, 10% (v/v) glycerol 
and 0.1% (w/v) Triton X-100 were followed by a final two washes with 
25mM Hepes pH 7.6, 10% (v/v) glycerol and 0.1 % (w/v) Triton X-100. 
Each step required centrifugation at 2500g for 3 minutes to pellet the 
immunoadsorbent before resuspension in the subsequent buffer. The 
immunoadsorbent was then resuspended in crude placental extract (2ml 
and 10ml, respectively, were used) and rotated end-over-end for 1 hour.
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The immunoadsorbent was then washed six times with 50mM Hepes pH
7.6, 1M NaCl, 10% (v/v) glycerol and 0.1% (w/v) Triton X-100. The 
immunoadsorbent was then resuspended in 750 pi of this buffer including 
0.2mM PMSF, 2.5mM benzamidine, lpg/ml pepstatin A, lpg/ml leupeptin 
and lpg/ml antipain. Protein concentrations were assayed directly by 
Lowry assay (Section 2.1.14.2).
2.1.3.4. Preparation of immunoadsorbents
Anti-insulin receptor monoclonal antibodies were partially purified 
from ascites fluid by precipitation with 40% (NH4)2S04 and then coupled 
to aminocellulose by diazotisation (Hales and Woodhead, 1980). The 
resulting immunoadsorbents, usually containing 200-300pg protein per mg 
of cellulose, were resuspended to 5mg/ml cellulose. For use in the studies 
presented here, immunoadsorbents were kindly provided by Dr M. Saville.
2.1.4. 1251 - insulin binding to solubilized insulin receptors
The insulin binding activity of the Triton X-100 extracts and 
purified receptors was measured by incubating the receptor preparations 
for 16-20 hours at 4°C with [125I]-insulin (50pM) in 75 mM Tris HC1 pH
7.8, 30mM NaCl, 0.5mM EDTA, O.lmM PMSF, lOmM glucose, 0.1% 
(w/v) dialysed BSA, 0.05% (w/v) Triton X-100 in a total volume of 200pl. 
Receptor bound radioactivity was separated from free insulin by the 
polyethylene glycol precipitation method of Cuatrecasas (Cuatrecasas, 
1972), which selectively precipitates the high molecular weight receptor - 
[125I]-insulin complexes. Ice-cold carrier human gamma globulin 
(0.625mg in 500pl of 0.05M sodium phosphate buffer pH 7.4) and 
polyethylene glycol 6000 (500pl, 25% (w/v) in distilled water) were added 
with thorough mixing. After 10-15 minutes on ice the samples were 
centrifuged at 1700g for 30 minutes at 4°C and the pellets were washed
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once with 9% (w/v) polyethylene glycol containing 0.05% (w/v) Triton X- 
100. Nonspecific binding was determined by addition of buffer only to the 
incubations. This gave similar values to binding in the presence of sample 
and 5pM insulin (less than 7% of total precipitated counts). Specific 
binding was calculated as the difference between total and non-specific 
binding.
2.1.4.1. Calculation of insulin binding activity
Human placental membranes were prepared and solubilized as 
described above. A sample of crude placental extract was used to construct 
a two-fold dilution series to which specific [125I]-insulin binding was 
assayed, again as described above. Total insulin binding activity 
(expressed as arbitrary units) was calculated as the product of the total 
placental extract volume (in this case 42ml) and the reciprocal of the 
sample dilution required to bind 5% of the counts added in the assay (in 
this case 185).
2.1.5. Kinase activity of purified human insulin receptor
Partially purified placental insulin receptors (10pl of a 10 fold 
dilution of preparation described in Section 2.1.3 (equivalent to 21ng per 
incubation)) were preincubated for 30 minutes at 4°C in a final volume of 
30pl containing 50mM Hepes pH 7.6, 0.1% (w/v) Triton X-100, 0.2mM 
sodium vanadate, 2mM dithiothreitol and 13.3nM insulin unless otherwise 
stated. In experiments where the receptor was pre-activated, this was 
achieved by incubating the receptor at this stage with lOfil lOOmM Hepes 
pH 7.6, 20mM MgCl2, 8mM M nCh and ImM 'cold' ATP for 15 minutes 
at 23°C. The assay reaction was initiated by the addition of lOpl of 
100mM Hepes pH 7 .6 ,20mM M gCh, 8mM MnCfe and ImM [y-32P]-ATP 
(0.5-2pCi), giving a final ATP concentration of 250|iM. After incubation
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at 23°C for the desired time the reaction was terminated by addition of 
20jxl of 0.19M Tris HC1 pH 6.8, 6% (w/v) SDS, 30% (v/v) glycerol, 15mM 
EDTA, 300mM DTT and 0.02% (w/v) bromophenol blue with immediate 
boiling for 5 minutes. These samples were subsequently analysed by 
electrophoresis in 7.5% SDS-PAGE gels which were then stained, dried 
and the p-subunit located by autoradiography. Results were quantified by 
excision of a gel chip corresponding to the desired band and determination 
of 32P by Cerenkov counting as well as by scanning densitometry.
2.1.6. Phosphorylation of the purified inhibitory guanine nucleotide 
binding protein Gi
This method, based on that of O'Brien et a l  (O'Brien, et al., 1987), 
consists of several pre-incubation stages for various reagents which are 
then added together to initiate the phosphorylation reaction. Purified G- 
protein used in these experiments, prepared by a series of chromatographic 
steps as described previously (Milligan and Klee, 1985) was a gift from Dr 
E. Tang. Pre-incubation mixture 1 was a total volume of 20pl and 
contained purified receptor (20ng/assay), together with 24nM MgCl2, 
4mM MnCl2, 0.2mM NaV03 and 2mM dithiothreitol in the presence or 
absence of lOnM insulin and was incubated for 15 minutes at 23°C. Pre­
incubation mixture 2 was 10pl of the purified G-protein plus 5mM MgCl2 
and was incubated for 10 minutes at 32°C. Both of these mixtures were 
mixed and incubated for a further 10 minutes at 23°C. Phosphorylation 
was commenced by adding lOpl of 0.4mM [y-^2P]ATP (0.5-2pCi) which 
was then incubated for various time periods, up to 60 minutes, at 23°C. 
Reactions were stopped and samples analysed as in Section 2.1.5.
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2.1.7. Phosphorylation of the peptide IRft by the immobilised insulin 
receptor
This procedure is based on that published by Shoelsen et al. 
(Shoelsen, et al., 1988). Partially purified placental insulin receptors (5pl 
of a 10 fold dilution of preparation described in Section 2.1.3 (equivalent 
to l in g  per incubation)) were pre-incubated for 30 minutes at 4°C in a 
final volume of 10pl containing 50mM Hepes pH 7.6, 0.1% (w/v) Triton 
X-100 and 13.3nM insulin unless otherwise stated. In experiments where 
the receptor was pre-activated, this was achieved by incubating the 
receptor at this stage with 10pl lOOmM Hepes pH 7.6, lOmM MnCl2 and 
25pM 'cold' ATP for 10 minutes at 23°C. Otherwise the same volume of 
this buffer lacking ATP was added instead. The peptide IRp 
(TRDIYETDYYRK) was used at a final concentration in the assay of 
0.33mM. The reaction was initiated by the additdon of lOpl of the peptide 
in lOOmM Hepes pH 7.6, containing 25pM [y-^2P]-ATP (0.5-2pCi per 
assay). The reaction was stopped by adding 60pl of 5% (w/v) TCA, 1% 
(w/v) BSA, incubating for 30 minutes at 4°C centrifuging at 13000g for 5 
minutes and applying 50pl of the resulting supernatant to 2x2cm squares 
of Whatman P81 phosphocellulose paper which were washed four times 
(15 minutes each) in 75mM phosphoric acid, rinsed in acetone, then dried 
and added to 3ml scintillant. Phosphate incorporation was determined by 
Cerenkov counting.
2.1.8. SPS-PAGE electrophoresis and immunoblotting of proteins
Immunoblotting combines the resolution of gel electrophoresis 
with the specificity of immunochemical detection. It can be summarized in 
six major steps;
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a. Preparation of the antigen sample.
Samples, normally containing lOOpg total protein, were mixed with 
an equal volume of x2 sample buffer and boiled for three minutes prior to 
loading onto SDS-PAGE gels.
b. Resolution of the sample by gel electrophoresis.
This procedure was carried out essentially as decribed by Laemmli 
(Laemmli, 1970). Since protein transfer will be better for low percentages 
of acrylamide and cross-linker as well as for thin gels, the lowest 
percentage of acrylamide giving the desired resolution and gels of -0 .4  
mm thickness should ideally be used. Resolving gels and subsequently 
stacking gels were cast, whereupon samples were loaded and gels run 
either at 60mA per gel for 2.5 hours or 6mA per gel overnight. At this 
stage gels were either stained, de-stained and dried for analysis or used for 
blotting as described below.
c. Transfer of the separated polypeptides to a membrane support.
Nitrocellulose is the most commonly used membrane. Electro­
phoretic elution was the method by which protein transfer was carried out. 
Each blot required one sheet of nitrocellulose paper and two sheets of 
absorbent filter paper cut to the size of the gel. As shown in Figure 2.1, the 
immunoblot apparatus was set up tightly in the following order; gel, 
membrane, filter paper and support pad sandwich. This was thoroughly 
soaked in blotting buffer, care being taken to exclude air bubbles. This 
sandwich was immersed in the transfer tank with the membrane closest to 
the positive electrode. Protein was transferred for two hours at 1mA with 
cooling.
Staining with ponceau S was often used at this stage to visualize 
proteins transferred onto nitrocellulose. Ponceau S was applied as a 0.2% 
(w/v) solution in 0.3% (w/v) trichloroacetic acid. Using PBS, blotting 
buffer was washed from nitrocellulose which was then shaken in ponceau
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S solution for approximately 1 minute. Nitrocellulose was washed briefly 
with PBS and proteins visualized. Ponceau S solution was washed off with 
blotting buffer followed by PBS and then the membrane was processed as 
normal.
d. Blocking nonspecific binding sites on the membrane.
It is essential at this stage to prevent nonspecific binding of 
immunological reagents to the membrane, hence the reason for blocking 
with protein detergent solution. In this case non-fat dried milk and donkey 
serum were chosen to provide clean backgrounds. Therefore, the 
membrane, rinsed several times with PBS, was added to blocking solution 
and incubated at room temperature for two hours with agitation.
e. Addition of antibody.
Nitrocellulose paper was removed from the blocking solution and 
rinsed three times for 15 mins with PBS / 0.05% (v/v) NP40. The first 
antibody solution was added to the nitrocellulose and incubated overnight 
at room temperature with agitation.
f. Secondary antibody detection system.
Nitrocellulose was removed from the first antibody solution and 
washed three times for 15 minutes in PBS / 0.05% (v/v) NP40. The second 
antibody solution was then added and incubated at room temperature, with 
shaking, for two hours.
g. Enhanced chemiluminescence detection system.
This system is summarized in Figure 2.2. In essence this is a light 
emitting non-radioactive method for detection of immobilized specific 
antigens, conjugated directly or indirectly with horseradish peroxidase- 
labelled antibodies. After treating blots, results were visualized by a short 
exposure to blue-light sensitive autoradiography film.
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2.1.8.1. Buffers associated with SDS-PAGE electrophoresis and Western
blotting.
- x2 sample buffer:
0.5M Tris HC1 pH 6.8 1.25ml
Glycerol 1.25ml
10% (w/v) SDS 2.00ml
p-mercaptoethanol 0.25ml (added on day of use)
Distilled H20  0.25ml
Bromophenol blue 0.2% (w/v)
- Resolving gel mixtures: 8%
Distilled H20  11.6ml
30% (w/v)Acrylamide / 6.7ml
0.8% (w/v) Bis Acrylamide
1.5M Tris HC1 pH 8.8 6.3ml
10% (w/v) SDS 0.25ml
10% (w/v) APS (prepared fresh) 0.25ml
TEMED 0.015ml
- Stacking gel mixtures:
Distilled H20  3.4ml
30% (w/v) Acrylamide / 0.83ml
0.8% (w/v) Bis Acrylamide
1M Tris HC1 pH 6.8 0.63ml
10% (w/v) SDS 0.05ml
10% (w/v) APS 0.05ml
TEMED 0.005ml
_m>
9.9ml
8.3ml
6.3ml
0.25ml
0.25ml
0.01ml
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Running buffer:
Glycine 72g per 5 litres distilled H2O.
Tris 15g
SDS 5g
Blotting buffer:
As for running buffer except using only 4 litres distilled H2O with 
1 litre methanol.
Phosphate buffered saline (PBS) (lOx):
NaCl 160g per 2 litres distilled H2O
KC1 4g
NaH2P 0 4 23g
KH2PO4 4g
Blocking solution:
2% (v/v) Donkey serum
4% (w/v) Dried milk (in PBS)
0.05% (v/v)NP-40
First antibody solution:
1% (w/v) Dried milk (including thimerosal if to be stored) in PBS 
containing desired antibody at the required dilution, herel:100 
unless otherwise stated.
Second antibody solution:
1% (w/v) Dried milk in PBS/0.05% (v/v) NP-40 containing lOOpl 
of HRP-linked anti-rabbit second antibody per 100ml of solution.
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2.1.9. Peptide conjugation and immuniziation of rabbits
Since many short peptide sequences them selves are poor 
immunogens they are often coupled to a suitable carrier and in this case 
keyhole limpet hemocyanin (KLH) was chosen, using glutaraldehyde as 
the coupling reagent. lOmg KLH and 3mg of peptide were dissolved in 
lm l of 0.1M phosphate buffer pH 7.0 (0.1M NaH2PC>4 added to 0.1M 
Na2HPC>4 until desired pH was reached). To this was added 0.5ml of 
21mM glutaraldehyde, dropwise and over as long a time period as possible 
(eg. 12.5pl every 15 minutes over 10 hours). This remained at room 
temperature overnight and was mixed with Freund's complete adjuvant for 
immunization the next day. Booster immunization was performed with 
material prepared in a similar fashion but with 5mg KLH and 1.5mg 
peptide using incomplete Freund's adjuvant. The entire 1.5ml provides 
enough material for immunizing at least three rabbits. A mixture of 
immunogen (± PBS to appropriate dilution) and adjuvant were well mixed 
to form a milky emulsion before injection.
Recommended dosage is between 50 and 1000 pg of immunogen 
per rabbit. Injection of large volumes is not recommended and injection of 
smaller volumes (~350pl) at multiple (3) sites is common practice. With 
this in mind lOOpl of immunogen (200pg peptide) was mixed with 400pl 
PBS and 500pl adjuvant before injection. Skin was pinched between 
thumb and forefinger, pulled away from body and the needle (25-gauge) 
inserted into the space created. Care was taken to ensure the needle was 
not inserted into muscle or body wall. The desired amount was injected 
then the needle slowly withdrawn and the wound rubbed gently to stop 
any of the inoculum from escaping.
A test bleed was taken at 7 - 10 days after initially injecting the 
animal. This involved collecting a small volume of blood (~5ml) from the 
ear vein in rabbits, a suitable site due to easy accessibility and low number
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of nerve endings. At this stage, and whenever other bleeds were taken, 
collected blood was allowed to clot for 30 - 60 minutes at 37°C then left 
overnight at 4°C to allow it to contract. Serum was then removed from the 
clot and any remaining insoluble material removed by centrifugation at 10 
OOOg for 10 minutes at 4°C. After normally several boosts, again ~350ml 
at three sites, if useful antibodies were produced a final bleed was carried 
out. Blood collected was treated as before then aliquoted into small 
volumes, snap frozen in liquid N2 and stored at -80°C until use.
2.1.10. Preparation of isolated hepatocytes
Preparation of isolated hepatocytes was performed essentially as 
described by Berry and Friend (Berry and Friend, 1969). Rats were 
anaesthetised by one intra-peritoneal injection of 0.4ml o f a 60mg/ml 
solution of Sagatal (sodium pentobarbitone solution containing 4mg/ml 
heparin). Upon loss of the flexor and corneal responses, the abdominal 
cavity was opened. The inferior vena cava and hepatic portal vein were 
ligated and the vena cava then cannulated with a 16 gauge needle 
containing a solution of heparin (lOmg/ml). The hepatic portal vein was 
also then cannulated with a 19 gauge needle and the ligatures tightened to 
secure the cannulae. The liver was perfused in the physiological direction 
with 80ml of Krebs buffer (25mM NaHCC>3, 1.2mM MgSC>4, 1.2mM 
KH2PO4, 5mM KC1 and 120mM NaCl) pH 7.4 containing lmg/ml EDTA 
at a constant temperature of 37°C and a flow rate of 30ml/min using a 
Watson - Marlow peristaltic pump. The EDTA containing buffer was 
washed out with 50ml of Ca2+ free Krebs buffer containing 20mM 
glucose. 60mg of collagenase was added to 100ml of this buffer and 
circulated for 30 minutes. After approximately 20 minutes it became 
apparent that the liver structure had become disrupted. At this stage 
cannulae were removed and the liver transferred to a plastic beaker
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containing 35ml of Ca2+ free Krebs buffer and gently disrupted. The 
resulting cell suspension was gently filtered through nylon mesh with a 
pore size of 150pM and washed with a further 20ml of buffer. The 
suspension was then centrifuged at lOOg for 2.5 minutes. The pellet was 
then washed several times by resuspending in Krebs buffer containing 
2.5mM CaCl2 and centrifuging as before.
2.1.11. Partial purification o f protein kinase C using DE52 ion- 
exchange chromatography.
2.1.11.1. Preparation of DE52 column
DE52 is an anion exchange cellulose obtained in pre-swollen form. 
To prepare, this was stirred in 0.5M Tris HC1 pH 7.5 buffer (20ml of 
buffer for every dry gram of cellulose). Whilst stirring, pH was adjusted to
7.5. Once pre-equilibration was complete the slurry was allowed to settle 
and the supernatant fraction decanted. The slurry was redispersed in buffer 
then allowed to settle, again the supernatant being decanted but this time 
leaving 20% of the wet settled volume on top of the resin. At this stage the 
slurry was used for packing columns.
This was done by pouring the stirred slurry into the chosen column 
as swiftly as possible to prevent convection currents in the slurry 
becoming established. Eluent from the column was allowed to run to 
waste then buffer run through the column until equilibration was complete 
(pH of eluate same as that of initial buffer) and the column bed height was 
constant. The sample, diluted appropriately in starting buffer, was then 
loaded onto the column at a controlled flow rate.
2.1.11.2. Partial purification of protein kinase C
The liver of an anaesthetised rat was perfused with ice-cold PBS 
containing 2mM EDTA and 2mM EGTA until all blood had been cleared
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and the liver was cold to touch. The liver was then immediately excised, 
weighed and placed in approximately 40ml ice-cold homogenization 
buffer where it was cut into fine pieces. This was homogenised with 15 
strokes of a motorized homogeniser. After sitting on ice for 20 minutes 
this homogenate was spun at 48000 rpm (4°C) using a Ti-50 rotor. The 
supernatant from this spin was made up to 200ml with column buffer and 
loaded onto a DE52 column which was then washed with column buffer 
for approximately 1-2 hours until protein concentration in the eluate fell 
sufficiently. At this stage protein kinase C was first eluted and collected in 
individual fractions (~3ml) by applying buffer A (80mM NaCl) until 
protein cocentrations of the eluate showed that peak 1 had passed. Buffer 
B (250mM NaCl) was then applied to elute the second peak of protein 
kinase C activity. All fractions were then tested for protein kinase C 
activity.
Homogenization buffer:
20mM Tris HC1 pH 7.5
lOmM EGTA
2mM EDTA
0.5% (v/v) Triton X-100
50mM p-mercaptoethanol
lOmM Sodium Vanadate
lOmM Sodium Fluoride
lOmM p-glycero phosphate
O.lmg/ml Trypsin inhibitor
Protease inhibitor cocktail (see Section 2.1.2.1)
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Column buffer:
20mM Tris HC1 pH 7.5
50mM p-mercaptoethanol
0.1 mg/ml Trypsin inhibitor
Protease inhibitor cocktail (see Section 2.1.2.1)
Buffer A:
(Prepared in column buffer)
80mM NaCl 
2mM EDTA 
Buffer B:
(Prepared in column buffer)
250mM NaCl 
2mM EDTA
2.1.12. Protein kinase C activity assay
Assay mixes for these assays were composed to represent three 
im portant conditions, nam ely including A) phosphatidylserine, 
diacylglycerol and calcium, B) phosphatidylserine, diacylglycerol, and 
EGTA and C) EGTA only. These were composed as follows:
A___________ B__________ C
Tris / HC1 pH 7.5 20mM 20mM 20mM
MgNC>3 20mM 20mM 20mM
Histone HI (III-S) lmg/ml lmg/ml lmg/ml
ATP 40pM 40pM 40pM
CaCl2 2mM
EGTA 2mM 2mM
(prepared in distilled water)
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The above were mixed with an equivalent volume of PS/DAG 
mixture (A + B) or an equivalent volume of 20mM Tris HC1 pH 7.5 (C) to 
complete the final assay mixture. To this was added y -p2P] ATP at 
5ji.Ci/ml.
Phosphatidylserine (0. lmg/ml) and diacylglycerol (6pg/ml) were 
prepared by m ixing well then drying under nitrogen, with final 
resuspension in 20mM Tris HC1 pH 7.5. Sonication using a Jencons 
ultrasonic probe processor for 3 x 30 seconds at 80 Watts with 30 second 
intervals was then performed.
The assay required incubating lOOpl of final assay mixture, 
including label, with lOOpl of column buffer containing the fraction 
sample at the appropriate dilution (approx 1:10) for 15 minutes at 37°C. 
After this time the reaction was stopped by adding 30pl of ice-cold 100% 
(w/v) TCA and the samples placed on ice. Using custom built 96 well 
vacuum filter apparatus and Whatman GF/C glass microfibre filter paper, 
samples were loaded into wells which were washed several times with 
10% (w/v) TCA and then with methanol containing bromophenol blue to 
fix samples and allow them to be visualized. Activity in each fraction 
sample was now represented by a specific spot on the GF/C paper which 
was cut out and counted for radioactivity.
2.1.13. Streptozotocin injections
Male Sprague-Dawley rats (200-270g) were used. Diabetes was 
induced as previously described (Gawler, et a l.y 1987) using one 
intraperitoneal injection of streptozotocin (80mg per kg body weight,
0.3ml per animal) in sterile 0.1M citrate buffer pH 4.5 (0.1M sodium 
citrate, and add 0.1M citric acid to desired pH). Urine glucose was 
monitored (Diabur-Test 5000 kit) and animals used when diabetic
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(normally several days after injection). Animals were only confirmed as 
diabetic if  elevated glucose was detected in the urine and if the blood 
glucose concentration was >12mM, as assessed using Dextrostix.
2.1.14. P rotein  assays
2.1.14.1 Bradford method
Protein content of samples was determined using the Bio-Rad 
protein assay kit based on the method of Bradford (Bradford, 1976). In all 
assays BSA was used as the standard. Standard solutions were prepared 
ranging from 0 - 20|ig protein and treated similarly to unknown samples 
(normally 5 - 50pl, containing 0.5 - 20pg protein or equivalent of standard 
curve) in being diluted to 0.8ml with distilled H 2O. To this was added
0 .2 . l  Bio-Rad dye reagent followed by thorough mixing. Absorbance at 
595nM of all samples was read, allowing determination of unknown 
protein concentrations from the standard curve.
2.1.14.2 Lowry method
Protein determination was also carried out by a method based on 
that of Lowry et al. (Lowry, et al., 1951). The following stock solutions 
are required:
1. Copper tartrate carbonate (10% (w/v) N a2CC>3, 0.1% (w/v) 
Q 1SO4.5H2O, 0.2% (w/v) sodium potassium tartrate)
2. 0.8M NaOH
3. 10% (w/v) SDS
Immediately before use, one part of each of these solutions was 
mixed along with one part H2O to give reagent 'A', which was gently 
warmed to dissolve any precipitate. Standard solutions of BSA were 
prepared in duplicate containing O-lOOpg of protein per ml and unknown 
protein solutions prepared in triplicate. All samples were made up to 1ml
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with H2O and then 1ml reagent 'A' added to each sample. After 10 minutes 
0.5ml reagent 'B' was added (Folin and Ciocalteau's reagent diluted 1:6 
with distilled H2O), mixed and colour development allowed to occur for 
30 minutes before absorbance at 750nM was measured.
2,1.15, Cell Culture
2.1.15.1. Growth medium for CHO cells
All cells required the following growth medium:
500 ml Ham's F12 medium
55 ml Foetal calf serum (heat-inactivated)
5.5 ml Penicillin / Streptomycin solution
In addition the following were added to the above medium as selection 
markers:
400 pg/ml G418 (for cells transfected with insulin receptor)
150 pg/ml Hygromycin (for cells transfected with PKC)
2.1.15.2. Passage of cells
Media was removed from 75cm cell culture flasks containing 
confluent cells with a sterile pipette. Approximately 3ml of trypsin 
solution was added to each flask and incubated for a few minutes. When 
the cells began to 'round-up', 3ml of growth medium was added to stop the 
action of trypsin. Cells not yet dislodged from the plate were displaced by 
gentle tapping of the plate and trituration of the media. This media was 
then transferred to a sterile centrifuge tube and spun for 3 minutes at 
~1000g. The media/trypsin solution was then aspirated and the pellet 
resuspended in fresh medium. The desired amount of these cells were then 
seeded in new 75cm flasks in a final volume of ~10ml.
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2.1.15.3. Freezing cells
When freezing cells, the cell pellet after centrifugation (Section 
2.1.15.2) was this time resuspended in freezing medium (1.0-1.5ml per 
flask of confluent cells). Freezing medium consisted of 10% (v/v) DMSO, 
25% (v/v) foetal calf serum and 65% (v/v) normal growth medium. After 
aliquoting into cryotubes, cells were frozen slowly overnight in a -80°C 
freezer then transferred to liquid nitrogen the following day and stored 
there until required.
2.2. Materials
2.2.1. Chemicals and General Reagents
Sigma Chemical Co, Antipain
Poole, ATP (disodium salt)
Dorset, U.K. Benzamidine
BSA
Bromophenol blue 
Calmodulin
Cyclic AMP (disodium salt)
Cyclic GMP 
Charcoal (Norit A)
DAG
Dowex 1-chloride 
Glucagon 
Glutaraldehyde 
Histone-Hl (III-S)
Human gamma globulin
IB MX
KLH
Leupeptin
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Nonidet-P40 
Pepstatin 
PGEi 
PMSF 
Ponceau S
Snake venom (Hannah ophiophagus)
Streptozotocin
TEMED
Thimerosal
TPA
Triton X-100 
Trypsin inhibitor
Amersham, ECL kits
Bucks, U.K. Hyperpaper
Molecular weight markers 
Nitrocellulose
Fisons, Hepes
Loughborough,
England:
TCA
Boehringer,
East Sussex, U.K.
Dithiothreitol
Tris
Diabur test-5000 kits
Hygromycin
TEA
BDH, Poole, p-mercaptoethanool
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Dorset, U.K. Universal indicator 
DMSO
Kodak Ltd, 
Manchester, U.K.
X -0  Mat-S film
Antibody Production Unit, HRP-linked sheep anti-rabbit IgG
Law Hospital, Donkey serum
Lanarkshire,
Scotland:
Ames,
Slough, U.K.
Dextrostix
FSA Lab Supplies, 
Loughborough, U.K.
Folin & Coicalteau's reagent
Schering Ltd, 
Berlin, Germany.
Rolipram
Pfizer,
Sandwich, U.K.
Cilostamide
Bio-Rad Laboratories Ltd, Bradford reagent 
Herts, U.K.
Lipid Products, 
London, U.K.
Phosphatidylserine
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Novo Laboratories Ltd, Insulin (porcine) 
Basingstoke, U.K.
SmithKline Beecham, IRp peptide
Epsom, U.K.
DIFCO Laboratories, Freund's complete adjuvant
Detroit, U.S.A. Freund's incomplete adjuvant
Hannah Institute 
Ayr, Scotland.
Peptides for antibody production
Packard, 
Groningen, N.L.
Scintillation fluid
Rhone Merieux, 
France.
Sagatal
Whatman, 
Maidstone, 
Kent, U.K.
P81 paper 
GF/C paper
DE52 ion-exchange resin
Worthington Biochemical Coiporation, Collagenase 
New Jersey, U.S.A.
All other chemicals were of analar grade or were of the highest grade 
available commercially.
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2.2.2. Radiochemicals
Amersham, [8-3H] - Adenosine 3', 5'-cyclic monophosphate
Bucks, U.K. [5',8-3H] - Adenosine 3', 5'-cyclic monophosphate
[125i] _ insulin
[y 32pj _ Adenosine 5'-triphosphate
2.2.3. Animals
Male Sprague Dawley rats (220-250g) were used as the source of 
tissue for partial purification of protein kinase C. Antibodies were raised 
in New Zealand White rabbits purchased at 3 months old from MRC 
accredited sources.
2.2.4. Cell Culture Materials
All materials required for cell culture, unless otherwise listed, were 
purchased from Gibco. BRL, Paisley, Scotland. Transfected CHO cells 
were a gift from Dr. J. Tavare, Bristol University.
2.2.5. Miscellaneous
Bovine adrenal glands were obtained (Duke St abattoir, Glasgow) 
immediately after slaughter, transported at 4°C and processed without 
delay. Human placenta were obtained (Rottenrow maternity hospital, 
Glasgow) as soon as possible after birth and again transported at 4°C then 
processed without delay.
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Figure 2.1. Diagram of immunoblotting apparatus
This digram highlights the composition of the gel/membrane 
sandwich and the orientation of these in relation to the electrodes of the 
immunoblotting tank.
•  Positive BlBctrode
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FiltBT paper ^
Support pad
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Figure 2.2. ECL method of protein detection
This diagram  highlights the basis of the enhanced chemi- 
luminescence method of detecting immunoreactive proteins, as was used 
here.
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\
Oxidized
product
Hyperfilm
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Chapter 3
Production of protein kinase C isoform specific antibodies
3.1. Introduction
3.1.1. The immune response
The immune system functions principally to protect animals from 
infectious organisms and from their toxic products. The system can be 
subdivided into two broad categories, adaptive and non-adaptive 
immunity. Non-adaptive immunity is mediated by cells which respond in a 
non-specific manner to foreign molecules and encompasses phagocytosis 
by macrophages, secretion of lysozyme and cell lysis by natural killer 
cells. Adaptive immunity is mediated by lymphocytes, cells which 
synthesize cell-surface receptors or secrete proteins that bind specifically 
to foreign molecules. These proteins are called antibodies and it is this 
system which can be exploited by introducing a specific immunogen into a 
host in order to induce formation of the corresponding specific antibody.
Lymphocytes can be grouped into three basic types - B cells, 
cytotoxic T cells and helper T cells. All three carry cell-surface receptors 
that can bind antigens. Note that one cell is capable of recognizing only 
one particular antigen as all of the antigen receptors on a single cell are 
identical. B cells secrete antibodies and carry a modified form of the same 
antibody on their surface, where it acts as a receptor for antigens. 
Cytotoxic T cells lyse foreign or infected cells upon binding to B cells via 
their surface antigen receptor, known as the T-cell receptor. Helper T cells 
play a key regulatory role in controlling the response of B cells and 
cytotoxic T cells.
Adaptive immunity can be further subdivided into two categories, 
humoral and cell mediated immunity. Cell mediated responses are typified 
by binding of cytotoxic T lymphocytes to foreign or infected cells and 
subsequent lysis of these cells. The humoral response results in the 
generation of circulating antibodies that bind to foreign antigens. It is
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mediated by B cells in conjunction with helper T cells and forms the basis 
of the techniques employed here.
When an animal first encounters an antigen the primary immune 
response is slow and weak. On second exposure to the same antigen a 
stronger and more rapid response ensues. This capacity to mount a strong 
and specific secondary response is termed immunological memory and is 
again exploited here.
3.1.2. Antibody molecules
Antibodies are a large family of glycoproteins that share key 
structural and functional features. Structurally, antibodies are often 
visualized as having a 'Y' shape. Each Y shaped antibody is composed of 
four polypeptides, two identical copies of both a heavy and a light chain. 
Antibodies are classified into five classes, IgG, IgM, IgA, IgE and IgD, on 
the basis of the number of Y-like units and the type of heavy chain 
polypeptide they contain. IgG's contain one Y unit and are the most 
abundant in serum.
Antibody-antigen binding is entirely dependent on noncovalent 
interactions and exists in equilibrium with dissociated components. These 
interactions include hydrogen bonds, van der Waals forces, coulombic 
interactions and hydrophobic backbones. Polyclonal sera tend to contain 
complex mixtures of antibodies of differing affinities.
3.1.3. Production of antibodies
Plasma cells are the main sites of antibody production. The cells 
live for three to four days and allocate approximately 40% of their total 
protein synthesis to antibody production. Antibody production is 
maintained by regulating the differentiation of B cells into plasma cells 
and memory cells.
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When producing antisera to a specific antigen, choosing the site of 
injection for the immunogen is very important. Ideal sites should have 
high numbers of antigen presenting cells and low rates of antigen 
degradation. To aid in this respect, immunogens are often mixed with 
adjuvants which protect the antigen from rapid dispersal by trapping it in a 
local deposit. Adjuvants may also contain substances which aggravate the 
host animal's immune response (see Section 3.1.5.).
Upon phagocytosis, antigen presenting cells degrade the antigen 
and display fragments of it on the cell surface, bound to an MHC (major 
histocompatibility complex) class II protein. If antigen fragments do not 
bind to MHC class II proteins of a given animal the antigen is masked 
from the immune system and no immune response occurs.
Not all molecules researchers wish to raise an antibody to, such as 
short peptide sequences in this case, are good immunogens due to T cell 
tolerance or lack of the appropriate class II proteins. This is most readily 
overcome by coupling such small molecules, or haptens, to soluble carrier 
proteins using a bifunctional coupling reagent. The carrier provides 
binding sites for MHC class II - T-cell binding sites, while the hapten 
provides an epitope for binding to the antibodies on the B cell surface. 
Both of these binding steps are essential in optimizing the immune 
response.
3.1.4. Coupling of the peptide
Most coupling methods rely on free amino groups (terminal or 
lysine side chains), sulphydryl groups (cysteine side chains), phenolic 
groups (on tyrosine residues) or carboxylic acid groups (terminal or on 
aspartate and glutamate). Coupling should be designed to link the peptide 
through a terminal amino acid.
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Proteins commonly used as carriers include keyhole limpet 
hemocyanin (KLH) or bovine serum albumin (BSA). KLH is often 
preferred as BSA is often a good immunogen in its own right.
Glutaraldehyde is also often used as a coupling reagent. A single- 
step coupling method involves mixing the peptide and carrier at the 
appropriate ratio with a limiting amount of glutaraldehyde to minimize 
overcoupling.
3.1.5. Adjuvants.
These are non-specific stimulators of the immune response and 
their judicious use is essential to induce a strong antibody response. 
Complete adjuvants have two active components. Firstly, mineral oils are 
present to form a deposit preventing rapid catabolism of the immunogen. 
Secondly, a substance that will nonspecifically stimulate the immune 
response is used. This normally relies upon heat killed bacteria, such as 
mycobacterium tuberculosis, as is present in Freund's adjuvant. Adjuvant 
lacking the latter component is termed incomplete adjuvant.
3.1.6. Injections.
Subcutaneous injections are widely used in rabbit immunizations 
as the injected inoculum will drain quickly into the local lymphatic system 
and become concentrated in the lymph nodes closest to the injected sites. 
The recommended dosage is between 50 and 1000 pg of immunogen per 
rabbit.
Injection of large volumes is not recommended and injection of 
smaller volumes (~350pl) at multiple sites is common practice. The skin 
should be pinched between thumb and forefinger, pulled away from body 
and a needle (25-gauge) inserted into the space that has been created. Care 
should be taken to ensure that the needle is not inserted into muscle or
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body wall. The desired amount is then injected, the needle slowly 
withdrawn and the wound then gently rubbed to stop any of the inoculum 
from escaping.
3.1.7. Sampling serum
Test bleeds are often taken before immunizations begin for control 
purposes. After the initial injection, antibodies to the immunogen appear 
in the serum at approximately seven days, reaching maximal levels at ten 
days. Test bleeds can be taken at this stage. This normally involved 
collecting a small volume of blood (~5ml) from the ear vein in rabbits, a 
suitable site due to its easy accessibility and low number of nerve endings. 
Subsequent boosts (normally approximately four weeks apart, although 
longer if desired as animal remains primed up to one year) are given until 
a high titre to the antigen of interest is obtained. At this time the rabbit is 
bled. Collected blood should be allowed to clot for 30 - 60 minutes at 
37°C then left overnight at 4°C to allow it to contract. Serum should then 
be removed from the clot and any remaining insoluble material removed 
by centrifugation at -10  OOOg for 10 minutes at 4°C.
One practical advantage of antibodies having compact and stable 
protein domains is that they are resistant to a broad range of mildly 
denaturing conditions. This makes storage for several years below -20°C 
possible. The only real problem associated with storing antibodies is 
contamination of these solutions with bacteria or fungi, which is best 
prevented by addition of sodium azide at a final concentration of 0.02% 
(w/v).
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3,2. Peptide sequences used to raise antibodies to individual protein  
kinase C isoforms
The peptide sequences displayed below were synthesized with the 
express intention of raising isoform specific PKC antibodies. Each one 
represents a distinct peptide sequence from within the amino acid structure 
of that particular isoform. Before synthesis each peptide sequence was 
checked for cross-reactivity with other PKC-isoform sequences to ensure 
specificity of the resultant antibodies.
PK C -a
Peptide used: (C) QFVHPILQSA V 
Amino acids 662-672
Gln-Phe-Val-His-Pro-Ile-Leu-Gln-Ser-Ala-Val
PKC-Pi/pn
Peptide used: (C) IQAHI EREVLI 
Amino acids 623-633
Ile-Gln-Ala-His-Ile-Glu-Arg-Glu-Val-Leu-Ile
PKC-e
Peptide used: (C) NQEEF KGFSY FGEDL M 
Amino acids 721-736
Asn-Gln-Glu-Glu-Phe-Lys-Gly-Phe-Ser-Tyr-Phe-Gly-Glu-Asp-Leu-Met 
PKC-y
Peptide used: (C) NYPLE LYERV RTG 
Amino acids 306-318
Asn-Tyr-Pro-Leu-Glu-Leu-Tyr-Glu-Arg-Val-Arg-Thr-Gly
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PKC-C
Peptide used: (C) GFEYI NPLLL SAEES V 
Amino acids 618-633
Gly-Phe-Glu-Tyr-Ile-Asn-Pro-Leu-Leu-Leu-Ser-Ala-Glu-Glu-Ser-Val
PKC-5
Peptide used: (C) SFSDK NLIDS MDQTA 
Amino acids 643-657
Ser-Phe-Ser-Asp-Lys-Asn-Leu-Ile-Asp-Ser-Met-Asp-Gln-Thr-Ala
All six antibodies raised exhibited immunoreactivity against 
purified protein kinase C from bovine brain and were used in subsequent 
experiments. For example, Figures 3.1-3.4 show immunoblots where 
samples of extracts from CHO cells transfected with individual PKC- 
isoform s w ere analysed by SD S-PA G E elec trophoresis  and 
immunoblotting (as described in Section 2.1.8) using antisera to the a , p, y 
and e isoforms of protein kinase C. The results obtained clearly highlight 
specificity of the raised antibodies for each individual protein kinase C 
isoform.
The CHO cells used in these blots were transfected with PKC-a (CHO-a),
PKC-p (CHO-p), PKC-y (CHO-y) and PKC-e (CHO-e) as well as control cells (CHO- 
T).
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Figure 3.1. Expression o f PKC-a in CHO cell clones
Extracts from Chinese hamster ovary (CHO) cells transfected such 
that they stably overexpressed an individual protein kinase C isoform were 
used to assess the specificity of the antibody raised against PKC-a peptide. 
Five cell clones were tested with the anti-PKC-a antibody (used at a 
dilution of 1 in 100); namely cells overexpressing PKC-a (a), PKC-Pi (p), 
PKC-y (y), PKC-e (e) and a control cell clone not overexpressing any protein 
kinase C isoform (T). Immunoreactivity was detected at ~80kDa.
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Figure 3.2. Expression of PKC-ft in CHO cell clones
Extracts from Chinese hamster ovary (CHO) cells transfected such 
that they stably overexpressed an individual protein kinase C isoform were 
used to assess the specificity of the antibody raised against PKC-p peptide. 
Five cell clones were tested with the anti-PKC-p antibody (used at a dilution 
of 1 in 100); namely cells overexpressing PKC-a (a), PKC-pi (p), PKC-y (y), 
PKC-e (e) and a control cell clone not overexpressing any protein kinase C 
isoform (T). Immunoreactivity was detected at ~80kDa.
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Figure 3.3. Expression of PKC-y in CHO cell clones
Extracts from Chinese hamster ovary (CHO) cells transfected such 
that they stably overexpressed an individual protein kinase C isoform were 
used to assess the specificity of the antibody raised against PKC-y peptide. 
Five cell clones were tested with the anti-PKC-y antibody (used at a dilution 
of 1 in 100); namely cells overexpressing PKC-a (a), PKC-Pi (p), PKC-y (y), 
PKC-e (e) and a control cell clone not overexpressing any protein kinase C 
isoform (T). Immunoreactivity was detected at ~78kDa.
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Figure 3.4. Expression of PKC-e in CHO cell clones
Extracts from Chinese hamster ovary (CHO) cells transfected such 
that they stably overexpressed an individual protein kinase C isoform were 
used to assess the specificity of the antibody raised against PKC-e peptide. 
Five cell clones were tested with the anti-PKC-e antibody (used at a dilution 
of 1 in 100); namely cells overexpressing PKC-a (a), PKC-pi ((5), PKC-y (y), 
PKC-e (e) and a control cell clone not overexpressing any protein kinase C 
isoform (T). Immunoreactivity was detected at ~85kDa.
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Chapter 4
Protein kinase C activity and expression in normal rat liver 
and liver of streptozotocin-indueed diabetic rats
4.1. Introduction
It has been suggested by a number of investigators that changes in 
either the expression or activity of protein kinase C might give rise to 
insulin-resistant states such as are seen in diabetes and obesity 
(Grunberger, 1991). One suggestion (Turinsky, et al., 1990) proposed that 
insulin resistance occurred as a consequence of a persistent increase in 
diacylglycerol levels, leading to increased protein kinase C activity and 
ultimately phosphorylation and inhibition of insulin receptor function 
(Kadowaki, et al., 1984; Shmueli, et al., 1993). Protein kinase C has also 
been implicated as part of the insulin stimulated signal transduction 
pathway (Considine and Caro, 1993) and in this respect changes in activity 
and/or expression of a specific isoform may also affect insulin signalling 
processes.
To date, however, observations describing alterations in protein 
kinase C activity, expression and distribution in diabetic states has not 
identified any consistent pattern. This is evident from the data summarised 
in Table 4.1. Results appear to vary both between the various model 
systems and the tissue examined. For example, using the streptozotocin- 
induced diabetic rat both an overall decrease (Kim, et al., 1991), as well as 
no overall change (Borghini, et al., 1994) in protein kinase C activity in 
sciatic nerve has been observed in the diabetic state. In addition, an overall 
increase has been detected in heart (Tanaka, et al., 1991). Interestingly, 
this increased protein kinase C activity seen in diabetic tissue can often be 
ameliorated by calcium channel blockers such as verapamil (Tanaka, et 
al., 1991), suggesting that calcium dependent protein kinase Cs are 
responsible for the increased activity in this case.
Evidence that increased protein kinase C activity (associated with 
serine/threonine phosphorylation of the insulin receptor) was responsible 
for decreased receptor tyrosine kinase activity has been shown in many
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studies (Bollag, et al., 1986; Takayama, et al., 1984). In streptozotocin 
diabetic rats, whilst a reduced insulin receptor kinase activity was found in 
one study, this was not paralleled by any increase in protein kinase C 
activity (Karasik, et al., 1990). There is considerable interest in the 
possibility that individual protein kinase C isoforms may have distinct 
functional roles, including regulation of insulin signalling. Their 
contribution might explain some of the anomalous results described in 
Table 4.1. In an attempt to further understand the role of protein kinase C, 
the enzym e was partly purified from the liver o f norm al and 
streptozotocin-induced diabetic rats and its activity assessed. Previous 
work in this laboratory has established that selectively altered expression 
of individual isoforms occurs upon streptozotocin-induced diabetes in rat 
hepatocytes (Tang, et al., 1993). Therefore, protein kinase C isoform 
specific antisera were also used to investigate isoform expression and 
relate this to activity in partially purified fractions.
4.2. Results
4.2.1. Protein kinase C activity in normal and diabetic states
Protein kinase C activity was resolved into two distinct peaks after 
DE52 ion-exchange chromatography as described in Section 2.1.11. 
Typical results of assays to determine protein kinase C activity in fractions 
collected after chromatography are shown in Figures 4.1 and 4.2, with the 
results being summarized in Table 4.2. These data show that, using this 
system, a significant overall decrease in the protein kinase C activity of 
peak 1 occurred upon induction of diabetes. No significant difference in 
the activity of peak 2 occurred with diabetes induction. The overall level 
of activity in peak 2 was much less than that observed in peak 1.
By assaying fractions under different conditions it was possible to 
break down the protein kinase C activity into that which was attributable
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to both the Ca2+-dependent and Ca2+-independent isoforms. Calcium 
dependent activity can be calculated as the activity expressed in the 
presence of PS/DAG/Ca2+ minus that activity expressed in the presence of 
PS/DAG/EGTA. Similarly, subtracting the activity expressed in the 
presence of EGTA alone from that activity expressed in the presence of 
PS/DAG/EGTA gave a measure of PS/DAG dependent protein kinase C 
activity. These results are summarized in Table 4.2. They indicate that a 
significantly greater amount of Ca2+-dependent protein kinase C activity 
was found in peak 1 from normal rat liver as opposed to diabetic rat liver. 
The amount of Ca2+-dependent protein kinase C activity in peak 2 
appeared, however, not to be significantly altered upon induction of 
diabetes. PS/DAG-dependent activity in peak 1 was, again, significantly 
reduced in diabetic tissue, while little PS/DAG-dependent activity was 
apparent in peak 2.
4.2.2. Immunohlotting of fractions with isoform specific antisera.
Western blot analysis with isoform specific protein kinase C 
antisera was performed in order to determine the expression of individual 
isoforms in the range of fractions which formed the two observed peaks of 
activity. These are shown in Figures 4.3 - 4.6. PKC-a was present in peak 
1 from both normal and diabetic animals (Figures 4.3 and 4.4). 
Interestingly, however, in samples from normal animals two distinct 
immunoreactive bands (-79 and ~83kDa) were observed whilst in samples 
from diabetic animals only one band (~80kDa) was seen. No PKC-a was 
observed in peak 2 from either normal or diabetic animals.
PKC-p expression was examined using an antiserum which could 
recognize both PKC-pi/pn forms. Previously (Tang, et al., 1993) only 
PKC-pn had been shown to be expressed in liver. As shown in Figure 4.5 
and 4.6, a single band of immunoreactivity (~8()kDa) was observed in
106
peak 1. Also, to a lesser degree, a similar band was also present in peak 2 
from normal rats. The pattern in diabetic tissue appeared to be similar.
PKC-e expression is shown in Figures 4.7 and 4.8. In normal 
animals one band of immunoreactivity at ~78kDa was observed in peak 1, 
whilst a doublet occurring at a higher apparent molecular weight (~8 lkDa) 
was detected in peak 2. In diabetic tissue one band at ~80kDa was detected 
in peak 1 and a single band, again at a higher apparent molecular weight 
(~85kDa), was detected in peak 2.
No PKC-C expression was found (Figures 4.9 and 4.10) in peak 1 
from either normal or diabetic tissue. However, a prominent band at -81- 
84kDa was observed in peak 2 of normal and diabetic samples. PKC-£ was 
expressed at lower levels in diabetic samples.
PK C -y was found not to be expressed in rat liver as no 
immunoreactive species consistent with the presence of the PKC-y isoform 
were observed in these studies.
4.3. Discussion
Previous studies have suggested that streptozotocin-induced 
diabetes in rats causes alterations in protein kinase C activity (Kim, et al., 
1991; Inoguchi, et al., 1992) and/or expression (Tang, et al., 1993). 
Changes in expression may selectively involve individual isoforms (Tang, 
et al., 1993), a fact which may at least partly explain the conflicting range 
of data reported in the literature concerning changes in activity (Wali, et 
al., 1990; Tanaka, et al., 1991; Borghini, et al., 1994). In order to assess 
whether changes in activity ensued as a result of the induction of diabetes, 
a protein kinase C activity assay was utilized, together with 
immunoblotting techniques.
The model of streptozotocin-induced diabetes reflects a type-I 
hypoinsulinaemic diabetic state. However, it also exhibits characteristics
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of insulin resistance seen in NIDDM. In this model, destruction of 
pancreatic [3-cells leads to reduced insulin secretion and, therefore, 
hypoinsulinaemia. If insulin activation of protein kinase C occurs as an 
endogenous phenomenon then a reduction in protein kinase C activity as a 
direct result of hypoinsulinaemia might be expected. This in turn might 
explain the increased expression (up-regulation) of the enzyme which 
tends to be seen in this model (Tang, et al., 1993).
Upon partial purification of protein kinase C from rat liver using 
DE52 ion-exchange chromatography two peaks of activity were observed. 
The first to elute contained a significantly greater proportion of protein 
kinase C activity than the latter. Immunoblotting analysis showed that the 
a  and £ isoforms were only present in one peak, whilst the e and Pn 
isoforms were found in both peaks. Individual isoforms might be expected 
to have different charges, and this phenomenon forms the basis of 
separation  using ion-exchange chrom atography. In addition , 
phosphorylation or dephosphorylation of protein kinase C species can be 
expected to result in an alteration of their charge and hence their 
chromatographic properties on ion-exchange resin. Another possible 
reason for elution at different salt concentrations could be specific binding 
of isoforms to cellular organelles.
Since the streptozotocin-diabetic rat is hypoinsulinaemic, it is 
expected that the results observed are most closely representative of the 
pathogenesis of insulin dependent (type I) diabetes. Results presented here 
show that protein kinase C activity observed in peak 1 from streptozotocin 
induced diabetic rat liver tissue was significantly decreased from that seen 
in normal rat liver. This suggests that insulin might activate protein kinase 
C to some extent under normal physiological conditions.
The assay conditions used allow resolution of protein kinase C 
activity into that which is Ca2+-dependent and Ca2+-independent. From
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results presented here, it is apparent that induction of diabetes caused a 
significant reduction in the proportion of both Ca2+-dependent and 
PS/DAG-dependent protein kinase C activity occurring in peak 1.
Immunoblotting studies allowed characterization of the protein 
kinase C isoform content of both peaks. This was then correlated with the 
proportion of Ca2+-dependent and Ca2+-independent activity present in 
each. Based simply on which isoforms were detected, it was concluded 
that in both normal and diabetic samples peak 1 was composed of the a, 
pH, and e isoforms. Peak 2 was composed of the Pn, e and £ isoforms, with 
the amount of PKC-pn and PKC-e expressed in peak 2 being less than in 
peak 1. Results using rat hepatocytes have suggested that overall 
expression of the a , Pn and e isoforms is increased in streptozotocin 
induced diabetic animals (Tang, et al., 1993). It is therefore possible that 
this increased expression might be a direct compensatory response for the 
decreased activity of protein kinase C in this model of diabetes.
Therefore, relating immunoblotting and activity assay results, it 
would appear that the reduced Ca2+-dependent protein kinase C activity 
observed in diabetic animals might be directly due to altered PKC-a or 
PKC-pn activity as neither of the other Ca2+-dependent isoforms (PKC-pi 
or PKC-y) are expressed in liver. Similarly, the only Ca2+-independent 
isoform detected in peak 1 in these studies was PKC-e, suggesting that 
altered activity of this isoform underlies the observed decrease in Ca2+- 
independent activity. Nevertheless, changes in other isoforms which we do 
not have antisera for may also occur.
It is worth highlighting the pattern of PKC-a expression which 
changed from two distinct bands in normal samples to one in diabetic 
samples. Others have also observed multiple forms of PKC-a detected in 
this tissue, one explanation mooted was that post-translational 
modifications may alter the apparent molecular size upon SDS-PAGE
109
(Pears, et al., 1992). This group also provided evidence to suggest that 
phosphorylation of PKC-a can account for the observed mobility shift 
observed upon SDS-PAGE (Pears, et a l ,  1992). They further suggest that 
phosphorylation on at least one site is required for PKC-a to be active as 
treatment with PPase-1 induces a time dependent loss of activity, although 
this particular phosphorylation did not lead to an apparent mobility shift. 
Subsequent autophosphorylation of the enzyme did however result in 
altered mobility. It is therefore worth bearing in mind that phosphorylation 
or dephosphorylation could account for the small mobility shifts of 
proteins observed upon SDS-PAGE, as well as changes in the activity of 
the enzyme. In the case of PKC-a expression observed here, it is likely 
that the switch from two bands to one upon induction of diabetes results in 
a reduction in activity, as the contribution of the 'upper' band seen in 
normal samples is lost. This theory is the most likely explanation of the 
changes in total protein kinase C activity observed between normal and 
diabetic tissue.
Activity in peak 2 was very much less than that in peak 1 in both 
normal and diabetic samples. Very little Ca2+-dependent activity was 
observed and immunoblotting studies confirmed that the detected activity 
was attributable to a small amount of PKC-pn isoform. No PKC-a was 
detected in this peak. Furthermore, little or no PS/DAG-dependent activity 
was observed in peak 2, despite the presence of PKC-e and PKC-£ 
isoforms. An explanation for this may be that as the PKC-e detected in 
peak 2 is of a higher molecular weight than that in peak 1 it may represent 
a phosphorylated form of the enzyme where this modification has resulted 
in inactivation. Lack of Ca2+- or PS/DAG-dependent activity suggests that 
total activity detected in peak 2 may be due to the presence of a 
constitutively active form of protein kinase C, perhaps as represented by 
the species of ~50kDa detected by PKC-e and PKC-£ antibodies.
110
In summary, results presented in this chapter highlight a decrease 
in total protein kinase C activity from normal levels in liver of rats made 
diabetic by streptozotocin treatment. This difference is accounted for both 
by altered Ca2+-dependent and Ca2+-independent protein kinase C 
activity. These studies suggest that the a , pn and e isoforms of protein 
kinase C might be responsible for the observed changes in activity, and the 
increased expression of these isoforms observed in streptozotocin induced 
diabetic rat hepatocytes may be the direct result of a reduction in their 
activity.
Histone kinase activity detected in peak 2 did not exhibit characteristics to 
suggest that it was entirely due to protein kinase C. This dubiety is somewhat 
resolved by the fact that protein kinase C expression is detected in peak 2.
I l l
Table 4.1. Summary of published data concerning changes in protein 
kinase C activity or expression in diabetic states
Listed in this table is an abbreviated summary of results published in 
recent years studying changes in protein kinase C activity or expression in 
diabetic models. A brief resume of the results in each case is presented, 
together with the diabetic model studied, the substrate employed in the 
assay (where applicable) and the tissue used in each case.
References for Table 4.1.
1.
2 .
3.
4.
5.
6 .
7.
8 .
9.
10. 
11. 
12.
13.
14.
(Xiang and McNeill, 1992) 
(Tanaka, et al., 1991) 
(Inoguchi, et al., 1992)
(Kim, et al., 1991)
(Borghini, et al., 1994) 
(Hoffman, etal., 1991)
(Tang, et al., 1993)
(Wali, etal., 1990)
(Craven and DeRubertis, 1989) 
(Garcia-Paramio, etal., 1993) 
(Williams and Schrier, 1992) 
(Nagy, eta l., 1991)
(Farese, etal., 1992b)
(Egan, et al., 1990)
CO
(—*■
c3
3«-*■o
N
O
r* -
o
o
CO CO c o
5 5 "CD CD CD
" 3 3
0 O O
N N N
O O O
O O O
3 . CD O
5 ' 3 ’ 5 '
CO
CD
- ar^-
o
N
O
o
o
CO
CD
3<—+
O
N
Or^-
o
o
CO
o
3
o
N
O
o
o
COr**
c3
3r f
o
N  O «—► 
o  o
CO
r* -
cB
3
o
NO
o
o
>
o
P
ffi
CD
3
P
o
o
cd00
>
CL
3
O
O
v ;
Pd
05
CO
o
c T
c
05
3
e
05
o
cT
CO
Ok-» •
Pi-»
o ’
3
CD■-»
cd
CO
o
P
•
o
8
3
CD
DC
cd
S
DC
cd
DC
cd
DC
</>
o
3
CD
DCH**00
o
3
O
DC
05*
r-+
o
3
cd
DC
So’
r^-
o
3
CD
* 5
^  3
S'S
f^g*3 CD
* 5
r
DCi—»•
05
O
3
CD
DCi—•
05<—»
o
3
CD
P5 <—(o 3  «—► 3
5 ’ °  S. tr
•3 §§
e ra
CD
C L
P  OO 
CD OO
? ’ < £
tr1
^  g
cd
p
05
CD
CL
CD
"DO *—<
1—1 o 
* 3  CD §CD X  CD
-  3 |OO 05 C L
CD CO. „
1- 1* o
c r  3OS
-
3
05
3
P
3
CL
3 s
l-H
3
►-» CL
O|- t
CD 00 CD
P CD P05
g X CD
CD 3>—t CL
3 CD P03
C/5.3 3
O ’
3
1—H 1—*
8 ar i  CD 
°
Pj CD
^  K
CD
CL
P
o
CD
C L
ON
p  t r 1 O  33. °
<  CD
^  g
CD
CL
8 OJ 4  CDS3’ cd <  *-»
~  8 v^< p
^  05
CD
CL
ON
0 5  °  °
£;£L£L 
^  PS Pd ^  32 3tV  CD CD 
O  CL CL 3^  CD O X|-*3’"0
O
<
CD
05 CD p  
O  05 2I—►> 05 ^O *'
05 o  •-*
p
o3.<
os
u»
W< °
P
O c3
0
3 *
P
3
OQ
CD
CL
P  t o  
CD i—•
!<
3 ‘ 31
^  g
CD
P
05
CD
CL
U>
■PL P  3
t—‘ O  3
t-H
3. CD 
<  CD
3 ' p
3
O CD
C L
p
05
CD
CL
t o 1— ‘
112
M
odel 
Tissue 
Substrate 
C
vtosolic 
Particulate 
R
ef
Insulin 
treatm
ent 
A
dipocytes 
Histone 
Increased 
overall activity
Z ffia  & D ^
5' 2 &
* ^
p  3  H
3 I Sg g o
3
3
033
3 ‘£  
S Sst <3 3
O3i
5'
CLco
cp
Cl
mo'<
P
cp
C L
cro^
3*oo
00
cp
00r-»-
3
X3
S
No
oo
OO
3TD
hho
NO
oo
OO
«-*
3•or^-o
N  O (—*■ o  o
>
C LH**T3oo
rHCP
00
8 2  
£ 3  o
0o 3  O 
3  
3  
O
cp*
£
CP
g <  3 p
O  §5
s s
^ pT
3
go
cT
5o
00
P
3
2o
3
CP
3
OO
3
&
HA*a
3
03
H^*
E5
CD
& aH**00
O
3
CP
w 113 cp
*■§
2  a - Jjcp
DCN^*</>r fo
3
CP
DCM •
0o
r to
3
CP
DC
00
Ho
3
CP
2  D
■O 8
3 3
8  II—* • O?o O
3  C L
CP tr*
* 3
3 °
03 g> 03 55 H-. CP 
O  C L
3o
*-l
CP
p
oo
CP
C L
O
<CP
3
po
<
(H
D
CPo
3
p
03
CP
C L
p  t r 4 
O  3s . °  < 3
CP
CL
8 a  
2
3 £ ’S
CP ■" 
3
3
C L
cr <<
03
03CP
C L
CP
P
3
CP
3  
O
3
<< gCP
C L
P  Os ~ O
$R
o
H v5 ' o
o CP°* 3  ^  E
3  p  
W  O
I—  •
3 S'«-►
S ' 3 *
O
3
gCP
C L
P
*■<
S» o
CPCLC<
? -S  
"S?o
3
u> to s o 00
113
M
odel 
Tissue 
Substrate 
C
ytosolic 
Particulate 
R
ef
Figure 4.1. Profile of protein kinase C activity in normal rat liver after 
partial purification on DE52 ion exchange chromatography
Protein kinase C activity was assayed (as described in Section
2.1.12) in each fraction collected after chromatography using the following 
three assay conditions: phosphatidylserine, diacylglycerol and Ca2+ (■); 
phosphatidylserine, diacylglycerol and EGTA (o); and EGTA only (o). Total 
activity in each fraction is expressed in units of pmoles of phosphate 
transferred from the y position of ATP onto the substrate histone per minute, 
and corrected per gram of liver (wet weight) used to allow comparison 
between animals.
F
raction
Pi Transferred (pmol/min/g)
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F igure 4.2. Profile of protein kinase C activity in diabetic ra t liver after 
partia l purification on DE52 ion exchange chrom atography
Protein kinase C activity was assayed (as described in Section
2.1.12) in each fraction collected after chromatography using the following 
three assay conditions: phosphatidylserine, diacylglycerol and Ca2+ (■); 
phosphatidylserine, diacylglycerol and EGTA (o); and EGTA only (o). Total 
activity in each fraction is expressed in units of pmoles of phosphate 
transferred from the y position of ATP onto the substrate histone per minute, 
and corrected per gram of liver (wet weight) used to allow comparison 
between animals.
F
raction
Pi Transferred (pmol/min/g)
cn
o
o
o
o
o
cn
o
o
o
o
o
o
o
o
cn
o
o>
o
115
2500
Table 4.2. Analysis of partially purified protein kinase C activity in 
normal and streptozotocin induced diabetic rat liver
Protein kinase C activity was assayed as described in Section 2.1.12 
and total activity in each peak calculated as the area under the peak of 
activity observed in the presence of PS/DAG and Ca2+ (see Figures 4.1 and 
4.2). Ca2+-dependent activity was measured as total activity minus the area 
under the peak of activity observed in the presence of PS/DAG and EGTA. 
PS/DAG-dependent activity was calculated as the difference in the area 
under the peaks observed in the presence of PS/DAG and EGTA and in the 
presence of EGTA alone. Results are expressed in arbitrary units (±S.D) and 
are representative of three normal and three diabetic subjects. Results were 
statistically assessed using a student's t-test and relevant p values shown in 
the table (nsd = no significant difference).
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F igures 4.3. - 4.10. Expression of protein  kinase C isoforms
corresponding to observed peaks of activity after partial purification of 
the enzyme from normal and streptozotocin induced diabetic rat liver
Antiserum specifically recognizing the a, pn, e and £ isoforms of 
protein kinase C were employed in studying expression of these isoforms in 
fractions exhibiting protein kinase C activity. Samples were taken from 
individual fractions and volumes corresponding to lOOpg total protein 
content were mixed with an equivalent volume of x2 sample buffer (Section 
2.1.8.1) and boiled before being analysed by SDS-PAGE in each study. 
Results representing isoform expression in peak 1 and peak 2 are presented 
here as Figure 4.3 (PKC-a normal), Figure 4.4 (PKC-a diabetic), Figure 4.5 
(PKC-Pn normal), Figure 4.6 (PKC-Pn diabetic), Figure 4.7 (PKC-e 
normal), Figure 4.8 (PKC-e diabetic), Figure 4.9 (PKC-C normal) and Figure 
4.10 (PKC-C diabetic).
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Chapter 5
Control of intracellular cyclic AM P metabolism in CHO cells
5.1. Introduction
The role of cyclic AMP as a second messenger was first revealed 
by the work of Sutherland and colleagues several decades ago (Sutherland. 
et al., 1962). This nucleotide, synthesized in cells from ATP by the 
membrane bound enzyme adenylate cyclase, is constantly turning over in 
cells, its production being counteracted by hydrolysis to 5'-AMP through 
the action of phosphodiesterases. Both cyclic AMP and adenylate cyclase 
exist in every tissue of higher organisms.
Many hormones bind to specific receptors on the cell surface to 
elicit changes in intracellular cyclic AMP concentrations. These changes 
can be brought about by changes in either the rate of synthesis or the rate 
of degradation of cyclic AMP. Examples of ligands which increase 
intracellular cyclic AMP concentrations include p-adrenoceptor agonists, 
histamine (via H2 receptors), prostaglandins, vasopressin and glucagon 
(via GR2 receptors). Ligands such as muscarinic receptor agonists, 012- 
adrenoceptor agonists, throm boxanes and opioids act to decrease 
intracelluar cyclic AMP concentrations. Both the number of ligands 
impinging upon this system and their physiological role again stress the 
fundamental importantance of cyclic AMP in the cell.
Binding of the agonist isoprenaline to the p-adrenergic receptor 
results in the activation of adenylate cyclase with consequent intracellular 
formation of cyclic AMP. Transduction of this signal involves sequential 
interaction of the p-adrenergic receptor and the stimulatory guanine 
nucleotide-binding protein Gs with consequent activation of the enzyme 
adenylate cyclase. As mentioned previously, other ligands acting via their 
own specific receptors can also stimulate adenylate cyclase. Two such 
agonists also used in these studies are PGEi and glucagon. As discussed in 
Section 1.10, insulin is known to influence cyclic AMP metabolism in
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various systems. Results presented in this chapter assessed this activity in 
CHO cells and particularly the part played by specific protein kinase C 
isoforms.
In the work presented in this Chapter and in Chapter 6, several 
Chinese hamster ovary-derived cell clones were used. These were as 
follows;
CHO-K (wild type cells),
CHO-T (CHO-K cells transfected such that they stably overexpressed the 
human insulin receptor),
CHO-a (overexpressed human insulin receptor and PKC-a),
CHO-p (overexpressed human insulin receptor and PKC-p),
CHO-y (overexpressed human insulin receptor and PKC-y),
CHO-e (overexpressed human insulin receptor and PKC-e).
5.2. Results
The first set of experiments set out to examine cyclic AMP levels 
under various conditions in the six CHO cell-clones available. Intracellular 
cyclic AMP levels in cells under normal growth conditions are shown in 
Figure 5.1. Only CHO-y cells and CHO-T cells showed significantly lower 
values than those of wild type control cells. None of the other cell types 
showed any significant difference in their basal cyclic AMP levels as 
compared to CHO-K cells.
Isoprenaline stimulated increases (or in CHO-y cells decrease) in 
intracellular cyclic AMP levels were then measured for all cell clones. 
Results are expressed in Table 5.1 as a percentage of the basal intracellular 
cyclic AMP concentration in that cell type, with basal values being 
designated as 100%. In all cell clones, with the exception of CHO-y cells, 
isoprenaline elicited a less than two fold increase in intracellular 
cyclic AMP levels (Table 5.1). CHO-y cells were different in that
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isoprenaline did not cause any intracellular cyclic AMP accumulation, and 
in fact a^large reduction was observed (Table 5.1).
Also displayed in Table 5.1 are results of studies examining the 
effect of insulin upon the ability of isoprenaline to elicit changes in 
intracellular cyclic AMP concentration. It was observed that only in those 
cells transfected with PKC-e, in addition to the human insulin receptor, did 
insulin exert an effect, namely to attenuate isoprenaline stimulated 
increases in intracellular cyclic AMP concentration.
This result made analysis of the influence of IBMX, a 
phosphodiesterase inhibitor, worthy of evaluation. As can be seen from 
Table 5.1 IBMX increased basal intracellular cyclic AMP concentrations 
between two and three fold, as well as consistently increasing such levels 
when used in conjunction with isoprenaline and insulin. In experiments 
where CHO-e cells were treated with IBMX, insulin could, to a certain 
extent, still act to reduce the increased intracellular cyclic AMP levels 
elicited by isoprenaline. Note, however, that treating cells with IBMX as 
well as isoprenaline and insulin increased intracellular cyclic AMP 
concentrations over that observed with either isoprenaline and insulin 
treatment. ' . In all other cell clones examined insulin, again, had no
significant effect on intracellular cyclic AMP concentrations.
Figure 5.2 represents data obtained upon the stimulation of cyclic 
AMP accumulation in CHO-e cells by using various agonists. 
Isoprenaline, acting via p-adrenergic receptors, PGEi, acting via its own 
specific receptors, and glucagon, acting via GR2 receptors, all stimulated 
adenylate cyclase to increase intracellular cyclic AMP levels. Under 
normal conditions, insulin had a dramatic effect upon intracellular cyclic 
AMP accumulation in response to these agonists. In the case of all three 
agonists, insulin attenuated their ability to increase intracellular cyclic 
AMP, and in each case caused cyclic AMP concentrations to fall below
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basal levels. This effect of insulin was lost, however, if cells were 
preincubated for 16 hours with lOOnM TP A to down-regulate protein 
kinase C prior to agonist challenge.
5.3. Discussion
All six CHO cell-clones were characterised in terms of basal 
intracellular cyclic AMP concentration as well as isoprenaline stimulated 
responses. Similar basal intracellular cyclic AMP levels were detected in 
CHO-a, CHO-p, CHO-e and CHO-K cells. With reference to results 
presented in Chapter 6, where phosphodiesterase activity was measured in 
cells under similar conditions and found to be elevated in CHO-e cells, it is 
surprising that CHO-e cells did not exhibit lower basal intracellular cyclic 
AMP concentrations than wild type control cells. One explanation for this 
may be that despite a clearly elevated phosphodiesterase activity in CHO-e 
cells, there was a compensatory up-regulation of adenylate cyclase activity 
under basal conditions. Thus, they would be expected to maintain the basal 
intracellular cyclic AMP concentration indicated. Indeed, a basal cyclic 
AMP level of this magnitude may be essential for viability of this 
particular cell clone. CHO-y cells, together with CHO-T cells, had a 
significantly lower intracellular cyclic AMP concentration compared with 
wild type cells. Therefore, the proteins overexpressed by these cells must 
somehow be affecting intracellular cyclic AMP metabolism, either by 
impairing adenylate cyclase activity or increasing phosphodiesterase 
activity. Overexpression of PKC-y could conceivably, for example, alter 
the phosphorylation state of either a relevant G-protein (Katada, et al. , 
1985), adenylate cyclase (Jacobowitz, et al., 1993) or phosphodiesterase(s) 
(Irvine, et al., 1986; Abou-Samra, et al., 1987) such that their activity is 
altered. Why transfection of insulin receptor alone should bring about 
these changes is more difficult to explain. It may be that since growth
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factors present in serum in cell growth medium will include insulin, which 
acts via these receptors, some exaggerated input upon cyclic AMP 
metabolism from the overexpressed insulin receptor might explain these 
changes. If this is the case, it must be assumed that transfection of PKC-a, 
-fj and -e in the other cell types somehow alleviated this problem.
With the exception of CHO-y cells, all other cell lines proved to be 
sensitive to isoprenaline stim ulation by exhibiting an increased 
intracellular cyclic AMP concentration. Surprisingly, not only did 
isoprenaline fail to elicit increased intracellular cyclic AMP levels in 
CHO-y cells, intracellular cyclic AMP was consistently found to be 
reduced from basal levels. An explanation for why PKC-y transfection 
should cause such an unlikely effect is difficult to rationalise. This could 
be hypothesized to be due to elevated phosphodiesterase activity, but other 
experiments (Table 6.1) suggest that ’ _ _ ‘ alterations in
phosphodiesterase activity do not account for this observation. Therefore, 
a defect in cyclic AMP generation, ie. at some stage between the receptor 
and catalytic unit of adenylate cyclase, seems more likely as PKC-y could 
potentially phosphorylate and attenuate the function of one of the 
components involved in cyclic AMP synthesis. Nevertheless, it is possible 
that using isoprenaline to stimulate adenylate cyclase in this cell type 
provides a system where the effects of various other ligands or inhibitors 
can be usefully investigated. This allows examination of, for example, 
whether observed phenomenon are common to all, or only receptor 
specific, adenylate cyclase mediated responses.
Having established the response to isoprenaline in each of the cell 
types, the effect of insulin upon this effect was then examined. Upon 
doing so, one exciting observation stood out. Only in CHO-e cells did 
insulin dramatically attenuate the ability of isoprenaline to elevate 
intracellular cyclic AMP, such that its concentration remained around
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basal levels after isoprenaline treatment. This dramatic effect represents 
one of the few clear demonstrations known where insulin directly 
influences intracellular cyclic AMP metabolism. The mechanisms 
underlying this effect may involve stimulation of a phosphodiesterase or 
inhibition of cyclic AMP synthesis, and these will be discussed further as 
results both in this and the following chapter contribute towards their 
understanding.
As expected, if cells were pretreated with IBMX, intracellular 
cyclic AMP concentrations were correspondingly increased two to three 
fold in all cases, a typical response in many cell types, albeit a small one. 
A slightly greater increase was observed in CHO-e cells. This suggests a 
higher basal phosphodiesterase activity in this cell type, as inhibition of 
this activity would be expected to result in a more pronounced increase in 
intracellular cyclic AMP concentration within these cells. Considering the 
difference between isoprenaline and combined isoprenaline/IBM X 
treatment of cells again shows that IBMX apparently causes a more 
significant increase in intracellular cyclic AMP in CHO-e, and to a slightly 
lesser extent in CHO-a, cells when compared with wild type cells. This, 
again, is in agreement with data presented in Table 6.1 showing an 
increased basal phosphodiesterase activity does indeed exist in CHO-e 
cells.
Looking specifically at the effect of IBMX on insulin's ability to 
alter intracellular cyclic AMP levels in CHO-e cells, it would be expected 
that if insulin was acting by stimulating phosphodiesterase activity then 
IBMX would prevent insulins action. Infact, IBMX appeared only to 
partly block the ability of insulin to attenuate isoprenaline stimulated 
increases in intracellular cyclic AMP concentration. This speaks in favour 
of an additional action of insulin at the level of cyclic AMP generation. 
Again results presented in Table 6.1 suggest that insulin stimulates
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phosphodiesterase activity in these cells. Therefore, only a partial block of 
insulin action here by IBMX means either that insulin may have a dual 
action both upon adenylate cyclase and cyclic AMP phosphodiesterase or 
that the type of phosphodiesterase(s) stimulated by insulin are somewhat 
resistant to IBMX inhibition, at least under these experimental conditions. 
Other possibilities include an effect at the level of the stimulatory ligand 
receptor or Gs, where in both cases insulin induced alteration in, for 
example, their phosphorylation state may cause inhibition. Similarly, some 
modification at the level of Gi could be influential. Indeed, insulin has 
been noted to reduce basal Gj-2 phosphorylation in rat hepatocytes (N. 
M om s, personal communication), an effect which would increase the 
proposed 'tonic* inhibition exerted by this G-protein on adenylate cyclase, 
and hence ultimately result in decreased intracellular cyclic AMP levels.
Finally, a separate set of experiments was conducted with the 
ultimate aim of further clarifying the molecular basis of the observed 
effect o f insulin on agonist stim ulated intracellular cyclic AMP 
accumulation in CHO-e cells. Three agonists known to stimulate adenylate 
cyclase and therefore to increase intracellular cyclic AMP concentrations 
were used to challenge CHO-e cells and the responses characterised. As 
can be seen from the results shown in Figure 5.2.Y, each of the three 
agonists induced an approximately sim ilar degree of elevation of 
intracellular cyclic AMP concentration, with PGEi being slightly the more 
potent of the three agonists.
Also shown in Figure 5.2.Y is the effect observed upon pretreating 
the cells with insulin and using the same agonists to repeat the above 
stimulations. After insulin treatment, these agonists were no longer 
capable of eliciting an overall increase in intracellular cyclic AMP 
concentration, with levels now falling below basal values, as was observed 
in previous experiments using isoprenaline. In identifying the molecular
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basis of this effect, the use of a cell-line such as CHO-e allows the 
opportunity to investigate the role played not just by protein kinase C in 
this effect, but by a specific isoform of the enzyme.
With this in mind, the experiments presented in Figure 5.2.Y were 
repeated in cells which had been treated with the phorbol ester TPA to 
down-regulate protein kinase C. The main observation was that after 
treating cells with TPA for 16 hours, insulin was no longer able to cause 
the dramatic reduction in intracellular cyclic AMP concentration seen 
previously (Figure 5.2.Z). This suggests that PKC-e is involved in insulin's 
action on agonist stimulated increases in intracellular cyclic AMP in this 
cell type. Whether this is via causing increased phosphodiesterase activity 
or by inhibiting synthesis will be further addressed in Chapter 6. It should 
be noted at this stage, however, that this loss of insulin action is less 
striking in the case of PGEi stimulated increases. This may be explained 
by hypothesizing that insulin reduces intracellular cyclic AMP 
concentration in these cells by two mechanisms, stimulation of a cyclic 
AMP phosphodiesterase and inhibition of a component involved in 
synthesis. If we assume that only phosphodiesterase stimulation is PKC-e 
dependent then phorbol ester treatment and PKC-e down-regulation will 
abolish this effect no matter what agonist is used. The other portion of 
insulin's effect may be PKC-e independent, hence a slight reduction in 
intracellular cyclic AMP is still elicited after phorbol ester treatment in all 
cases. This only appears to be significant in the case of PGEi induced 
increases. This suggests that the location of this portion of the insulin 
effect could be at the level of the receptor, since it appears to be fairly 
specific for one agonist compared to the others used. Nevertheless, a 
subtle modification of Gs that influences receptor interaction, with the 
PGEi receptor binding site being most greatly affected by this, is also 
possible.
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In summarizing these results it must be concluded that PKC-e plays 
a crucial role at some stage in the pathway whereby insulin attenuates 
agonist stimulated increases in intracellular cyclic AMP concentration. 
Exactly how insulin's input upon control of cyclic AMP metabolism is 
achieved may be more complex than envisaged, such that it allows for 
fine tuning in antagonism to specific ligands. It is suggested that in CHO-e 
cells, under the experimental conditions imposed here, insulin acts both by 
causing phosphorylation , and stim ulation , of a cyclic  AM P 
phosphodiesterase and by inducing ligand receptor phosphorylation, with 
attenuation of activity. PKC-e appears to play a crucial role in the former 
explanation, the latter effect perhaps being achieved via a protein kinase 
C-independent pathway.
Finally, one other potential reason for the apparently agonist specific effects of 
PKC down-regulation observed could simply be due to the times that agonists were 
allowed to act after insulin pretreatment. For example, loss o f insulin action upon 
PKC down-regulation is less marked in the case of PGEi stimulated increases in 
intracellular cyclic AMP, and PGEi is added only for 2 minutes as opposed to 3 
minutes for glucagon and 5 minutes for isoprenaline.
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Figure 5.1. Analysis of intracellular cyclic AMP levels in CHO cells
Results to determine basal intracellular cyclic AMP levels for each 
of six cell clones (designated CHO-a, -p, -y, -e, -K and -T) are summarized 
(n>3) in both graphic and tabular form. Values represent pmoles of cyclic 
AMP per million cells. Statistically significant results are indicated as 
p<0.05 (*), p<0.01 (**) and p<0.001 (***).
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Table 5.1. Control of intracellular cyclic AMP levels in CHO cells
Results for each of six cell types (designated CHO-a, -p, -y, -e, -K 
and -T) are summarized for the conditions listed (n>3). All values are 
expressed as a percentage of the basal value (designated 100%) for each 
individual cell clone, unless otherwise stated. Basal specific activities in 
each clone was as follows; 3.1±0.2 (CHO-a), 3.0±0.2 (CHO-p), 1.9±0.4 
(CHO-y), 3.5±0.6 (CHO-e), 3.0±0.3 (CHO-K) and 1.9±0.2 (CHO-T). 
Isoprenaline stimulation in each case was over 5 minutes at 10-4M, while 
insulin pretreatment was for 5min at 10‘8M and IBMX pretreatment for 
15min at 10‘3M. Statistically significant results are indicated as p<0.05 (*), 
p<0.01 (**) and p<0.001 (***).
o
DC
XP3o
ocr
W
O X gera 
cd
cd
CO
on
On
On
©
VO
L  co
§  ^  xg
+ p  P  33 CUco ^
to
OO
ON
1+tO
O
ro■o
g
ON
VO
VOin­to
ON
to
gVO
to-&>
g
to
tou>4^
1+I—k
u>
Q.
r*» a
3  s  
5
x
50P3 .O
op
P
30QCP
U>
to
ON
COo
T 3
r! ™ X 3 EL
3
CD
U>to
gU>
V/l
tot-o
g
ooto
1+
u>
On
V/i
1+U>U>
to
VO
i+toto
to
00 toin­to
01
0*50s s. 
s °
3  D? 
x ^ S *
n X §
(TO 
CD
n
DCo
CD
u>
o
VO
to4^-o
t t
to4^to
1+oo
to to 
-o 
1+ I—k
V/t
to
■o
1+t—*
oo
to
u>
u>in­to
U>
toto
gtoo
n
3 *
P
P  3
3 eraCD 
Cl
c
CD
Vyi
to
rR
+
4^
3^
* VO
* p*
to
u>
3^
V/l
c$
Z _I CO
3  O
CO P
3 c3
3 3 3 £L
3
CD
VO
to
ts
u>
ON
! i
O n
f t
o
£
ON
-o
On
U>
COoT3
c3
3
EL
3CD
VO
-o
f t
4^
oo
Kt o
ON
gOO
VO
oo
1+
to
VO
6
On 
OO 
1+ I—k
ON
n
DC
01
p
ha:
01
■CO
n
DC
O
n
DC
01
n
DC
01
X
n
DC
01
H
W
p00
EL
p
1+o
to
u>
g
O
to
VO
6
p
Lo
1+o
ON
u>
g
o
Lo
VO
1+o
to
135
Figure 5.2. Agonist induced increases in intracellular cyclic AMP levels 
in CHO-e cells and the effects of insulin and phorbol ester
R esults in this figure display in tracellu lar cyclic AMP 
concentrations (expressed as pmoles cAMP per 106 cells) in CHO-e cells 
under basal conditions and after treatment with various ligands (n=l). Three 
agonists were used to stimulate cyclic AMP formation; (A) isoprenaline 
(5min, 10'4M), (B) PGEi (2min, 10_5M) and (C) glucagon (3min, 10'6M). 
Treatment of cells with each of these three agonists was also carried out 
after insulin pre-treatment (A, B or C +ins), (5min, 10‘8M). These results 
are expressed in Figure 5.I.Y. Finally, all of these conditions were repeated 
on cells which had been treated with the phorbol ester TPA (lOOnM) for 16 
hours to down-regulate protein kinase C (see Figure 6.2), results of which 
are shown in Figure 5.I.Z.
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Chapter 6
Phosphodiesterase activity in CHO cells
6.1. Introduction,
The only known enzymatic reaction for the degradation of cyclic 
nucleotides is their conversion to the corresponding 5'-nucleotide via 
hydrolysis of the 3', 5'-phosphodiester bond. This is catalyzed by cyclic 
nucleotide phosphodiesterases, as discussed in Section 1.9.
Results presented in this chapter were obtained using the 
phosphodiesterase assay described in detail in Section 2.1.2. Chinese 
hamster ovary cell clones transfected with insulin receptor alone or 
combined with a specific protein kinase C isoform (see Section 5.1), were 
used in all experiments and compared to wild type, non-transfected CHO 
cells as an appropriate control. This allowed analysis of the role of 
individual protein kinase C isoforms in regulating cyclic AMP 
phosphodiesterases, under both basal and insulin stimulated conditions. 
This was determined in order to help clarify the mechanism by which 
insulin attenuated agonist induced increases in intracellular cyclic AMP 
concentrations in CHO-e cells (Chapter 5).
Given the significant importance of cyclic nucleotide second 
messengers, hormonal control of phosphodiesterase activity is of great 
importance within cells. Regulation of phosphodiesterase activity by 
insulin was established in 1985 (Beebe, et al., 1985) and has been 
reinforced by many subsequent studies (Lonroth and Smith, 1986; Kather 
and Scheureer, 1987). More specifically these studies suggest that, in liver, 
insulin specifically regulates activity of individual phosphodiesterase 
isoforms. Activation of both a type III ('dense vesicle') and a type IV 
('peripheral plasma membrane') phosphodiesterase have been observed 
(Heyworth, etal., 1983; Marchmont and Houslay, 1980).
Evidence that phosphodiesterase activity can be controlled by 
protein kinase C has now been suggested by several observations. For 
example, protein kinase C phosphorylates the rod photoreceptor
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phosphodiesterase in vitro such that the inactive form is stabilized 
(Udovichenko, et al., 1994). Protein kinase C mediated inhibition of 
phosphodiesterase activity has also been shown in rat hepatocytes (Irvine, 
et al., 1986) and anterior pituitary cells (Abou-Samra, et al., 1987). 
Altered expression of phosphodiesterases is another way in which their 
overall activity may be regulated. There is evidence, for example in L6 
cells, to show that insulin can increase protein expression, an effect which 
it mediates via protein kinase C activation (Thompson, et al., 1993). 
Indeed, differential control of transcription factors by individual protein 
kinase C isoforms has been established, at least in vitro (Goode, et al., 
1993). Hence, the possibility exists that insulin and protein kinase C might 
combine to regulate phosphodiesterase expression.
6.2. Results
Basal phosphodiesterase activity in each cell clone was first 
assessed and results presented in Table 6.1. Values are expressed both as 
specific activity (pmol/min/mg protein) and relative to basal activity in 
wild type cells, which were assigned an arbitrary value of 1. Significantly, 
CHO-e cells exhibited a higher basal phosphodiesterase activity than 
control cells. Activity in all other cell clones was not significantly 
different from that of control cells.
Phosphodiesterase activity was next assessed after insulin 
treatment of cells. These results are shown in Table 6.1. Insulin treatment 
had no effect on phosphodiesterase activity in CHO-y, CHO-K and CHO-T 
cells. It did, however, stimulate an increased phosphodiesterase activity in 
CHO-e, CHO-a and CHO-p cells, the effect in CHO-e cells being much 
greater than that observed in the others.
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The effect of acute phorbol ester treatm ent of cells on 
phosphodiesterase activity was then investigated. Preliminary results are 
presented in Table 6.1. It does appear, however, that such treatment may 
stimulate phosphodiesterase activity with the most significant effects 
appearing to be in CHO-a, CHO-p and CHO-y cells.
Phosphodiesterase activity was then assessed after long-term 
phorbol ester treatment of cells to down-regulate protein kinase C. Results 
are presented in Table 6.1. The most striking consequence of such 
treatment was that it caused a marked decrease in phosphodiesterase 
activity in CHO-e cells. This effect was no longer evident when insulin 
treatment was combined with TPA induced down-regulation. In all other 
cells, long-term phorbol ester treatm ent resulted in an increased 
phosphodiesterase activity. When combining insulin treatment with TPA 
induced down-regulation the increase in phosphodiesterase activity was 
still observed in CHO-a, CHO-p, CHO-y and CHO-K cells.
Figure 6.1 shows the inhibition of phosphodiesterase activity by 
the non-specific phosphodiesterase inhibitor IB MX in all cells. Under the 
assay conditions used, approximately 90% of phosphodiesterase activity 
was inhibited by IBMX in all cells with the exception of CHO-y cells, 
which exhibited an inhibition of -80% .
The effects of various activators and inhibitors which exhibit 
selectivity for particular isoforms were then assessed. It was noted (Table 
6.2) that Ca2+/calmodulin acted to stimulate phosphodiesterase activity in 
all cell clones, and rolipram, cilostamide and cyclic GMP inhibited 
activity in all cases. Analysing the results in more detail highlighted the 
fact that Ca2+/calmodulin had a greatly enhanced stimulatory effect on 
phosphodiesterase activity in CHO-a cells. In addition, cilostamide and 
cyclic GMP mediated inhibition of phosphodiesterase activity was
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significantly enhanced only in CHO-e cells. Cyclic GMP mediated 
inhibition was also enhanced in CHO-p cells.
The same param eters of stim ulation/inhibition were then 
investigated in cells which had been pretreated with either insulin, or TPA 
(16hours) or TPA (16hours) plus insulin. These results are displayed in 
Tables 6.3-6.6.
F irstly , insu lin  p re trea tm en t alone had no e ffec t on 
Ca2+/calmodulin stimulated phosphodiesterase activity in any of the cell 
clones (Table 6.3). Long-term phorbol ester treatment had a significant 
inhibitory effect upon Ca2+/calmodulin stimulated phosphodiesterase 
activity, such that stimulation was almost totally abolished. This effect 
was still apparent when insulin treatment was combined with long­
term phorbol ester treatment.
Rolipram mediated inhibition was found to be enhanced by long­
term phorbol ester treatment in CHO-a, CHO-p and CHO-y cells (Table 
6.4). This observation was still apparent if insulin treatment was combined 
with long-term phorbol ester treatment. Insulin pretreatment alone had no 
effect on rolipram sensitive activity compared with that in untreated cells.
From results shown in Table 6.5, the only significant change in 
cilostamide sensitive phosphodiesterase activity occurred in CHO-p cells 
upon long-term TPA treatment, where an increased inhibitory effect of 
cilostamide was observed. Cyclic GMP sensitive phosphodiesterase 
activity was unaffected by insulin or long-term TPA treatment of cells 
whether alone or combined together (Table 6.6).
Antisera specific to the a, p, y and e isoforms of protein kinase C 
were used in immunoblotting studies to monitor down-regulation of 
protein kinase C in cells treated with TPA. Results are displayed in Figure
6.2. They show that TPA treatment for 16 hours was sufficient to cause 
down-regulation of protein kinase C.
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6.3. Discussion
By calculating basal phosphodiesterase activity in each of the cell 
types, an assessment of the influence of overexpression of the human 
insulin receptor, with or without each of the protein kinase C isoforms, 
was possible. On doing so, overexpression of PKC-e (CHO-e cells) 
resulted in a 2.3 fold increase in basal phosphodiesterase activity. 
Overexpression of the human insulin receptor alone (CHO-T cells), 
however, did not alter basal phosphodiesterase activity. This suggests that 
the observed increase in CHO-e cells arose solely as a consequence of 
PKC-e overexpression, the endogenous concentration of PKC-e in CHO-T 
cells not being sufficient to allow a functional effect (see Figure 3.4). A 
possible explanation for this may be that under normal cell growth 
conditions some activation of PKC-e is apparent and that this allows 
phosphorylation and activation of a phosphodiesterase by PKC-e. Indeed 
another kinase, or phosphatase, located downstream of PKC-e, whose 
activity is regulated by PKC-e , may be responsible for the ultimate effect 
on a phosphodiesterase. Another possible explanation for this increased 
activity in CHO-e cells may be that PKC-e phosphorylates and activates a 
transcription factor, such that increased phosphodiesterase expression 
results. Both of these theories assume that under normal growth conditions 
basal diacylglycerol levels in CHO-e cells are sufficiently high enough to 
allow activation of PKC-e.
The observation of increased phosphodiesterase activity in CHO-e 
cells confirms the increased basal phosphodiesterase activity, 
suggested by the fact that IBMX treatment of cells, whether alone or 
combined with isoprenaline, caused a greater increase in intracellular 
cyclic AMP concentration in CHO-e cells than in any of the other cell 
clones (Table 5.1). However, basal intracellular cyclic AMP concentration
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was not lower in CHO-e cells compared with control cells, as would be 
expected.
Upon insulin treatm ent of cells, som e stim ulation  of 
phosphodiesterase activity was seen in CHO-a, CHO-p and CHO-e cells. 
Interestingly, however, the most substantial increase occurred in PKC-e 
cells. This would at least partly explain the observed ability of insulin to 
attenuate agonist stimulated increases in intracellular cyclic AMP 
concentrations in these cells (Chapter 5). A possible explanation of this 
may be that insulin interacts with its receptor to initiate a signalling 
cascade, in which PKC-e is involved at some stage, the ultimate result of 
which is activation of an insulin-stimulated protein kinase. This might then 
phosphorylate a phosphodiesterase such that activation of the enzyme 
results, or phosphorylate a transcription factor such that increased 
expression of the enzyme results.
Short-term phorbol ester treatment of cells, and hence activation of 
protein kinase C, appeared in general to increase phosphodiesterase 
activity, especially in CHO-a, CHO-p, CHO-y and CHO-e cells. This 
would suggest that in cells transfected with these particular protein kinase 
C isoforms there is the capacity for protein kinase C stimulation to 
increase phosphodiesterase activity. If the increased activity seen in CHO- 
e cells upon, for example, insulin treatm ent was due to direct 
phosphorylation and activation of the enzyme, then short-term phorbol 
ester treatment of cells would be expected to result in an increased 
activity. These results, therefore, confirm that direct phosphorylation of a 
phosphodiesterase enzyme appears to be at least partly responsible for the 
stimulatory effect of PKC-e upon phosphodiesterase activity.
The contribution of PKC-e in mediating phosphodiesterase activity 
within CHO-e cells was further highlighted upon assessem ent of 
phosphodiesterase activity after long-term phorbol ester treatment of cells,
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which results in the down-regulation of protein kinase C. Such treatment 
resulted in a significantly reduced phosphodiesterase activity compared 
with that in untreated cells. Combining insulin treatment with long-term 
phorbol ester treatment elevated phosphodiesterase activity to around 
basal levels in untreated cells. This small increase due to insulin, however, 
was only approximately one third of that which insulin elicited in 
untreated cells, confirming that a large part of the insulin effect is 
mediated via PKC-e.
These results suggest that as well as being essential in regulating, 
for example, insulin induced stimulation of phosphodiesterease activity, 
PKC-e plays a vital role in controlling endogenous phosphodiesterase 
activity within CHO-e cells, as was suggested by the increased basal 
phosphodiesterase activity seen in this particular cell clone. This does not 
appear to be the case for any other protein kinase C isoforms studied here, 
as in each case they exhibited an increased phosphodiesterase activity 
upon down-regulation of protein kinase C. This suggests that there may be 
some degree of negative control over phosphodiesterase activity in these 
cells which is relieved upon protein kinase C down-regulation.
The availability of activators and inhibitors specific for individual 
phosphodiesterase species allowed the phosphodiesterase isoenzyme 
profile in each cell to be established. They also allowed an assessment of 
individual isoenzyme activities and their contribution to overall activity 
changes upon treatment of cells with insulin, long-term phorbol ester 
treatment, and a combination of these. They included: Ca2+/calmodulin, 
which stimulates type I phosphodiesterase activity; rolipram, which 
inhibits type IV activity; cilostamide, which inhibits type III activity; and 
cyclic GMP, which stimulates type II and inhibits type III activity.
Using Ca2+/calmodulin established the fact that all cell clones 
contain some class I phosphodiesterase activity since Ca2+/calmodulin
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increased activity in all cases. Ca2+/calmodulin stimulated activity in 
untreated cells was greater in CHO-a cells than in any other clone used. 
This suggests that PK C-a might be involved in regulating class I 
phosphodiesterase activity. Confirming this role of PKC-a was the 
observation that phorbol ester induced down-regulation of protein kinase 
C blocked the stimulatory effect of Ca2+/calmodulin in CHO-a (and CHO- 
p) cells.
All clones appear to contain a sim ilar amount of type IV 
phosphodiesterase activity, rolipram causing a similar degree of inhibition 
of activity in each case. This was unaffected by treating cells with insulin. 
Rolipram mediated inhibition was enhanced in CHO-a, CHO-p and CHO-y 
cells upon down-regulation of protein kinase C, suggesting that the degree 
of negative control exerted upon phosphodiesterase activity in these cells 
discussed earlier may have been due to some extent to a specific effect on 
class IV phosphodiesterases, (type III effect also evident in CHO-p cells - 
see below). This enhanced inhibition persisted after combining long term 
phorbol ester treatment with insulin treatment, which was in agreement 
with the fact that insulin alone had no effect on type IV activity in any of 
the cell clones.
All cell clones contained type III phosphodiesterase activity. The 
increased cilostamide mediated inhibition of activity seen in CHO-e cells 
suggests a greater amount of type III activity in this cell clone. Increased 
total phosphodiesterase activity in CHO-e cells was still observed after 
insulin treatment of cells, but not after phorbol ester induced protein 
kinase C down-regulation. The enhanced cilostamide mediated inhibition 
observed in CHO-p cells after long-term phorbol ester treatment suggests 
that an increased type III activity contributes to the overall increased 
phosphodiesterase activity observed in this cell clone after long-term 
phorbol ester treatment.
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Since cyclic GMP inhibited phosphodiesterase activity in all cell 
clones under various conditions it appears that all cell clones contain more 
type III than type II phosphodiesterase activity. Ratios of the levels of 
these isoenzymes in all cells seem to be similar, with the possible 
exception of CHO-p cells where cyclic GMP caused an increased 
inhibition of activity. This suggests either an increased type III activity or 
an even lesser type II activity in these cells. No specific type II inhibitor 
was used to directly determine the contribution of this isoenzyme to total 
activity in each clone.
It seems that activity of individual classes of phosphodiesterase 
isoenzymes is regulated by intracellular factors, including protein kinase 
C, which can, in turn, be regulated by distinct signals impinging upon the 
cell. This provides another example of the fine tuning within cells, where 
the existence of a group of related isoenzymes allows for the influence of 
different extracellular ligands to be integrated at a similar intracellular 
regulatory system in a synergistic or antagonistic manner.
In conclusion, there is an elevated basal phosphodiesterase activity 
only in CHO-e cells, and this appears to be at least partly due to increased 
type III activity. The fact that down-regulation of protein kinase C by 
phorbol ester eliminates this observation further suggests a critical role for 
PKC-e in mediating this effect. Similarly, only in CHO-a cells is an 
elevated type I activity observed and this observation is also lost upon 
protein kinase C down-regulation, highlighting the role played by PKC-a.
Insulin was found to stim ulate phosphodiesterase activity 
principally in CHO-e, but also in CHO-a and CHO-p cells. However, 
insulin  apparently  had no sign ifican t effects on indiv idual 
phosphodiesterase isoforms, hence a cumulative general stimulatory effect 
across phosphodiesterase isoforms seems a more likely explanation of 
insulin's effect than an effect targetted specifically at one individual class.
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The observation that insulin no longer had the same magnitude of effect 
on phosphodiesterase activity in CHO-e cells after protein kinase C down- 
regulation again demonstrates the importance of this protein kinase C 
isoform in controlling phosphodiesterase activity.
Phorbol ester induced down-regulation of protein kinase C, 
however, resulted in an increased phosphodiesterase activity in all cells 
other than CHO-e. It is suggested that one explanation for this effect could 
be the relieving of an inhibitory constraint upon phosphodiesterase activity 
in these cells. More specifically, an elevated type IV activity, with some 
suggestion of an elevated type III activity in CHO-p cells, seems to be 
responsible.
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Table 6.1. Phosphodiesterase activity in Chinese hamster ovary cell 
clones: the influence of insulin and phorbol ester on total activity
Phosphodiesterase activity was measured in six Chinese hamster 
ovary cell clones including control cells (CHO-K), cells overexpressing 
human insulin receptor (CHO-T) and cells overexpressing both the human 
insulin receptor and a specific protein kinase C isoform (CHO-a, -p, -y or 
-e). Activity was first assessed in untreated cells. The resulting specific 
activities (pmol/min/mg protein) are expressed here. These results are also 
expressed relative to basal activity in wild type cells (CHO-K), designated 
an arbitrary basal value of 1. Activities were then assessed in cells after 
insulin treatment (lOnM, 5minutes), acute phorbol ester treatment (lOOnM, 
lOminutes), long-term phorbol ester treatment (lOOnM, 16hours) and a 
combination of long-term phorbol ester and insulin treatment. Specific 
activities are again presented in each case. All results represent means for 
the number ofexperimentsindicated and include S.D. values. Statistically 
significant results are highlighted as p<0.()5 (£), p<0.01 (**) and pcO.OOl
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Figure 6.1. Inhibition o f phosphodiesterase activity in CHO cells by 
IBMX
The inhibitory effect of IBMX on phosphodiesterase activity in CHO-a (A), 
CHO-P (B), CHO-y (C), CHO-e (D), CHO-K (E) and CHO-T (F) cells was 
investigated and results expressed as the percentage of total enzyme activity 
which was IBMX sensitive (o) and IBMX insensitive (■). IBMX was used in 
the assay at a fmal concentration of ImM.
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Figure 6.2. The effects of TPA on expression of protein kinase C
isoforms in CHO cells
Antiserum specifically recognizing the a , p, y and e isoforms of 
protein kinase C were employed (final dilution 1:100) in studying 
expression of these isoforms in CHO-a (PKC-a), CHO-(3 (PKC-(3), CHO-y 
(PKC-y) and CHO-e (PKC-e) cells under basal conditions (A), after TPA 
treatment (lOOnM) for 10 minutes (B) and after TPA treatment (lOOnM) for 
16 hours (C). Samples were prepared from cells as described in Section 
2.1.2.1. Volumes of cell extract corresponding to lOOpg total protein 
content were mixed with an equivalent volume of x2 sample buffer (Section 
2.1.8.1) and boiled for 5 minutes before being analysed by SDS-PAGE in 
each case.
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Table 6.2. Phosphodiesterase activity in Chinese hamster ovary cell 
clones: characterization of the isoenzyme profile present in each
Phosphodiesterase activity was measured in six Chinese hamster 
ovary cell clones including control cells (CHO-K), cells overexpressing 
human insulin receptor (CHO-T) and cells overexpressing the human 
insulin receptor and a specific protein kinase C isoform (CHO-a, -p, -y and 
-e). All values in this table represent the amount (change in units of specific 
activity) of stim ulation caused by Ca2+/calmodulin (lOOpM final 
concentration and 200ng/assay, respectively) or the amount of inhibition 
caused by rolipram (lOpM final concentration), cilostamide (10pM final 
concentration) or cyclic GMP (lOpM final concentration). Basal specific 
activities for each cell clone were 8.9 ±1.3 pmol/min/mg protein (CHO-a), 
7.3 ±0.4 (CHO-P), 4.9 ±3.4 (CHO-y), 19.4 ±2.1 (CHO-e), 8.6 ±3.7 (CHO-K) 
and 7.7 ±1.6 (CHO-T). All results represent means for the number of 
samples indicated and include S.D. values. Statistically significant results 
are highlighted as p<0.05 (*), p<0.01 (**) and pcO.OOl (***).
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Table 6.3. Phosphodiesterase activity in Chinese hamster ovary cell 
clones: the in flu en ce  o f in su lin  and phorbol ester on
calcium/calmodulin sensitive activity
Ca2+/calm odulin stim ulated phosphodiesterase activity was 
measured in six Chinese hamster ovary cell clones including control cells 
(CHO-K), cells overexpressing human insulin receptor (CHO-T) and cells 
overexpressing both the human insulin receptor and a specific protein 
kinase C isoform (CHO-a, -p, -y or -e). Activity was first assessed in 
untreated cells then in cells after insulin treatment (lOnM, 5minutes), long­
term phorbol ester treatment (lOOnM, 16hours) and a combination of long­
term phorbol ester and insulin treatment. Results are expressed in the table 
as the degree of stimulation (change in units of specific activity) caused by 
Ca2+/calmodulin (lOOpM final concentration and 200ng/assay, respectively) 
under normal conditions and after insulin or TPA treatment of cells. Basal 
specific activities for each cell clone were 8.9 ±1.3 pmol/min/mg protein 
(CHO-a), 7.3 ±0.4 (CHO-p), 4.9 ±3.4 (CHO-y), 19.4 ±2.1 (CHO-e), 8.6 ±3.7 
(CHO-K) and 7.7 ±1.6 (CHO-T). All results represent means for the number 
of samples indicated and include S.D. values. Statistically significant results 
are highlighted as p<0.05 (*), p<0.01 (**) and pcO.OOl (***).
Changes in phosphodiesterase activity listed for insulin, TPA or insulin 
and TPA treated cells refers to the appropriate controls as illustrated in Table 6.1.
+I—1u>
+u>
s
+
O n
$
+tO
VO
+ 
h—4
to
+I—*
3
IV .  to >
r fP^  E
ON
!± +  r-
i+ +OO v^ ,
^  to
S t
^  to
1+ +  p  ui 
^  NO
!+ +  r 4 to
* °  C/i
1+ +  to to
^  <i
+o
§ *s £
S ' d pivto >  o
S’
£ 3
3o
CLe
ft +P  toVO V
to
+
M
SP S tONto
+
lo
+
O n
ft +P  to 
^  ©
ft +P  to
00 L*
f t  +  P  •—»
^  to
+
looUi
$
+M->
$
+
l o
00
*R
+to
C/1
^  3* O  
IV I  £L to E  o
o o
3  £•
s t
</i C/i 
< 1
tt +r *  c/i
to v
ft +P  co 
^  <1
ft +P  oo 
°  NO
ft + P  to
1/1
ft +
to NO
+t—I
ON
$
+
oo
o
$
+C/1-o
$
+
CO
+to
-p*>
$R
+to
O n
cR
IVto
c n3 E  
cr oO f-'
o 3 
<=^ 0 
o  e
£ 303 O 
CL 
3
1+ +  
Ln 4^ . 
O n
1+ +  r  ui 
M  vo
ft +P  to 
bo
ft +P  oo 
o c/1
ft +P  to 
to • ,
i+ +  P  to oo ^
O
ECo
n
a
01XD
n
ao
n
a
01co
n
a
01
o
EC
01
H
151
Table 6.4. Phosphodiesterase activity in Chinese hamster ovary cell 
clones: the influence of insulin and phorbol ester on rolipram sensitive 
activity
Rolipram inhibited phosphodiesterase activity was measured in six 
Chinese hamster ovary cell clones including control cells (CHO-K), cells 
overexpressing human insulin receptor (CHO-T) and cells overexpressing 
both the human insulin receptor and a specific protein kinase C isoform 
(CHO-a, -p, -y or -e). Activity was first assessed in untreated cells then in 
cells after insulin treatment (lOnM, 5minutes), long-term phorbol ester 
treatment (lOOnM, 16hours) and a combination of long-term phorbol ester 
and insulin treatment. Results are expressed in the table as the degree of 
inhibition (change in units of specific activity) caused by rolipram (lOpM 
final concentration) under normal conditions or after insulin and TPA 
treatment of cells. Basal specific activities for each cell clone were 8.9 ±1.3 
pmol/min/mg protein (CHO-a), 7.3 ±0.4 (CHO-P), 4.9 ±3.4 (CHO-y), 19.4 
±2.1 (CHO-e), 8.6 ±3.7 (CHO-K) and 7.7 ±1.6 (CHO-T). All results 
represent means for the number of samples indicated and include S.D. 
values. Statistically significant results are highlighted as p<0.05 (*), p<0.01 
(**) and p<0.001 (***).
Changes in phosphodiesterase activity listed for insulin, TPA or insulin
and TPA treated cells refers to the appropriate controls as illustrated in Table 6.1.
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Table 6.5. Phosphodiesterase activity in Chinese hamster ovary cell 
clones: the influence o f insulin and phorbol ester on cilostamide 
sensitive activity
Cilostamide inhibited phosphodiesterase activity was measured in 
six Chinese hamster ovary cell clones including control cells (CHO-K), 
cells overexpressing human insulin receptor (CHO-T) and cells 
overexpressing both the human insulin receptor and a specific protein 
kinase C isoform (CHO-a, -p, -y or -e). Activity was first assessed in 
untreated cells then in cells after insulin treatment (lOnM, 5minutes), long­
term phorbol ester treatment (lOOnM, 16hours) and a combination of long­
term phorbol ester and insulin treatment. Results are expressed in the table 
as the degree of inhibition (change in units of specific activity) caused by 
cilostamide (lOpM final concentration) under normal conditions and after 
insulin or TPA treatment of cells. Basal specific activities for each cell 
clone were 8.9 ±1.3 pmol/min/mg protein (CHO-a), 7.3 ±0.4 (CHO-p), 4.9 
±3.4 (CHO-y), 19.4 ±2.1 (CHO-e), 8.6 ±3.7 (CHO-K) and 7.7 ±1.6 (CHO- 
T). All results represent means for the number of samples indicated and 
include S.D. values. Statistically significant results are highlighted as 
p<0.05 (*), p<0.01 (**) and p<0.001 (***).
Changes in phosphodiesterase activity listed for insulin, TPA or insulin
and TPA treated cells refers to the appropriate controls as illustrated in Table 6.1.
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Table 6.6. Phosphodiesterase activity in Chinese hamster ovarv cell 
clones: the influence of insulin and phorbol ester on cyclic GMP 
sensitive activity
Cyclic GMP inhibited phosphodiesterase activity was measured in 
six Chinese hamster ovary cell clones including control cells (CHO-K), 
cells overexpressing human insulin receptor (CHO-T) and cells 
overexpressing both the human insulin receptor and a specific protein 
kinase C isoform (CHO-a, -p, -y or -e). Activity was first assessed in 
untreated cells then in cells after insulin treatment (lOnM, 5minutes), long­
term phorbol ester treatment (lOOnM, 16hours) and a combination of long­
term phorbol ester and insulin treatment. Results are expressed in the table 
as the degree of inhibition (change in units of specific activity) caused by 
cyclic GMP (lOpM final concentration) under normal conditions and after 
insulin or TPA treatment of cells. Basal specific activities for each cell 
clone were 8.9 ±1.3 pmol/min/mg protein (CHO-a), 7.3 ±0.4 (CHO-p), 4.9 
±3.4 (CHO-y), 19.4 ±2.1 (CHO-e), 8.6 ±3.7 (CHO-K) and 7.7 ±1.6 (CHO- 
T). All results represent means for the number of samples indicated and 
include S.D. values. Statistically significant results are highlighted as 
p<0.05 (*), p<0.01 (**) and p<0.001 (***).
Changes in phosphodiesterase activity listed for insulin, TPA or insulin
and TPA treated cells refers to the appropriate controls as illustrated in Table 6.1.
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Chapter 7
Kinase activity o f partially purified insulin receptor
7.1. Introduction
The majority of proposed models for the transduction of the insulin 
signal across the membrane are based on the nature of the insulin receptor 
as a tyrosine kinase. According to these, insulin binds to the extracellular 
«-subunit of the receptor, activating the tyrosine kinase activity of the 
transmembrane {3-subunit. Many effects of insulin ultimately involve 
altered phosphorylation of target proteins, usually on serine residues, 
including, for example, phosphorylation of acetylCoA carboxylase and 
dephosphorylation of glycogen synthase. This model has been supported 
by studies with mutant receptors lacking kinase activity (Fujita- 
Yamaguchi, et al.y 1983) and by antibodies that inhibit receptor tyrosine 
kinase activity (Morgan and Roth, 1987), both of which lead to loss of 
insulin action.
In intact cells the insulin receptor is phosphorylated on serine 
residues in response to insulin (Stadtmauer and Rosen, 1986a) although 
most partially purified preparations of insulin receptor lack serine kinase 
activity. When amino acids are analyzed by two-dimensional tryptic 
phosphopeptide mapping using intact cells, this results in the appearance 
of two phosphopeptides not evident using soluble receptor preparations 
(Smith, et al.y 1988). However a purification protocol has been devised 
which allows receptor purification with associated serine kinase activity 
(Smith, e ta l.y 1988).
Other studies have suggested that autophosphorylation is not a 
necessary feature of insulin signalling. For example, antibodies to the 
insulin receptor can stimulate its kinase activity towards exogenous 
substrates without inducing receptor autophosphorylation (Tavare, et al.y 
1988). It may be, however, that in such cases antibodies induce a 
conformational change akin to that resulting from autophosphorylation, 
hence allowing signal transduction.
155
The range of substrates phosphorylated in vivo upon interaction of 
insulin with its receptor are becoming more clearly established (Kasuga, et 
al., 1990). Several of these substrates have proved ideal for in vitro work. 
In addition, a synthetic peptide repesenting part of the receptor p-subunit 
sequence w hich con tains all th ree m ajor insu lin  recep to r 
autophosphorylation sites has been specifically designed for such in vitro 
assays.
The influence of insulin on G-proteins is one theory to explain 
certain actions of this hormone (Houslay, 1990). For example, studies 
using the streptozotocin-induced diabetic rat show that, in liver tissue, 
there is a decreased inhibitory constraint upon adenylate cyclase (Gawler, 
et al.y 1987). This loss of activity is associated with a reduction in the 
amount of the a-subunit of Gi in liver membranes m easured by 
immunochemical techniques, an effect partially reversed by insulin 
therapy.
Work presented in this chapter will investigate various aspects of 
insulin receptor function using a partially purified preparation of the 
receptor.
7.2. Results and discussion
7.2.1. Studies on insulin hinding to its receptor
The binding of 125I-insulin to the insulin receptor was assessed as 
detailed in Section 2.1.4. In order to find the linear range of insulin 
binding to its receptor, samples of crude placental extract were used to 
construct a 2-fold dilution series. For such a dilution series the total insulin 
binding activity was calculated by determining the sample fold dilution 
required to bind 5% of the total added counts then multiplying the 
reciprocal of this dilution by the total volume. From Figure 7.1, which
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depicts insulin binding at various dilutions of crude placental extract, the 
number of units of insulin binding activity in this preparation was 
calculated to be 8064 (192x42).
Fold purification can be assessed by examining the percentage of 
total insulin binding activity of crude placental extract exhibited by the 
preparation after incubation with IMMAD. Results presented in Table 7.1 
show that a yield of 49% and a fold purification of 113 were achieved.
Table 7.1. Partial purification of human placental insulin receptor
Protein Concn % Total Insulin Binding Activitv
mg per mg protein
Crude placental 
extract
155 100 0.645
Pooled
discarded
supernatant
fractions
53
IMMAD after 
incubation 0.67 49 73.1
with CPE
In terms of the yield obtained, this purification procedure 
compared favourably with other methods designed for the same purpose 
(Fujita-Yamaguchi, et al.y 1983). When attempting to elute the receptor 
from the IMMAD, using a low pH sodium acetate buffer (pH 5.0), a loss 
of receptor activity was found, hence in subsequent experiments an 
immobilised receptor preparation was used.
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7.2.2. Characterization of the parameters of insulin receptor autophos- 
phorvlation
To characterize the partially purified insulin receptor preparation, 
autophosphorylation was first examined. Phosphorylation assays were 
conducted as described in Section 2.1.5. Firstly, autophosphorylation over 
a one hour time period in the presence and absence of insulin was 
examined (Figure 7.2), and secondly an insulin dose response curve of 
receptor autophosphorylation was carried out (Figure 7.3). These show a 
clear insulin and time dependency for autophosphorylation of the receptor.
7.2.3. Substrate phosphorylation using the partially purified insulin 
receptor
7.2.3.1. Studies using the peptide IRp
The peptide IRp corresponds to residues 1142-1153 of the insulin 
receptor p-subunit. Its amino acid composition is as follows:
COOH NH2
Thr-Arg-Asp-Ile-Tyr-Glu-Thr-Asp-Tyr-Tyr-Arg-Lys 
As it contains all three major autophosphorylation sites of the insulin 
receptor p-subunit it is the ideal artificial substrate for the insulin receptor 
kinase, as shown in Figure 7.4. The insulin dependent nature o f this 
phosphorylation is confirmed in Figure 7.5. W ork by Dickens et al. 
(Dickens, et al.y 1991) has shown that under appropriate conditions all 
three tyrosine residues in this peptide are phosphorylated. Using a series of 
peptide analogues in which each tyrosine was substituted by 
phenylalanine they predicted the order of tyrosine phosphorylation to be 
tyrosine residue 9, followed by tyrosine 10, then finally tyrosine 5 
(Levine, et al.y 1991). This confirmed earlier work suggesting that tyrosine 
1152 (residue 9) was preferentailly phosphorylated (Stadtmauer and 
Rosen, 1986b). Note, however, that bis- and tris-phosphopeptides do not
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bind to phosphocellulose paper. This order of phosphorylation contrasts 
with that deduced (residues 1148 (5), 1152 (9) then 1153 (10)) in another 
study (Flores-Riveros, et al., 1989) where digests of insulin receptor were 
analysed. Results from the latter study also suggested that the transition 
from the doubly to the triply phosphorylated forms was primarily 
responsible for the activation of IRS-1 phosphorylation. This result was 
contradicted by other work which suggests that phosphorylation of 
residues 1152 and 1153 was the only requirement to induce full kinase 
activity of the receptor (Zhang, e ta l., 1991).
7.2.3.2. Studies using the purified inhibitory G-protein Gi
It has been suggested that insulin can interact with the guanine 
nucleotide regulatory protein system based upon its ability to inhibit 
adenylate cyclase (Heyworth and Houslay, 1983) and activate specific 
species of cyclic AMP phosphodiesterase (Heyworth, etal., 1983a).
Phosphorylation of the inhibitory guanine nucleotide binding 
protein G* by insulin receptors purified from human placental membranes 
has previously been shown, in an analagous way to ADP-ribosylation, to 
be dependent on the protein being in its GDP bound holomeric form 
(O'Brien, et al., 1987a). Thus, its activation by the non-hydrolyzable 
analogue GTPyS was able to attenuate phosphorylation. High 
concentrations of Mg2+, a physiological regulator of G-protein function, 
were also noted to abolish this phosphorylation. A conformational change 
induced in the G-protein by this divalent ion was proposed as a logical 
explanation (Houslay, 1990). In addition, this phosphorylation of Gi was 
found to occur exclusively on tyrosine residues.
Some studies suggest that insulin can influence G-protein function 
by a noncovalent interaction (Luttrell, et al., 1990). These authors suggest 
a direct interaction, with the tyrosine kinase activity of the receptor not
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playing a significant role. A functional interaction between insulin and Gi- 
proteins has also been shown in the plasma membrane of pancreatic acinar 
cells (Profock, et a l., 1991), a tissue where insulin potentiates 
cholecystokinin stimulated amylase release. These experiments, which 
examined the effect of insulin on GTPyS binding (increased) and pertussis 
toxin induced ADP ribosylation (decreased) again suggested a direct 
association of receptor and G-protein as opposed to a phosphorylation 
mediated control.
Figure 7.6 clearly illustrates the relationship between insulin 
receptor autophosphorylation and phosphorylation of Gi purified from 
bovine brain. In this case the insulin receptor was not pre-activated with 
’cold' ATP prior to addition of substrate, partly explaining the lag seen 
between the rates of receptor autophosphorylation and Gi phosphorylation. 
Another reason for this lag might, understandably, be due to the receptor 
kinase having a much lesser affinity for Gi than it does for the insulin 
receptor p-subunit. Determination of the molecular weight associated with 
the bands detected by autoradiography showed values of 91 (insulin 
receptor p-subunit) and 39.5 (G-protein a-subunit). These results clearly 
demonstrated that under appropriate conditions the purified insulin 
receptor could cause the phosphorylation of the ec-subunit of Gi.
7.2.4. Effect of the tyrosine kinase inhibitor ST271 on substrate 
phosphorylation hv the insulin receptor kinase
ST271 was first identified as an inhibitor of the epidermal growth 
factor receptor kinase (Shiraishi, et al., 1989). These studies showed 
ST271 to be a relatively specific inhibitor of tyrosine kinase, as opposed to 
serine/threonine kinases.
Figure 7.7 shows the inhibitory effect of ST271 on substrate 
phosphorylation, and highlights the differences observed when the insulin
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receptor was not previously activated by incubation with 'cold' ATP. 
Using pre-activated receptor the effect of ST271 was apparent after several 
minutes, with a minimal increase in peptide phosphorylation over a ten 
minute period in the presence of the inhibitor. W ithout previously 
activating the insulin receptor preparation there was a lag of some 10 
m inutes before there was a discernable d ifference in peptide 
phosphorylation in the presence and absence of ST271. After this time, 
however, a dramatic inhibitory effect was seen as before. In this case an 
initial increase in peptide phosphorylation was observed over the first two 
minutes before a plateau phase was reached.
7.3. Conclusions
A valuable tool in examining insulin receptor phosphorylation 
using purified receptor has been synthetic peptides representing distinct 
domains of the receptor p-subunit. The peptide used in the work presented 
here was an ideal substrate for the insulin receptor kinase, showing 
definite insulin- and time-dependency for phosphorylation. Unlike other 
studies, the stoichiometry of phosphorylation was not assessed here, 
although it was assumed that the assay used in this work measured the 
level of monophosphorylated peptide since bis- and tris-phosphopeptides 
have been reported not to bind to phosphocellulose paper. From analysis 
of the literature it is apparent that similar purification protocols can yield 
receptor preparations that either possess or lack an associated serine kinase 
activity. However, since phosphoaminoacid analysis was not conducted in 
this particular study, it is unclear if Gi phosphorylation was due to 
phosphate incorporation into tyrosine or serine, although previous work 
suggested phosphorylation exclusively on tyrosine residues (O'Brien, et 
al., 1987a).
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Using the tyrosine kinase inhibitor ST271 produced a significant 
reduction in insulin receptor mediated phosphorylation of the peptide IRp. 
Interestingly, however, without pre-activation of the insulin receptor 
before assaying phosphorylation there was a period of approximately 10 
minutes required before the inhibitory effect of ST271 was apparent. In 
addition, over the first two minutes a small but definite initial increase in 
peptide phosphorylation was observed. In explaining these observations, 
we must concede from previous observations that a delay of several 
minutes would be expected to occur before peptide phosphorylation was 
apparent if  the receptor was not pre-activated. Even when the receptor 
became activated it is apparent from the data presented here that several 
minutes more elapsed before normal and ST271 inhibited phosphorylation 
patterns were significantly different. This reasoning accounts for the 
plateau phase seen in Figure 7.7(B). The initial slight increase in 
phosphorylation, however, was unexpected. The explanation may be that, 
for this purified receptor preparation, challenge by insulin immediately 
elevated the receptor to a state of partial kinase activity, with full kinase 
activity ensuing after approximately 2 minutes exposure to insulin as 
expected. Finally, this being the case why should phosphorylation of IR(3 
plateau and not continue to increase slowly unless the initial burst of 
kinase activity exhibited by the receptor was transient?
Previous work in this laboratory established that insulin inhibits 
adenylate cyclase activity in rat hepatocytes, an effect lost in cells taken 
from streptozotocin diabetic animals. Although evidence has been 
somewhat contradictory, it seems that Gi is not involved in transducing 
this insulin mediated inhibition. However the GTP-dependent nature of 
this effect does suggest that the action of insulin is mediated at some point 
by a guanine nucleotide binding protein, perhaps p21ras or a novel G- 
protein (Gins)- Results presented here confirm the findings of other groups
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which suggested that, under appropriate conditions, the purified insulin 
receptor can infact phosphorylate a preparation of purified Gi. The 
functional significance of this Gi phosphorylation by the insulin receptor 
kinase however is still debatable and it will be interesting to establish 
whether such a phosphorylation event occurs in situ in the intact cell. In 
conclusion, it would seem that it is possible to phosphorylate Gi by the 
insulin receptor using purified preparations of both of these proteins, 
although it is doubtful if this is of major physiological relevance.
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Figure 7.1. M easurement o f total insulin binding activity in crude 
placental extract.
Samples of Triton X-100 solubilized human placental membranes 
were serially diluted two fold and 125I-insulin binding activity assayed as 
described in Section 2.1.4. The dilution factor at which 5% of added counts 
were bound was used to calculate the total insulin binding activity.
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Figure 7.2. Time-course of immobilised insulin receptor autophos­
phorylation
This graph shows the level of insulin receptor autophosphorylation 
in the presence (— o— ) and absence (— •— ) of insulin. Phosphorylation 
assays were performed as described in Section 2.1.5. Values represent 
means and errors are expressed as ± S.D. in a typical experiment. 
Incorporation of phosphate into insulin receptor was quantified by excision 
of the appropriate SDS-PAGE gel chip and Cerenkov counting.
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Figure 7.3. Insulin dose response curve of immobilised insulin receptor 
autophosphorylation
Phosphorylation assays were performed as described in Section
2.1.5. In this case, samples were incubated at 23°C for 1 hour. Values 
represent means and errors are expressed as ± S.D. in a typical experiment. 
Incorporation of phosphate into insulin receptor was quantified by excision 
of the appropriate SDS-PAGE gel chip and Cerenkov counting.
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Figure 7.4. Time course of phosphorylation of the peptide IRp bv the 
partially purified insulin receptor kinase
Phosphorylation assays were performed as described in Section
2.1.7. Values represent means and errors are expressed as ± S.D. in a typical 
experiment. Incorporation of phosphate into the peptide IRp (final 
concentration 0.33mM) was measured by absorbing the peptide onto P81 
paper and Cerenkov counting.
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Figure 7.5. Insulin dependence of phosphorylation of the peptide IRp by 
the immobilised insulin receptor kinase
Insulin dependency of IRp phosphorylation by the insulin receptor is 
shown by phosphate incorporation in the presence of lOOnM insulin (— o— 
) and in the presence of 0.1 nM insulin (— •—). Phosphorylation assays were 
performed as described in Section 2.1.7. Values represent means and errors 
are expressed as ± S.D. in a typical experiment. Incorporation of phosphate 
into the peptide IRp (final concentration 0.33mM) was measured by 
absorbing the peptide onto P81 paper and Cerenkov counting.
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Figure 7.6. Phosphorylation of the purified G-protein G| by partially 
purified insulin receptor
Purified Gi was examined as a substrate for the partially purified 
insulin receptor as described in Section 2.1.6. The graph presented shows 
simultaneous analysis of insulin receptor autophosphorylation (—o— ) and 
Gi phosphorylation (— ■—) in a typical experiment. Incorporation of 
phosphate into insulin receptor was quantified by scanning densitometry of 
the resulting autoradiograph. Values represent data from a typical 
experiment.
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F igure  7.7. E ffect o f the  ty rosine kinase in h ib ito r ST271 upon 
phosphorylation of the peptide IRp by the partially  purified  insulin 
receptor
Phosphorylation assays were performed as described in Section
2.1.7, except that in (A) partially purified insulin receptor was activated by 
pre-incubation with lOnM insulin, whereas in (B) no such pre-incubation 
was carried out. The graphs show phosphate incorporation into the peptide 
under normal assay conditions (— o— ) and in the presence of the tyrosine 
kinase inhibitor ST271 (— •— ). Values represent means and errors are 
expressed as ± S.D. in a typical experiment. Incorporation of phosphate into 
the peptide IRp (final concentration 0.33mM) was measured by absorbing 
the peptide onto P81 paper and Cerenkov counting.
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Chapter 8 
Discussion
The protein kinase C family is a widespread group of kinases 
responsible for many diverse and critical cellular functions. It is now 
appreciated, however, that individual protein kinase C isoforms might 
have quite separate and well defined actions. Thus, with the advent of 
activators and inhibitors for specific protein kinase C isoforms, the 
understanding of the complexity of protein kinase C function is becoming 
better understood. As yet, however, there is no conclusive evidence for a 
specific protein kinase C isoform being activated in a distinct cellular 
compartment leading to phosphorylation of one defined physiologically 
relevant substrate. There have been indications that certain substrates, for 
example the EGF receptor, can be phosphorylated to varying degrees by 
individual protein kinase C isoforms (Ido, et al.y 1987). More importantly 
with reference to work presented in this thesis, this was also recently 
shown to apply to the insulin receptor where PKC-a, -pi and -y but not 
PKC-e could attenuate insulin receptor function via causing its 
phosphorylation (Chin, et a l.y 1993). In the case of P K C -a , 
phosphorylation of the insulin receptor inhibited insulin-stimulated 
tyrosine phosphorylation of IRS-1 and PI 3-kinase (Chin, etal., 1994).
The phenomenon of protein kinase C regulating insulin receptor 
function by altering its phosphorylation state has been extensively studied, 
as detailed in earlier text, and is now widely accepted. The suggestion that 
protein kinase C was part of the insulin signalling pathway has been more 
controversial. I feel, however, that enough evidence now exists to suggest 
that this is definitely the case, at least for certain insulin mediated 
responses. For example, treatment of adipocytes with insulin elicited 
translocation of protein kinase C to the membrane, indicative of activation 
(Farese, et al.y 1992b). More recent evidence has also shown that insulin 
stimulation of the Na+-K+ pump in skeletal muscle occurred via activation 
of protein kinase C (Sampson, et a/., 1994). In addition, my own work has
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shown that protein kinase C, and more specifically PKC-e, appears to play 
a central role in insulin's ability to regulate intracellular cyclic AMP 
metabolism in CHO cells.
In some of the work presented in this thesis prolonged treatment 
with phorbol esters was used to down-regulate protein kinase C. This is a 
common procedure which invariably has been shown to decrease 
expression of protein kinase C and result in decreased functional 
responsiveness of cells to subsequent stimulation with the relevant ligand. 
However, some doubt has been cast upon the reliability of this criteria in 
investigating the role of protein kinase C (Wilkinson and Hallam, 1994). 
Reservations principally concern the fact that more recently identified 
isoforms, such as PKC-J, do not down-regulate in response to TP A. The 
isoforms studied in my work, however, do respond to phorbol ester by 
down-regulating and so their function can usefully be examined in this 
way.
Care must also be taken in using phorbol ester stimulation as a 
yardstick of protein kinase C function as other proteins are now known to 
be capable of binding phorbol ester. Neuronal chimaerin, for example, can 
bind phorbol esters, allowing this protein to regulate p21rac-GTPase 
activity (Ahmed, et al., 1993). Hence, activation of the ras cascade leading 
to activation of MAP kinase might mediate the effects of phorbol esters in 
some systems.
The development of phorbol ester-derived isoenzyme specific 
agents will facilitate future investigation of the role of individual protein 
kinase C isoforms in cell signalling pathways. For example, the TPA 
analogue sapintoxin has been developed which will activate PKC-a, -pi, -y 
and -e to the exclusion of other isoforms (Ryves, et al., 1991). The use of 
specific protein kinase C activators and inhibitors would further studies 
presented in this thesis, and thus represents a potential future development
172
in this research. This would, for example, circumvent the doubts cast upon 
the reliability of phorbol esters, as discussed above.
On a broader perspective, protein kinase C inhibitors might prove 
to be of substantial clinical importance. Their possible therapeutic uses 
include the treatment of chronic inflammatory or auto-immune diseases, 
such as rheumatoid arthritis, as well as for the prevention of graft rejection 
and in treatment of cancers. Due to the fairly ubiquitous distribution and 
fundamental importance of protein kinase C to many physiological 
processes, systemic effects of such agents are likely to inhibit their 
therapeutic prospects. Progress has been made in designing inhibitors 
selective for protein kinase C over a broad range of serine/threonine and 
tyrosine specific protein kinases, one of the best being R o318425 
(Bradshaw, et al., 1993). Furthermore, it is hoped that agents selective for 
the individual protein kinase C isoform of interest in specific cases might 
circumvent this problem to an extent which will allow their therapeutic 
exploitation and, indeed, initial results are surprisingly encouraging 
(Birchall, 1994).
Results presented here indicate that reduced protein kinase C 
activity occurs upon streptozotocin-induced diabetes. In these studies, no 
assessment of the corresponding activity of the insulin receptor was made. 
One recent study has suggested, however, that under hyperglycaemic 
conditions, as would be expected in hypoinsulinaemic streptozotocin- 
diabetic rats, a reduced insulin receptor tyrosine kinase activity is observed 
(Berti, et a l., 1994). This was found to be mediated by protein kinase C 
activation and serine phosphorylation of the insulin receptor (Berti, et al., 
1994). However, my work showed that in the streptozotocin-diabetic rat 
model a reduced protein kinase C activity occurred. This contradiction in 
results seems typical of the literature published in this area of research. 
Why this should be quite so marked is surprising, although since most
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studies have identified changes in total protein kinase C activity, rather 
than in individual isoforms, it is likely that the varying complement of 
protein kinase C isoforms present in different tissues, and their differential 
regulation in diabetic states, underlies the disparity of published results.
With the elucidation of more precise details of various intracellular 
signalling pathways, the extent of cross-talk between different signalling 
systems in cells is becoming appreciated. For example, protein kinase C 
and cyclic AMP-dependent kinase can act antagonistically: they are 
known to phosphorylate the glycine receptor in vivo with opposite 
functional consequences (Vaello, et al.y 1994). This means that in 
controlling intracellular cyclic AMP levels, protein kinase C might be 
envisaged as being able to switch off or reduce cyclic AMP-dependent 
kinase signalling and enhance its own effect. Conversely, the potential for 
a negative feedback control of protein kinase C activated responses exists.
An important point at which the convergence of cyclic AMP and 
protein kinase C signal transduction occurs is at the level of adenylate 
cyclase. The influence of protein kinase C on adenylate cyclase has been 
investigated in many instances. For example, phorbol esters were recently 
shown to synergistically increase cyclic AMP production when adrenaline 
simultaneously activated receptors via an effect on adenylate cyclase 
(Morimoto and Koshland, 1994). Another study suggests that protein 
kinase C is directly involved in mediating bradykinin-dependent activation 
of adenylate cyclase (Stevens, et al.y 1994). Control of adenylate cyclase 
by protein kinase C has been examined further by Jacobowitz and co­
workers who provided evidence that protein kinase C could selectively 
stimulate specific types of adenylate cyclase (Jacobowitz, e ta l.y 1993).
Individual signalling pathways may also act synergistically within 
cells. Indeed, it appears that hormonal signal transduction systems often 
have a specialized kinase for signalling at high concentrations of a ligand
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and another second messenger regulated kinase to mediate signalling at 
low concentrations of ligand. With reference to insulin action, for 
example, it appears that, in controlling Na+-H+ antiport function in 
hepatocytes, insulin acts at high concentrations via protein kinase C and at 
low concentrations via a tyrosine kinase pathway (Incerpi, et al., 1994).
Stable overexpression of protein kinase C isoforms has recently 
become used to examine the roles of particular isoforms. Overexpression 
provides a useful indication of which isoforms are involved in individual 
receptor mediated processes, yet signalling via non-physiological 
pathways may arise due to unrepresentatively exaggerated levels of these 
proteins. The availability to us of the CHO cell line overexpressing 
specific protein kinase C isoforms together with the human insulin 
receptor allowed investigation of responses to insulin and parallel analysis 
of the contribution of protein kinase C isoforms to insulin's action.
Using this system, I have shown that PKC-e plays a central role in 
regulating both basal and insulin stimulated phosphodiesterase activity 
within CHO-e cells and in allowing insulin to attenuate agonist induced 
increases in intracellular cyclic AMP concentrations in these cells. These 
results suggest that expression of PKC-e in individual tissues is of 
importance in mediating at least part of insulin's ability to control 
intracellular cyclic AMP levels. The influence of protein kinase C on 
cyclic AMP metabolism was investigated in another recent study in PC 18 
cells (Yingling, et al.y 1994). It was also concluded from these studies that 
protein kinase C controlled cyclic AMP metabolism at both the level of 
synthesis and degradation. On a broader perspective, the concept of such 
specific intracellular regulatory mechanisms means that certain effects of 
ligands can be confined to particular tissues where the appropriate 
signalling molecules are expressed, despite the ligand interacting with 
receptors in other tissues.
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